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Abstract 
This thesis explores the ethics of mental health diagnosis and treatment in children 
and adolescents through a collection of different perspectives based on literature analysis and 
interviews with practicing clinicians.  Compared to other medical fields, paediatric psychiatry 
is considerably novel; it has only recently become a medical specialty and differs from other 
medicine by involving both biological and psychological aspects of care.  Recently, human 
brain development has become better understood, but the effect of mental illness on the 
trajectory of development is only just beginning to be studied.  Despite this limited 
understanding, children who may not have been diagnosed for psychiatric disorders in the 
past are increasingly receiving off-label prescription treatments.  This trend may be due to 
improved sensitivity of diagnostic practices as well as the medicalisation of normal, 
classifying previously healthy borderline behaviours as pathological.  What are the 
implications of increasing medicalisation?  How are child-specific diagnoses and treatment 
plans determined?  I focus on identity development in young people with mental disorders, 
specifically depression, and try to explain the effects of labelling and medication on that 
development.  Also the physiological impact of psychopathology and psychotropic treatment 
on neurodevelopment is examined, as well as the lack of long-term clinical data for drug 
treatment in children.  Though the key source material has been from literature in the US and 
UK, the thesis broadens to an international perspective with a global look at the relationship 
between culture and paediatric psychiatry practices.  Finally, mental health care professionals 
were interviewed to provide a clinical perspective to supplement the literature analysis.  By 
drawing historical, philosophical, psychological, biological, cultural, and professional 
perspectives together in this novel way, ethical considerations necessary in the psychiatric 
care of paediatric patients are given a more thorough understanding, and a framework for 
assessing these considerations is presented through a focused interdisciplinary lens. 
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CHAPTER 1 
Introduction 
 
 
In Western society, the practice of medically diagnosing and treating children for 
psychiatric illness is rapidly growing.  Not only are more diagnoses being defined and 
extended to the paediatric population, but the rate of development of new diagnoses is being 
outpaced by the increasing rate at which children are being diagnosed and treated within 
psychiatry.  While research has provided significant understanding of the human brain, the 
interplay between psychology and biology, particularly during development, remains largely 
unclear, though technology has allowed doctors some level of psychological manipulation 
through biological treatments.  Although adult psychiatry continues to evolve as a relatively 
new medical science, it is supported by well over a century of study and decades of clinical 
drug trials.  On the other hand, paediatric psychiatry is a considerably more recent and less 
studied field, and lacks comparable data evidence provided in adult practice.  There is 
extensive research discussing specific elements of ethical concerns in paediatric psychiatry, 
including what data is available, the issue with treating despite lack of data and the future of 
paediatric psychiatry (e.g. Vasa, Carlino & Pine, 2006; Moreno et al., 2007; Alacqua et al., 
2008; Parens & Johnston, 2011), but no one study that pulls all this together to investigate the 
overall context and implications of paediatric psychiatry. 
In one literature review, Lakhan and Hagger-Johnson (2007) highlight five major 
points of interest when treating children with psychotropic medication.  Firstly, though the 
human brain continues to change over an entire lifetime, the developing brain is changing 
more rapidly than the adult brain; this implies not only that children and adolescents may 
respond differently to drug treatments than adults do, but it also suggests that it may be more 
ethically challenging to conduct research to study paediatric brain-drug interactions because 
the immature brain is more susceptible to insult.  Secondly, children and adolescents are at 
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high risk for developing depression and other mood disorders due to the combination of 
experiencing increasingly stressful events as they age and possessing a particularly malleable 
identity as they develop a sense of self-understanding.  Thirdly, the symptoms and extent to 
which these symptoms are considered meaningful in terms of the impact it has on an 
individual is different in children from that in adults; hence, the same disorder may present 
differently depending on the age of the patient.  Fourthly, psychotropic drug dosages should 
not simply be lowered for children, based on age and body size; the difference between 
metabolic rate in children versus adults and unknown long term effects on neurodevelopment 
must also be considered.  Lastly, despite the tendency to rely on psychotropic treatment, it is 
important to remember that there are other psychiatric treatments that have been proven 
effective in the paediatric population, not only drugs.  Cognitive behavioural therapy (CBT) 
and parent training are examples of alternative interventions. 
In order to draw together a picture of current paediatric psychiatry, this thesis will 
illustrate the major ethical concerns in the field by focusing on depression to demonstrate the 
issues as they appear in the child and adolescent population.  Before exploring this disorder in 
the context of paediatrics, however, the implications of modern medicine‘s understanding of 
adult depression should be discussed.  Adult psychiatry also faces a number of issues similar 
to those which affect paediatric treatment.  Specifically addressing depression in adults, 
recent literature calls attention to the impact the disorder and treatment has on personal 
experience, the growing reliance on psychotropic medication, neglect of context, and 
medicalisation of normal (e.g. Elliott, 2000; Healy, 2000; Parens, 2004).  Previously, 
melancholic individuals experiencing depression appeared to possess a superior virtue and 
ability to question and understand human life, a virtue which has faded in modernity; as 
Kramer (2000, p. 17) eloquently notes,  
I have asked why we are no longer charmed by suicidal  
melancholics—Goethe‘s Werther or Chateaubriand‘s Rene  
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or Chekov‘s Ivanov.  Because we see major depression and  
affectively driven personality disorders as medically  
pathologic, what once exemplified authenticity now looks like  
immaturity or illness—as if the romantic writers had made a  
category error. 
Yet, correlated with the depth of depressive experience and its associated insight, a number of 
these affected individuals became influential cultural, social, and political leaders throughout 
history (Kramer, 2000; Ghaemi, 2003), e.g. George Washington, Ulysses S. Grant, and 
Abraham Lincoln (Ghaemi, 2003).  However, with the increased awareness of depression as a 
disorder and the availability of effective psychotropic treatment, Western society shows an 
increasing trend toward medicating depressed individuals as the go-to treatment approach, 
while discounting the experience and context that gives rise to and results from depression 
(Healy, 1997).  Kramer (2000) argues that this trend reflects society‘s attempt to mainstream 
human experience, treating who people are and human authenticity as a disease that needs to 
be cured.  Rather than viewing depression as a different version of normal or an extreme 
response to significant life stress and grief, what used to be considered within normal life 
experience has become more often medically diagnosed as a disorder and treated, particularly 
through psychopharmacology (Horwitz & Wakefield, 2007).  This may not be a bad trend, 
but it does question the value of experience and prompts questions of how such practices may 
impact both individuals and the larger society. 
Led by a series of questions, this study involves an interdisciplinary analysis of the 
treatment of depression in the young population in the US and UK by addressing six key 
aspects: historical background, the concept and ethics of medicalisation
1
, identity 
development and psychological implications of treatment, physiological implications of 
treatment, cultural influences, and professional opinions.  Considering the historical 
perspective in the form of a literature review, the development of the psychiatric diagnosis 
                                                 
1
 ‗Medicalisation‘ refers to the shift toward medically diagnosing previously ‗normal‘ experience/behaviour, and 
while the term itself does not imply medication, it does often lead to medication treatment. 
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and its extension to the paediatric population will be discussed; particular attention will be 
given to emerging treatment and prescription trends over the past few decades.  The concept 
of psychiatric diagnosis, along with its associated drug treatment, is considerably novel and it 
is only recently that both have been broadened to include children and adolescents.  Next, the 
section on medicalisation will consist of an examination of the purpose of diagnosis and 
treatment, an evaluation of what is normal, and a comparative analysis of neurostimulant and 
antidepressant use for neuroenhancement purposes.  As the definition of normal narrows, 
more children are receiving psychiatric treatment than ever before.  Further, there has been 
much debate over the use of neurostimulants not only for treatment of ADHD but also 
cognitive enhancement.  Based on this trend of neurostimulant enhancement in children and 
the practice of Prozac enhancement in adults, it may be likely that similar issues are on the 
rise for antidepressant use in arguably healthy children in order to attain a desirable effect, 
including decreased anxiety, increased confidence, or less negative temperament, for 
instance.  Psychotropic treatment for both ADHD and depression, among other psychiatric 
disorders, raise concerns about the identity and concept of self as young individuals may 
integrate their disorder and treatment into their understanding of themselves.  The 
psychological implications of depression treatment will be ethically assessed through a 
discussion of the available literature, taking into account the development of identity, 
experience of the disorder and the effects of treatment on the individual.  Additionally, a 
similar analysis of known physiological effects will follow.  This perspective will investigate 
the interaction between neurodevelopment, disorder, and treatment.  As policy is a significant 
factor in protecting the rights and safety of vulnerable populations, including paediatrics, and 
driving the future of developmental research, an overview of the relevant legislation will be 
summarised.  It has also been observed that culture and social influences play a large part in 
the treatment available and sought after, particularly for mental health; such influences will 
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be investigated as they pertain to the treatment of paediatric depression.  A comparison of a 
range of international literature will be presented, and the implications of Western practices 
will be analysed within this international context.  To conclude the study, professional 
opinions are sought in order to speak more directly to the issues presented in this thesis as 
they appear in clinical practice by conducting semi-structured interviews with a small sample 
of paediatric mental healthcare professionals. 
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CHAPTER 2 
What is the context of paediatric depression in 
psychiatry?: A historical perspective 
 
 
2.1  How did paediatric psychiatry develop? 
 The concept of paediatric depression is a recent development in the field of 
psychiatry.  Compared to other fields, psychiatry itself is very young.  Further, within this 
specialty recognizing the paediatric population separately from adults is even more novel.  
Child psychiatry only became an official subspecialty of psychiatry in 1959 (Chess & 
Hassibi, 1978).  While children have been incorporated into mental health care schemes since 
the turn of the twentieth century, until this point children were simply treated for adult-centric 
disorders.  No consideration was given to the possibility that immature minds perceive and 
experience psychiatric illness differently than adult minds.  Originally, professional attention 
toward mental health specific to the paediatric population came only as a means to help 
juvenile delinquents, the first recognized program being in 1909 in Chicago (Chess & 
Hassibi, 1978).   
While stages of child development have been acknowledged, a disconnect appears 
between this awareness and the determination to apply adult diagnoses in a similar manner to 
such a dissimilar population.  Without further investigation, it is easy to assume adult 
diagnoses remain applicable.  However, when brain development is considered, significant 
differences in the child brain beg the question, are the set diagnostic criteria and even the 
diagnoses themselves appropriate?  For the adult population, valid diagnoses may be 
attributed to individuals based on relatively objective criteria.  Even later in life psychiatric 
disorders are difficult to define precisely for each individual because no two people have 
exactly the same experiences or mental processes, but through adults‘ matured 
comprehensive and communicative abilities, experiences may be roughly generalized by 
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defined disorders.  Yet, diagnoses themselves are continually evolving, so there will always 
be a level of subjectivity.  Turning to a young population then, applying diagnostic criteria 
must be even more subjective because the degree of significance that any one experience will 
have for a given child will be much more variable due to the limited life experiences and 
comprehension.  As such, diagnostic criteria must be approached differently when dealing 
with children. 
 
2.2  How are children and adolescents incorporated into their own medical treatment? 
Before investigating the application of diagnosis and effects of treatment and 
medication on this population, their needs and integration into the medical system require an 
introduction and understanding.  Paediatric care is unique in that it incorporates not only the 
physician and immediate child patient, but also includes parents as ‗patients‘ because they are 
affected by and consent to treatment given to their child.  Specifically in the US, if the patient 
is under 18 years of age then treatment requires parental consent (with few exceptional 
circumstances), so parents must be included in clinical visits and receive all pertinent 
information.   
Taylor et al. (2010) conducted a qualitative study in the UK interviewing 20 families 
about their personal feelings about their paediatric consults.  The purpose of this study was to 
investigate the attitudes toward the inclusion of the paediatric patient in the management of 
their own care.  There were a number of factors deemed important in determining child 
involvement levels that were mentioned by participants, including age, maturity, 
communication skills of child, comfort levels of child, gender, cognitive ability, confidence, 
family dynamics, doctor‘s judgment, and illness severity.  Involvement was encouraged in 
order to provide the best service, but there was also a counter to such involvement in hopes of 
protecting the child patient; typically, families looked to the doctors to decide the extent to 
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which the child should be included.  Including the child patient in his or her treatment was 
viewed as the only means of fully communicating the illness that caused the child (and 
parent) to seek help.  In fact, the researchers suggested consulting adolescent patients both 
with and without their parents present to both aid treatment determination and give the patient 
more responsibility for their own health.   
Despite the benefits of including the child in the communication during consultation, 
a child patient is not an equal player in the clinical setting and continues to contribute less to 
his or her own care, with a number of identified barriers.  Often the patient, both child and 
parent, are afraid of taking up too much of the doctor‘s time, wanting to use as little time as 
possible, and fear that the clinical process would only be slowed down by a child trying to 
articulate his or her condition.  Concern was noted by a minority of families that the doctor 
should consult the parent first.  This would allow the parent to understand the diagnosis 
before including the child in order to better support and protect the child, and to alleviate 
some responsibility from the child of making difficult decisions with serious long term 
effects.  Also, ‗doctor knows best‘ tends to shy away the child patient, and to an extent the 
parent, from involvement, assuming the doctor is the expert and, thus, does not need the help 
of the patient in determining diagnosis and treatment.  Ultimately, most families felt 
comfortable leaving the decision to the doctor to choose how best to include the child patient.  
It should also be noted that child involvement in their own care has been increasing over the 
past few generations, marking a social trend, and has been reflected in medical practice to 
enhance this trend (Taylor et al., 2010). 
 
2.3  What does it mean to have the diagnosis of depression? 
Firstly, what does it mean to have a diagnosis?  What is the purpose of diagnosing a 
patient, whether it be for depression or any other disorder?  There are a number of 
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perspectives necessary to consider in order to fully answer these questions.  In the most 
general sense, a diagnosis provides a label.  For the physician, this offers a lead on the 
appropriate treatment plan.  Particularly in the US, this allows third party insurance claims to 
subsidize the cost of care.  For a given diagnosis, a patient‘s insurance coverage will pay for 
specific amounts and types of care, for example consults, tests, and prescriptions, which 
would otherwise be at the expense of the patient without an identified diagnosis.  
Additionally, disability services or accommodations may be provided if the diagnosis calls 
for such facilities.  In other healthcare systems, such as the NHS in the UK, diagnosis is less 
vital to healthcare access, but may be necessary to obtain disability services or to create an 
effective treatment plan.   
The diagnosis may be equally important for the patients themselves.  Putting a label 
on their experiences helps some individuals recognize what may otherwise be an 
overwhelming and isolating complexity of feelings.  It provides something real and definitive 
that they can identify with, albeit something abstract.  Through the identification of a 
diagnosis, patients are also able to find support and create a community with others who 
share similar experiences.  Due to its influence not only on treatment but also a patient‘s own 
identity, it is crucial to consider a diagnosis thoroughly before applying such a heavy label. 
Before addressing its application to the paediatric population, it is important to 
understand the diagnosis as it is written.  Generally, diagnoses are made based using either 
the Diagnostic Statistical Manual of Mental Disorders (DSM) or by the International 
Statistical Classification of Diseases and Related Health Problems (ICD); currently, 
diagnoses are based on the DSM-IV (1994) or ICD-10 (1992), both of which are in the 
revision stages for new editions to be published shortly.  While the two classification tools 
are separate, they are not competing theories.  The ICD, published by the World Health 
Organization (WHO), is meant to be more generalized to the entire (Western) population, 
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whereas the American Psychiatric Association‘s DSM is more specific and sensitive toward 
American culture and social understanding. 
In the ICD, the diagnosis of depression is broken into two categories, Recurrent 
Depressive Disorder and Depressive Episode, within which there are four subcategories: mild 
(with and without somatic symptoms), moderate (with and without somatic symptoms), 
severe without psychotic symptoms, and severe with psychotic symptoms (see Appendix A 
for full ICD 10 diagnostic criteria).  As stated under the Depressive Episode diagnosis, 
‗Differentiation between mild, moderate, and severe depressive episodes rests upon a 
complicated judgment that involves the number, type, and severity of symptoms present‘ 
(IMH, 2009).  In other words, the authors are calling attention to the subjectivity of this 
classification method.  Further, the mention of diagnosing adolescents is specified as 
commonly showing an atypical presentation.  If this is the case, then such a presentation will 
not likely fit the criteria marked out by the authors, making the diagnosis even more 
subjective. 
Similarly, the DSM divides the diagnosis of Major Depressive Disorder into either a 
single Major Depressive Episode or recurrent Major Depressive Episodes (see Appendix B 
for full DSM IV diagnostic criteria).  Depression is diagnosed given the presence of at least 
five of the listed symptoms, regardless of severity, which is later listed as a specifier.  With 
this minimum number of symptoms required for diagnosis, however, there is less flexibility 
in the DSM classification than the ICD, which adjusts the severity based partially on number 
of symptoms present.  The DSM gives attention to paediatric diagnosing with respect to two 
of the nine listed symptoms.  First, there is a note following depressed mood indicating that 
this symptom may be perceived as irritable mood in children and adolescents.  Second, 
significant weight and/or appetite changes may also be observed as a child‘s failure to meet 
expected weight gains, a variable not relevant to adult depression.  Are these the atypical 
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features in paediatric depression that the ICD is alluding to?  Or is the DSM missing a catch-
all clarification that paediatric depression may present differently, not only in the two 
specified symptoms? 
Regardless if a physician is trying to diagnose a child, adolescent, or adult, are the 
diagnoses outlined above adequate?  According to Saito et al. (2010), following a comparison 
of the two diagnostic systems, ‗the ICD-10 seems more sensitive to the mild range of the 
depressive continuum, while the DSM-IV seems to be more sensitive to the moderate and 
severe ranges‘ (p. 220).  Still, when using the DSM and less so the ICD, ticking off a set 
number of symptoms seems to be an overly simplified method of diagnosing.  If psychiatric 
disorders are acknowledged as highly subjective, it is counterintuitive to use strict numbers as 
a measure.  Indeed, the line separating ‗disordered‘ and ‗normal‘ individuals needs to be 
drawn somewhere, which is a markedly difficult task requiring classification of something so 
intangible and subject to constant amendment and redefinition.  Diagnosis as a tool can only 
be as effective as its measure.  Despite lacking the most accurate measure of psychiatric 
illness, a diagnosis should not be discounted.  As described above, the diagnosis does hold 
significance both to the physician and the patient.  However, while the care for most medical 
disorders benefits from diagnosing as a means to outline the treatment plan, perhaps those 
approaching psychiatric disorders should consider the treatment plan first in order to 
determine a suitable diagnosis.   
In theory, the diagnosis is made based on the symptoms, so it should match the 
appropriate treatment plan; yet, the match is not always as clear when treating psychiatric 
disorders.  Compare a testable infection such as streptococcal pharyngitis (strep throat) to a 
subjective psychiatric diagnosis such as Obsessive Compulsive Disorder (OCD).  The 
physician can say without reasonable doubt that the patient has strep throat based on a 
positive test for the bacteria causing the infection.  With the symptoms and positive test to 
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support the diagnosis, the physician will prescribe an antibiotic treatment, and most patients 
would recover in the following days.  Of course, there are cases that do not resolve as easily 
or that take a different course due to variability between individual patients, but such results 
are unusual and do not discredit the diagnosis overall.  On the other hand, a physician can 
diagnosis OCD based on symptoms exhibited by a patient, and will use this diagnosis in order 
to develop a treatment plan.  However, often patients experience comorbid psychiatric 
disorders, so there may be other less prominent disorders that are overlooked once the 
physician directs focus on the specific disorder of OCD.  It is also possible that the OCD 
tendencies exhibited by the patient are a symptom of an even greater disorder, such as a 
developing psychosis.  Particularly with psychological disorders, patients require very 
specific individualized treatment plans that are not easily directed strictly by diagnosis. 
 
2.4  What does it mean for a child to be ‘depressed’? 
 Given that both the ICD and DSM note the atypical presentation of depression in 
children and adolescents, how can depression be identified in this population?  The ICD does 
not clarify what to look for as an ‗atypical presentation,‘ which leaves the notion that the 
diagnosis as stated there is of little use when dealing with the paediatric population.  
Alternatively, the DSM is slightly more specific about the presentation in children and 
adolescents, but even so, suggestions made to identify paediatric depression, such as ‗irritable 
mood,‘ are much more difficult to distinguish from normal adolescent behaviour.  As stated 
earlier, depression, in line with other psychiatric disorders, is subjective in nature, and even 
the same symptoms may have different levels of impact from person to person.  Such 
variation is exaggerated in the paediatric population as this age group is still developing 
coping mechanisms.  Temperament at this age is constantly in flux as young people learn to 
deal with life in addition to hormonal and other physiological changes occurring.  As a result, 
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some children and adolescents may appear to struggle to cope due to out of control emotional 
expression, but will naturally overcome these challenges with time.  Others may appear to 
handle life stress with a more agreeable demeanour, but are actually unable to express 
internal turmoil due to limited juvenile ability to communicate.  Typically, the symptoms 
exhibited in adults are severe enough that a diagnosis of depression is made due to 
insufficient coping mechanisms necessary for dealing with life stress and/or other biological 
causes.  In children, on the other hand, it is difficult to determine if an individual‘s lack of 
appropriate coping mechanisms will develop over time or must be compensated by diagnosis 
and treatment. 
 
2.5  What are the prescription trends in the paediatric population? 
 Known for its overmedicated population, the US shows some interesting trends in its 
treatment of disordered youth.  There are a number of papers investigating these trends, one 
example being Rushton and Whitmire (2001).  The authors conducted a study describing 
paediatric prescription trends in the US from 1992 to 1998, specifically tracing prescriptions 
of Selective Serotonin Reuptake Inhibitors (SSRIs) and psychostimulants, which are the two 
most prevalent classes of medication in paediatric psychiatry and are commonly given for 
depression and ADHD, respectively.  This study included children in the North Carolina 
Medicaid Program between the ages of 1-19, and found that the number of prescriptions 
filled, number of patients treated, and percentage of children on medication all increased over 
the decade.  The prescription prevalence, which is the number of patients in a specific age 
group within the sample receiving a prescription, of stimulants in school-aged children (ages 
6-14) increased from 4.4% to 9.5% over the seven year study, while that of SSRIs increased 
from 0.2% to 1.5%.  Additionally, the study showed an increase of combining stimulants and 
SSRIs, which brings up serious concerns due to extreme lack of experimental data in 
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combining medications.  While SSRI treatment was relatively novel in the early 1990s, by 
1998 nearly one third of those children included in the study who were taking SSRIs were 
also prescribed stimulants.  Finally, this work also highlights age, sex, and racial differences 
that require further investigation.  While there was a slight increase in the mean age for 
stimulant prescriptions from 8.5 to 9.1 years old, that for SSRI prescriptions dropped from 
14.9 to 13.1 years old.  Gender differences in prevalence appear to be converging, though 
male stimulant prescriptions remain noticeably, and expectedly, higher than that for females.  
More concerning are the racial differences between prescription recipients.  Despite not being 
the majority of Medicaid patients, the white population notably received the majority of 
prescriptions for both stimulants and SSRIs; is this an indication of different mental health 
risks in different racial backgrounds, different values/stigma for seeking care, or an issue of 
access to care?  Further study is required to untangle this trend (Rushton & Whitmire, 2001).   
A particular concern has also been the increase in prescriptions for preschoolers, 
specifically stimulants, because this group is faced with such high off-label use.  Zito et al. 
(2000) published a now well-known study investigating prescription trends in 2- to 4-year-
olds through the years of 1991 to 1995 in a sample including multiple state Medicaid 
programs and a health maintenance organization (HMO) to gather data across age, gender, 
geographic location, and varying health care system groups.  Findings were similar to those 
found for older children and young adolescents, with significant increases in the number of 
prescriptions during the study period in the early 1990s.  These trends are alarming 
considering the significant lack of data for such young patients, leaving these patients at even 
greater risk than older children.  Preschooler stimulant use was the most prevalent 
psychotropic treatment in this age population, particularly methylphenidate (Ritalin).  The 
article cites the following possible reasons for the increasing trend in stimulant use: 
(1) a larger pool of eligible youths because of expanded  
diagnostic criteria for ADHD since 1980; (2) more girls being  
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treated for ADHD as evidenced by the narrowing of the gender  
ratio even among preschoolers; (3) greater acceptance of  
biological treatments for a behavioural disorder; and (4) the  
expanded role of school and preschool health personnel in  
identifying medical needs.  (Zito et al., 2000, p. 1028) 
While all plausible reasons, they also raise more questions and room for possible concern.  
Expanding the diagnostic criteria allows children to be diagnosed who may not have been 
treated in the past.  To what extent, however, do these newly included children need 
treatment and medication, presuming that they would have previously been considered 
borderline cases?  Diagnosing more girls highlights similar concerns; what is allowing the 
gender gap to narrow?  Is it the expanded diagnosis?  Are clinicians better able to recognize 
symptoms, particularly how they may present differently between genders?  Turning to 
biological treatments for behavioural disorders can be incredibly effective to the patient.  At 
the same time, connections between biology and behaviour, as well as biological mechanisms 
of these medications themselves, remain widely unknown.  While the noted benefits 
encourage treatment use, such treatments should also be approached with caution.  
Comparable results were found with antidepressant treatment, which ―were the second most 
commonly prescribed psychotropic class of drugs for preschoolers‖ (Zito et al., 2000, p. 
1028).  Tricyclic antidepressants (TCAs) proved to be the most prevalent of this class, but 
during this period the trend began shifting toward SSRI use (more so in Medicaid groups than 
HMOs), mirroring previous trends in older populations.  In general, differences found 
between geographic regions as well as health care systems may be attributed to such factors 
as state policies and access to care, including who is eligible for Medicaid services, training 
of and assessment by professionals working with children in different regions, and 
sociocultural variations, including economic, ethnic, and cultural value differences. 
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  As Rey, Walter and Hazell (2000) in Australia point out, preschool prescriptions are 
a worldwide problem with serious ethical implications.  Highlighting six major concerns that 
arise when treating preschoolers, the authors state: 
Firstly, with few exceptions, in most countries these  
medications are not approved for use in the very young.   
Secondly, there are very few controlled data showing whether  
they are effective in this age group.  Thirdly, psychiatric  
diagnoses in preschoolers generally lack validity and reliability 
[...] Fourthly, there is little knowledge and considerable  
apprehension about the long-term effect of psychotropics on the  
developing brain.  Fifthly, there are scarce data about the  
pharmacokinetic and pharmacodynamic characteristics of these  
drugs in the very young.  Finally, rather than placing the best  
interests of the child first, some practitioners may react to  
pressure from preschools, childcare services or parents. [...]  
The problem is magnified if the child is reviewed infrequently,  
as seems the case for many of those taking stimulants.  (Rey,  
Walter & Hazell, 2000, p. 172) 
 
Over all, these concerns broadly extend to older children and adolescents.  Though more 
safety and efficacy data do exist for older paediatric populations, this knowledge base 
remains significantly limited.  A key issue in the lack of data is due to ethical concern, which 
creates a ‗vicious cycle‘ (Rey, Walter & Hazell, 2000, p. 173).  Treatments are often 
prescribed off-label due to the lack of research done for this particular population.  However, 
carrying out many studies in this vulnerable population is ethically problematic, as well.  
(This issue will be further addressed in Chapter 5.)  Rey, Walter and Hazell (2000) suggest 
improved education in paediatric psychopharmacology and particularly in alternative 
treatments, rather than simply tighter control of prescriptions. 
 
2.6  What information is provided to the public about antidepressant use in children? 
 As data is gradually becoming available, particularly over the past ten years, the NHS 
in the UK, in accordance with the European Medicines Agency (EMEA), and the Food and 
Drug Administration (FDA) in the US have issued recommendations for antidepressant use in 
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children.  The NHS outlines for public access the three different generations of antidepressant 
medications, monoamine oxidase inhibitors (MAOIs) and TCAs (first generation), SSRIs 
(second generation), and serotonin-norepinephrine reuptake inhibitors (SNRIs) (third 
generation).  The safety information provided clearly states that antidepressant use in children 
under the age of 25 has been correlated with increased suicidality, referring to suicidal 
thoughts and attempts, in the first few weeks of treatment (NHS, 2010a).  Included in the 
‗caution‘ information, the NHS notes that all three types of antidepressants are not usually 
recommended for use in children, with the exception of the SSRI fluoxetine (NHS, 2010b).  
This recommendation follows a statement made in 2006 by the EMEA that it is safe to give 
children fluoxetine if they are over the age of eight (Lancet, 2006).  Further, the NHS 
recommendations are outlined for clinicians in the guidance presented by the Committee on 
Safety of Medicines (CSM) and the National Institute for Health and Clinical Excellence 
(NICE) in 2005, which resulted in the majority of UK clinicians opting to prescribe 
fluoxetine as the antidepressant of choice.  Despite the recommendation for psychotherapy 
first and prescribing practices described in this guidance as second-line treatment, there is a 
noticeable discrepancy between the guidance and actual practice (Shearer & Bermingham, 
2008; Haw, James & Gralton, 2010).  The majority of clinicians continue to prescribe 
antidepressants for most moderately to severely depressed paediatric patients, and want to see 
revisions in the guidelines to include other SSRIs that may be as safe and beneficial as 
fluoxetine, such as citalopram and sertraline, which are also commonly prescribed to 
paediatric patients in the UK (Haw, James & Gralton, 2010). 
Following a meeting of the Psychopharmacologic Drugs Advisory Committee and the 
Pediatric Advisory Committee on 13-14 September 2004, the FDA sent a letter to 
pharmaceutical companies on 15 October 2004 requesting a label change for antidepressants 
to include a black box warning noting increase risk of suicide in children and adolescents 
25 
 
(FDA, 2010a).  A list of drugs requiring this updated box warning, product label, and 
medication guide was printed on 3 February 2005 (see Appendix C).  The FDA produced a 
revised product label on 2 May 2007 to be inserted into all antidepressant prescription 
packages.  The new label extended the black box warning to include adults under the age of 
24, and is the most recent information available (FDA, 2010b).  Included on the revised label, 
the FDA states that fluoxetine (Prozac) is the only FDA-approved treatment for paediatric 
depression.  Further, the use of fluoxetine, sertraline (Zoloft), and fluvoxamine (Luvox) are 
approved for OCD treatment.  All other antidepressants are not FDA-approved for use in 
children (see Appendix D for full product label; FDA, 2010c). 
 
2.7  What major ethical issues arise in psychiatric care of children and adolescents?  
In the US, the American Psychiatric Association published the Ethics Primer to 
provide a useful reference for typical ethical issues that present themselves in psychiatric 
practice.  The chapter regarding child, adolescent, and family treatment calls attention to the 
following major issues relating to this thesis: informed consent, psychopharmacology, and 
confidentiality (Arroyo, 2001).   
In treating children, ‗consent‘ generally falls to the parents until the patient is 18 years 
of age, with few exceptions, as it refers to the legal permission to treat.  The approval of the 
treatment by the child patient, then, comes in the form of ‗assent,‘ which is not to be 
discounted even though it is not a legal requirement.  To consent, and by extension assent, 
means to agree that the patient has been provided with all the necessary information 
concerning the proposed treatment, potential risks and benefits, and any alternatives.  In fact, 
inclusion and compliance on the part of the child patient becomes increasingly important as 
the child gets older, taking more responsibility for their own care and nearing the transition to 
requiring their own consent.  In the US, exceptions to parental consent for minors come in the 
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form of child emancipation, legal custody issues as related to divorce, foster care, emergency 
care, and specific procedures as indicated by state legislation. 
Particular attention needs to be given to psychopharmacology in the paediatric 
population.  With considerable lack of child-specific data for indications, risks and benefits of 
psychotropic drugs, psychopharmacological treatment should be taken with caution.  The 
major aspects of concern here are developmental differences, that is physiological differences 
across the different stages of development, metabolic and toxic vulnerability differences 
between children and adults, long term effects of a treated versus untreated mental disorder, 
stigma during an age of identity development, and compliance with parental administration or 
self-administration of the drugs, especially during adolescence. 
Confidentiality is another significant ethical issue in psychiatry which is further 
complicated when working with children and adolescents.  In order to provide the most 
effective care, the patient must trust the physician, and this trust relies heavily on the 
physician keeping the patient‘s consult confidential.  As a major issue in adult practices, the 
physician needs to make it very clear to the patient from the beginning of the consult that 
confidentiality will be kept except when absolutely necessary to include third parties, such as 
insurance claims, disclosures that threaten harm to others or the patient him or herself, or 
indications of child abuse.  Where paediatric patients are involved, full confidentiality is 
hampered by the presence and/or inclusion of parents in the consult and treatment plan.  
Particularly by adolescence, paediatric patients may become less willing to disclose sensitive 
information when they know that their parents will be accessing this information; this is less 
of a dilemma with very young patients, as the young children are typically willing and 
wanting to disclose details to their parents about what they discuss with the physician. 
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2.8  In summary, what are the ethical concerns in regards to the development of 
paediatric diagnosis and care, particularly paediatric depression? 
 As paediatric care is relatively novel in psychiatry, a number of aspects should receive 
significant attention when addressing depressed children and adolescents.  Firstly, it is 
important to note the difference in treating a child patient versus an adult.  Including the 
parent in the administration of care to the child raises the issue of what information gets 
extended to the parent.  In general, the parent should be provided with all information 
required to make appropriate decisions in regards to the child‘s treatment because the parent 
must provide consent.  However, inclusion of the parent also interferes with doctor-patient 
confidentiality, and particularly with adolescent patients, this may create difficulty in 
developing rapport with the patients if they know everything said between the doctor and 
patient will also be shared with the parent.  Further, in terms of child off-label psychotropic 
use, informed consent is complicated by the doctors withholding the extent to which the risks 
of such treatment are unknown in the paediatric population, as noted by Shearer and 
Bermingham (2008). 
 In terms of the diagnosis itself, this systematic label continues to evolve.  Neither the 
DSM nor the ICD are flawless systems to identify depression even in adults.  Using one 
system versus the other may result in individuals receiving a slightly different diagnosis or 
none at all, specifically in regards to various severities of the disorder.  Additionally, 
considering the limited paediatric clarifications included in the diagnostic description of 
depression, this raises the question of whether either of these systems provides adequate 
diagnostic criteria for the paediatric population in particular.  Due to the subjective nature of 
psychiatric diagnosis (to be discussed further in Chapters 3 and 4), systematic classification 
cannot be perfect, so diagnosis may be approached with a certain degree of scrutiny.  As both 
the DSM and ICD undergo future revisions towards a more dimensional rather than 
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categorical approach, hopefully the paediatric diagnosis of depression will become 
increasingly accurate. 
 Following diagnosis, treatment and availability of information, especially in regard to 
psychopharmacology, is concerning at present.  Despite a lack of long term safety and 
efficacy data, prescription rates continue to increase significantly.  The issue, however, is the 
vicious cycle referred to by Rey, Walter and Hazell (2000), in that it is ethically problematic 
both to treat without the availability of safety data but also to conduct extensive paediatric 
drug research.  As more data is presented, trends may change, as reflected in SSRI 
prescription prevalence following suicide warnings presented over the past decade in both 
Europe and the US.  Until there is a better understanding of what the long term effects of 
psychotropic treatment are in paediatric application, it should be delivered with caution; 
however, this is complicated by the observed short term benefits of treatment experienced by 
many disordered children and long term data presented in adult studies (this topic will be 
covered in further detail in Chapter 5). 
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CHAPTER 3 
What is disorder and what is normal?: A philosophical 
perspective 
 
 
3.1  Why is a diagnosis important? 
 The previous chapter discussed how diagnoses are made and what it means to be 
given the diagnosis of paediatric depression.  Aside from the mentioned necessity for 
developing a treatment plan and obtaining insurance coverage, as discussed in Chapter 2, 
what is meant to be accomplished by psychiatric diagnosis and treatment?  According to the 
Oxford specialist handbook for Child and Adolescent Psychiatry, a psychiatric diagnosis 
serves to ‗collect and organize information collected at assessment‘, ‗to guide treatment 
planning‘, and ‗to inform about prognosis‘ (Coghill et al., 2009, p. 6).  The handbook 
describes the use of diagnosis and its categorization, matching the discussion of diagnosis in 
the Hastings Center Special Report on Troubled Children: Diagnosisng, Treating, and 
Attending to Context (Parens & Johnston, 2011).  Despite the acknowledgment in the DSM-
IV that psychiatric disorders are dimensional, describing a continuum of behavioural 
symptoms, diagnoses are categorical based on the presence of an arbitrary number of 
symptoms (Coghill et al, 2009; Parens & Johnston, 2011).  This clinical judgment whether to 
diagnosis a patient with a specific disorder or not is based on a categorical system that ‗was 
chosen to maximize the chance that an individual meeting these criteria will be suffering 
from impairment as a consequence of their [...] symptoms, and that these symptoms and 
impairments will respond to treatment‘ (Coghill et al, 2009, p. 6).  Therefore, a diagnosis is 
generally made in order to identify and treat an impairment that is presumed to hinder 
everyday life.   
However, diagnoses are heavily influenced by social and cultural values and 
expectations (Singh, 2002; Singh, 2008; Parens & Johnston, 2011).  Is it possible that not all 
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unusual behaviours need to be corrected, even if they lead to a different way of life?  Does 
the resulting ‗abnormal‘ lifestyle mean that the quality of life will be damaged?  Diagnosis 
and treatment attempt to improve quality of life, but like diagnosis itself, quality of life is also 
subjective.  The extremities of impairment and quality of life are less subjective; it is clear 
when individuals have a very good or very poor quality of life, but between the two is more 
ambiguous, as are the benefits of diagnosing mildly impaired individuals or not, as discussed 
by Parens and Johnston (2011).  Individuals are satisfied with different levels of comfort, 
both physical and psychological, and often ‗impairment assessments are [...] not always 
included in diagnostic work-ups‘ (Parens & Johnston, 2011, p. S10).  Additionally, some 
discomfort does not always require treatment, but is part of the human experience.  So when 
does discomfort become a disorder? 
 For adults, it is relatively more clear when discomfort should be classified as a 
disorder than for children, in part because adults may have a greater ability to process and 
articulate their experiences, and also because children‘s behaviour and mood changes as they 
continue to develop.  Keeping these ideas outlined by Parens and Johnston (2011) in mind, 
while the boundary between disordered and not may still be slightly blurry in some particular 
cases, on the whole a disorder can be identified due to an individual‘s inability to perform 
necessary everyday functions.  In such a way, those adults who may have ‗abnormal‘ 
tendencies that actually contribute to their occupation or lifestyle are not ‗disordered‘ but 
simply eccentric compared to the ‗average‘ person (Groopman, 2000).  Rather than 
interfering with daily functions, certain oddities in adults may facilitate a chosen occupation; 
for instance, obsessive tendencies may be appropriate in strictly regimented jobs but not in a 
less structured work environment, whereas unconventionality may be fitting in contemporary 
art but not in very ordered settings.  In an article published in The New Yorker, Groopman 
(2000) describes a group of colleagues discussing their own obsessive compulsive tendencies.  
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These individuals‘ obsession with perfection and thoroughness is well suited for their work in 
a research lab or medical facility where such care to every procedure, safety measure and 
organization is a valued skill.  However, such behaviours may only come to be helpful and 
appreciated once the individual finds him or herself in an occupation that encourages such 
behaviours.  Life leading to this occupational niche may leave the individual struggling to fit 
in and make success more difficult in this early environment of primary education and other 
youth activities, where the individual‘s differences are not so easily accepted and even 
frowned upon, as the group goes on to discuss how such behaviours in today‘s children are 
often medicalised and treated. 
 This early struggle is one of the difficulties in identifying disorders in children.  A 
diagnosis is made when the individual cannot normally function; however, at an age when 
‗normal‘ functioning is seen only as mainstream abilities, children who are merely ‗different‘ 
become identified as requiring closer psychological examination and diagnosis.  There will 
be a greater divide between those who are successful in the mainstream environment and 
those who are not in this population.  During childhood and adolescence, individuals are still 
developing coping mechanisms, so those who are struggling will demonstrate even greater 
difficulty until they learn how to manage with adversity.  Both developing adequate coping 
skills and finding a more appropriate environment take time and experience, and expecting 
children to automatically either adjust or seek treatment is too simplistic. 
 There are cases, however, of genuine paediatric disorders that should not be 
discounted as simple discomfort regardless of whether they will be overcome naturally with 
time due to significant impairment experienced in the present.  The difficulty lies in 
determining the severity needed to warrant treatment, which possibly includes medication.  
Since the baseline for a child‘s ability to function is largely academic performance and social 
inclusion, certain individuals may present as disordered based simply on context, while others 
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would find difficulty anywhere.  The former might present as a child who does poorly on 
schoolwork, shows little interest in participating in activities with other children during and 
after school, and appears to have few if any friends.  The latter might present as a child that 
often refuses to leave the house and suffers extreme, debilitating anxiety when forced to do 
so, for example.  In the first, albeit an unpleasant experience, the child is struggling but not 
unable to perform necessary daily activities, whereas the second child cannot function.  It 
may be beneficial for the first child to receive some non-invasive treatment, such as 
psychotherapy or enrolling in a more specialized or smaller school program, but the second 
child may require more intense treatment, such as psychotherapy and medication.   
Nevertheless, all cases will not be this clear, and any obvious divergence from the 
norm often raises red flags and causes teachers to suggest and/or parents to seek psychiatric 
consultation (Parens & Johnston, 2011).  Theoretically, physicians will not medicate children 
who are simply not adjusting to a conventional lifestyle or succeeding in expected ways, in 
academic or social settings for example, but there is an argument for treating these children 
presenting with less severe symptoms, as they are experiencing discomfort that interferes 
with their ability to live a more enjoyable life, which in turn affects their mental health
2
.  In a 
commentary on cognitive enhancement by Greely et al. (2008), the authors note that once the 
child comes in for a consult, the issue of the role of the physician arises: do physicians only 
heal patients or do they help their patients live better lives?  While there is certainly overlap 
between these two roles, they are not always the same.  The preference may lie with the 
physicians themselves as they decide which patients should receive treatment, as in the US 
for instance, or the decision to treat may depend on the policy of the greater health care 
system, such as the NHS which only treats notable impairment. 
 
                                                 
2
 According to the WHO, ‗Mental health is defined as a state of well-being in which every individual realizes 
his or her own potential, can cope with the normal stresses of life, can work productively and fruitfully, and is 
able to make a contribution to her or his community‘ (WHO, 2009). 
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3.2  What is trying to be accomplished through the diagnosis and treatment of 
paediatric depression? 
 Treating any psychiatric disorder often only addresses the presentation of symptoms 
of the disorder, not the cause.  This approach reflects a diagnostic system based on 
behavioural assessment that lacks applicable physiological tests (Singh, 2008; Parens & 
Johnston, 2011).  At present, psychiatric symptoms present as manifestations of causes not 
readily identifiable or understood, as research indicates that ‗psychopathology results from 
exceedingly complex and ever-changing interactions among biological and environmental 
variables‘ (Parens & Johnston, 2011, p. S6).  There are many biological and genetic markers 
that may indicate the presence of psychiatric disorder, but such indicators are not always as 
they would suggest.  That is to say, the presence of these biological indicators are often 
linked to a particular psychiatric illness, but sometimes the biological symptoms are present 
without a psychiatric dysfunction, just as psychiatric disorders may exist without the 
expected biological symptoms. 
 Assuming, then, that treatment will not cure a psychiatric illness, a diagnosis serves as 
an identifier of the symptoms that need to be treated.  Parens & Johnston (2011, p. S17) 
indicate that ‗many medications used in pediatric psychiatry [...] reduce the severity of 
symptoms, or even eliminate them, but they do not ―repair‖ the underlying causes of those 
symptoms.‘  Therefore, diagnosing a child or adolescent patient with depression, for example, 
indicates that the patient has identifiable and treatable symptoms that may be treated by 
antidepressants and/or appropriate psychotherapy in order to alleviate the symptoms.  Based 
on this projected treatment plan, these symptoms may be linked to the criteria of ‗depression,‘ 
yielding the ‗paediatric depression‘ label for the patient.  However, this treatment will not 
cure the cause of depression, which may be rooted in a complex interaction between biology 
and environment (Parens & Johnston, 2011). 
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 Referring back to the role of physicians now, if there is no cure, then psychiatrists can 
only help their patients live better lives, not heal their patients per se.  Consequently, the 
question for physicians becomes not ‗to help or to heal?‘ but ‗who gets help?‘ and this raises 
difficult issues about which treatments actually help, particularly in regards to medication, 
and issues about those ambiguous cases that may or may not be serious disorders.  These two 
issues are closely related, as well.  With scarce longitudinal safety and efficacy data for use of 
most psychotropic drugs in the paediatric population, the long-term effects of taking these 
prescriptions in childhood is widely unknown, and as such, it is difficult to assess whether the 
benefits of these drugs for treating psychiatric symptoms will outweigh potential long term 
risks, particularly as these medications are often prescribed off-label (Shearer & 
Bermingham, 2008; Singh, 2008; Parens & Johnston, 2011).  The decision to medicate the 
most severe cases is often agreed upon among clinicians as an appropriate method of 
treatment.  In contrast, whether to medicate more mild cases of psychiatric disorders and 
arguably normal children is an ethical dilemma of overwhelming dispute.  In the case of 
depression, this begs the question of whether or not to give antidepressants to children and 
adolescents who suffer from mild depression or depressive symptoms.  Presumably, these 
children could likely benefit from medication in the present, but are their experiences and 
impairments so far out of the normal experience to warrant taking risks that could bring 
potential unforeseen harm in later years?   
 
3.3  What is normal? 
 As mentioned above, reason for concern arises when a child does not appear to be 
‗normal.‘  Western society has an obsession with ‗normal‘ that pushes psychiatric care in two 
directions.  The first is the desire to normalize ‗abnormal‘ individuals, and the second is the 
desire to enhance ‗normal‘ to improve those who already exhibit healthy mental status 
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(Singh, 2002; Parens & Johnston, 2011).  Before discussing the implications of these 
directions, ‗normal‘ must first be understood.  Based on the work of Parens and Johnston 
(2011) and Singh (2002), and akin to disorder, normal is a subjective social construct and 
thus is culturally dependent.  It may be deduced that in this context, a normal person is an 
individual who has the common and/or average ability to function in mainstream society 
and/or a specific societal niche.  Normal may be approached as the opposite of disorder and 
the lack of diagnosis. 
Within the paediatric population, normality is measured by such indicators as 
individuals‘ academic abilities, interest in activities, social interactions, general mood, motor 
skills, and eating and sleeping habits (Carey, 2011).  Adult normality may be determined 
based on similar components, but also has the added context of occupation, ambition, and 
comprehension of surroundings.  While adults have the opportunity to find an appropriate 
occupation that may complement their way of thinking and functioning to provide a suitable 
context, children are limited to school and home life; there are only two mainstream measures 
of normality for children, whereas there are countless contextual and occupational measures 
of adult normality.  For the average child, success falls well within the realm of possibility in 
the school setting, but for an abnormal child, the same environment is more of an obstacle 
than a means to success. 
 
3.4  What does it mean to ‘medicalise normal’?  
 By treating individuals for a medical condition that could otherwise conceivably be 
‗normal‘, a trend of ‗medicalisation‘ of normal has appeared in modern medicine, a 
classification that is often followed by associated medication treatments.  What has been 
considered within the realm of ‗normal‘ life experience in the past is becoming medically 
classified and treated (Parens & Johnston, 2011).  As described by Peter Conrad in a sidebar 
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of the Hastings Center Special Report (2011), this expansion of medical jurisdiction shifts the 
causes of any difficulty in life toward internal disorder of the patient rather than the influence 
of external context and environment.  This idea suggests that removing context from 
psychiatric disorder is excluding a significant factor of mental illness, and becomes a 
classification of an individual‘s ability to cope and behavioural tendencies while discounting 
the experiences that are producing these responses.  As described above, normality is relative, 
and without consideration of environment, any response to life experience could in theory be 
subject to medicalisation and treatment in order to adjust toward a preferred ‗normal‘ 
behaviour.  Further, if this medicalisation is based solely on the individual, then the treatment 
will only address the internal symptoms, disregarding the possibility of a needed change in 
the environment (Shearer & Bermingham, 2008; Conrad, 2011). 
Particularly for children, who are still developing, medicalisation requires a closer 
look.  Young brains are in the process of developing, and individual responses to this process 
may present as noticeable changes in psychological state, which are reflected in mood and 
behavioural changes that may or may not continue to develop over time into a more 
recognised ‗normal‘ state.  As explained by Parens and Johnston (2011, p. S10): 
Determining whether a given child‘s moods and behaviors are  
intense enough to be labeled disordered is further complicated  
by the fact that, as still-developing organisms, their moods and  
behaviors can be very different from those we see in adults and  
can vary greatly depending on the age of the child (it may be  
normal for a four-year-old child to talk with an imaginary friend,  
but not for a fourteen-year-old or an adult).   
As it would seem, in the process of brain development, it is possible that the issue truly is 
internal, as medicalisation assumes, but classifying this ‗abnormal‘ behaviour and prescribing 
treatment may not necessarily be the appropriate action.  However, just as long term effects 
of treatment are unknown, perhaps long term effects of no treatment should also be a 
concern.  For disorders such as ADHD, Lahey et al. (2004) show that failure to provide 
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treatment often results in continued impairment.  In regards to depression, Licinio and Wong 
(2005) note that, while unmonitored antidepressant use puts children at risk of suicide, so too 
does untreated major depression.  Further, Shearer and Bermingham (2008, p.710) suggest 
that ‗[social] withdrawal, low self-esteem, substance abuse, self-harm, early pregnancy, 
academic failure and an increased risk of depressive episodes in the future‘ may result if 
depression in children goes untreated.  It is difficult to discern if a young patient has the 
potential to improve with time as he or she develops appropriate coping mechanisms, or if the 
experienced struggles are too extreme to de-escalate naturally.   
Regardless of whether an individual can or cannot naturally overcome psychological 
distress, though, anyone can benefit from help in times of suffering or difficulty, even 
‗normal‘ individuals (Singh, 2008; Parens & Johnston, 2011).  In this sense, medicalisation 
should not be avoided absolutely, just approached with caution.  Motivation of medicalisation 
requires some inspection.  Is the aim of treatment to achieve ‗normality‘?  Or taking 
medicalisation even further, is ‗normal‘ being diagnosed and improved?  And if so, what is 
the issue with improving what is already normal?  
 
3.5  Why medicalise as a means toward achieving normality? 
 In accordance with the physician‘s role to help patients live better lives, as noted 
above, the aims of psychiatry may be split into two subcategories.  One is to treat patients in 
order to approach normality.  The intention is to facilitate an easier adjustment to normal 
expectations, such as academic and social development.  Even when an individual is not 
suffering from severe symptoms, care providers want to provide any amount of support 
necessary to help the child achieve their greatest potential (Singh & Kelleher, 2010; Parens & 
Johnston, 2011).  Based on this notion, it is ideally assumed that this desire to fulfil potential 
is a common goal, and that both the parent and particularly the child patient are seeking 
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success within conventional standards to which he or she is confined.  Therefore, in theory, 
this attempt to be ‗normal‘ does not need to be permanent; presumably, it is only necessary 
insofar as the child is restrained to the mainstream environment.  After this time, the choice to 
be normal may or may not be as relevant depending on the values of the patient and his or her 
needs to achieve an acceptable quality of life and success, again subject to the values of the 
patient.  Thus, success within mainstream society in early life often serves as a means to 
achieve success in the broader spectrum of environments later in life that will follow the 
generalised early education. This concept is reflected in the discussion by Groopman and 
colleagues described above; once an individual has completed early education, where 
abnormal tendencies may hinder more than help, these same tendencies can actually be a 
valuable attribute for a desired occupation (Groopman, 2000).  But before such an occupation 
can be possible, the individual must be capable of succeeding to some extent within the 
educational system, which may be allowed through the implementation of medical treatment.  
Therefore, the idea of correction toward normal in this way is a more accepted aim of 
psychiatry.  It is more closely aligned with the concept of medicine that treats a problem.  
However, given the ambiguous distinction between disordered and normal, Western culture, 
in particular, is shifting treatments toward enhancement purposes.   
 
3.6  Why medicalise normal individuals for enhancement purposes? 
 The second and more ethically challenging aim of psychiatry is treating ‗normal‘ 
individuals.  These patients are capable of functioning within the mainstream environment 
without medical treatment, and do succeed in this context to varying degrees.  Medicalising 
normal in this way is not treating a problem, but rather is enhancing present abilities, 
manipulating consciousness to a certain extent through the use of psychotropic medication, 
hence labelling this treatment ‗neuroenhancement‘ (Singh, 2008, p. 962; Singh & Kelleher, 
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2010, p. 4) or ‗cognitive enhancement‘ (Greely et al., 2008, p. 702; Farah et al., 2009, p. 
541).  Enhancement implies that the desired effect is not correcting for deficiencies or 
atypical behaviours; instead, it is a means of improving normal functioning further than the 
individual is able to achieve alone.  In other words, treatment is not necessary, but it can still 
advance the patient‘s quality of life and ability to function.  Generally, these patients are 
those that may exhibit more minor symptoms of a disorder, which act as barriers to achieving 
their highest potential, so the patients and/or parents attempt to remove these obstacles by 
seeking treatment (Singh, 2002; Singh & Kelleher, 2010). 
 Currently, the predominant practice of cognitive enhancement in the paediatric 
population is the prescription of neurostimulants, such as Ritalin or Adderall, which are 
typically used to treat ADHD, but also show enhancement qualities pertaining to focus and 
attention in non-disordered individuals (Greely et al., 2008; Singh & Kelleher, 2010).  
Increasing neurostimulant enhancement trends are also found in the adult population, as a 
means to stay alert in shift work, military service, and within the academic setting to assist in 
particularly intellectually challenging projects or jobs (Sahakian & Morein-Zamir, 2007; 
Greely et al., 2008). Proponents of cognitive enhancement prescriptions have equated such 
treatment to any other form of enhancement.  Not unlike exercise, healthy diet, vitamin 
supplements, sleep, education, tutoring, and other brain-stimulating activities such as reading 
or music learning, any sort of cognitive enhancement, medicalised or not, will produce 
changes in the brain (Greely et al., 2008; Singh & Kelleher, 2010).  In the commentary by 
Greely et al. (2008, p. 703), the authors state, ‗Three arguments against the use of cognitive 
enhancement by the healthy quickly bubble to the surface in most discussions: that it is 
cheating, that it is unnatural and that it amounts to drug abuse.‘  The cheating issue is difficult 
to address because there are no set rules to indicate what is and is not ‗allowed,‘ and if rules 
did exist, particularly in the academic setting, how would they account for other 
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enhancements such as caffeine, computer and internet access, hiring of private tutors, etc, 
which are providing significantly improved learning capabilities and are similarly unnatural 
(Greely et al., 2008)?   Singh and Kelleher (2010, p. 4) suggest that in time ‗the acceptance of 
drug delivery techniques will normalize, as more and more people choose to take these 
drugs,‘ so this form of enhancement will not stand out as any more unnatural than the other 
methods mentioned.  Further, these drugs are regulated for safety purposes, so if such 
regulations are followed abuse should not be a worry (Greely et al., 2008).  The motivation to 
medicate in this context, then, is not unlike any other measures taken to aid intellectual 
development and academic achievement. 
 
3.7  What additional ethical considerations arise when medicating normal children? 
 Based on the arguments above, medicating normal children, that is cognitive 
enhancement, is not entirely different than other aids in the benefits that it could provide 
individuals.  On the other hand, there are other serious risks and ethical concerns that are 
distinct about medicating otherwise normal children and adolescents.  Greely et al. (2008) 
highlight three major considerations, safety, freedom, and fairness, which mirror similar 
concerns raised in regards to neuroenhancement of adults, as well (Sahakian & Morein-
Zamir, 2007).  For children, whose brains are still in the process of developing, giving them 
psychotropic drugs which will significantly alter brain chemistry can cause unforeseen effects 
both at present and later in life (Singh & Kelleher, 2010).  Furthermore, the effects that 
psychotropic medication has on disordered versus normal brain development may be 
significantly different, as well, due in part to different dosing and to variation in 
neurophysiology.  In their discussion on neuroenhancement, Singh and Kelleher (2010) 
identify this as an issue in regard to methylphenidate enhancement noting:  
There are likely to be different implications of treatment use of 
methylphenidate and enhancement use of methylphenidate for  
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the developing brain.  This is because dosing practices for these  
two different uses of the drug will likely differ, with  
enhancement doses focused on short-term events and treatment  
emphasizing ongoing use over long periods; in addition, pre- 
existing structural and functional variations in the brains of  
those diagnosed with a clinical disorder as compared to  
undiagnosed persons may mediate the impact of  
methylphenidate on the developing human brain. (p. 6) 
The long term data for use of these medications in children is still fairly limited even in 
severely disordered children.  While such treatments may possibly be safe to use in children, 
both prescribed at a young age and/or over a long period of time, until there is significantly 
more data to prove such safety, the question becomes is it worth unknown risks in children 
that are essentially normal (Shearer & Bermingham, 2008)?  (Physiological concerns will be 
addressed further in Chapter 5.)   
Freedom, the second concern raised by Greely et al. (2008), needs to be considered, 
particularly in regard to coercion.  The authors suggest that if cognitive enhancement 
becomes the norm, then individuals may feel that they have to seek medication to compete 
with their peers.  This idea implies that even if individuals theoretically have the choice to 
either medicate or not, they will be pressured to medicate in order to be on the same level as 
their medicated classmates.  Moreover, children are not free to make their own medical 
decisions, so they are left to their parents‘ decisions.  Parents may be pressured by the general 
desire to see their children succeed, but also to fulfil the cultural construct of a ‗good parent.‘  
In the words of Singh and Kelleher (2010, p. 9), ‗cultural notions of ―good mothering‖ place 
a burden on mothers in consumer-driven Western societies to access and exploit all available 
resources to ensure a young person‘s success.‘  Such resources could include cognitive 
enhancing drugs, e.g. neurostimulant, and if these enhancement practices do become normal 
practice then withholding psychotropic resources will be viewed as restrictive (Singh & 
Kelleher, 2010). 
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With competition as a driving force to medicate, fairness becomes an issue.  Greely et 
al. (2008) explain that if the enhancement is temporary, boosted performance is an unfair 
advantage of taking medication, whereas long term enhancement could be more comparable 
to other non-medical resources used for enhancement to improve learning.  The authors 
equate the use of short-term enhancement to allowing some students to use a calculator on a 
maths exam while others cannot; in such a case, comparing those with enhancement to those 
without is not a fair measure.  Based on this argument, if enhancement was a more long-term 
aid, an individual‘s performance would better reflect actual competency as the medication 
would improve overall learning abilities, not simply the direct effects of a drug that would 
allow one to learn a specific task or piece of information.  However, most research suggests 
that stimulants, at least, show short-term, not long-term, improvements (Singh & Kelleher, 
2010; Parens & Johnston, 2011).  Therefore, it would seem unfair to allow the use of 
neurostimulants unless everyone had access to this resource.  At present in the U.S., 
‗prescription rates vary by race/ethnicity, religion, gender, and socioeconomic status‘ (Singh 
& Kelleher, 2010, p. 9), trends which appear indicative of different social influences across 
these varying demographics.  Since the choice to medicate could interfere with sociocultural 
values, even fair access could also be tied back to coercive influences on freedom as 
discussed above.  As a result, depending on its accessibility, costly medication may further 
splinter socioeconomic classes, yielding an increasingly advantaged wealthy class (Greely et 
al., 2008; Farah et al., 2009).  Though, if distribution did become more even, then issues of 
the upper limits of human capacity and threshold for disorder and/or disability would alter 
significantly, skewing concepts of normality even further (Singh & Kelleher, 2010).  
Therefore, being human would no longer be enough; one must medicate to be successful in 
the enhanced society.  
43 
 
Another ethical issue suggested by Farah et al. (2009, p. 542) is ‗the effect of 
cognitive enhancement on what could be called ―cognitive style.‖‘  This concept is referring 
to the way people think.  Enhancement has been addressed as a means of improving patients‘ 
ability to think clearly, but does treatment also affect what an individual thinks in addition to 
how well he or she processes thought?  This questions whether a medicated brain actually 
changes the thoughts themselves, as indicated by creativity for instance, which is defined as 
‗the process of accessing seemingly irrelevant or unrelated information in ways that serve a 
purpose or solve a problem‘ (Farah et al., 2009, p. 542).   But why should it matter if 
medication changes thought?  The authors suggest that this change would create negative 
societal effects, resulting in ‗less creativity in our workforce and in our leaders‘ (Farah et al., 
2009, p. 542).  Though what do they mean by this, and is this assumption too pessimistic?  
Based on the definition given above, creativity would seem an essential element of progress, 
so if modern industry and leadership became lacking in creativity, as Farah et al. suggest, 
then novel solutions to current and forthcoming issues may become less productive, stunting 
improvements in business, politics, society, and culture.  However, the results of this study 
indicate that there is ‗no evidence of a general impairment‘ (Farah et al., 2009, p. 546), and 
even an improvement was shown in less creative individuals.  There was only a concern 
raised regarding the lowered convergent creativity, which is making associations between 
elements of provided information, in highly creative individuals, suggesting that similar to 
the effects on cognitive abilities, neuroenhancement may actually impair high ability 
individuals.  Given that overall, there is no impairment of creativity, and further, a possibility 
of improved creativity in previously less creative individuals, the research would actually 
seem to suggest a more collective positive societal effect if enhancement becomes normal 
practice, despite the negative effect on the most creative individuals. 
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3.8  How might cognitive enhancement relate to antidepressant use? 
In the adult population, there has been a notable trend over the past couple decades of 
antidepressant enhancement use, especially with Prozac (fluoxetine).  Paralleling, and 
perhaps fuelling, medicalisation, which has increased the number of diagnosable disorders 
and associated drug treatments, extended indications of Prozac for enhancement purposes 
allows a new way to describe, categorise, and evaluate individuals and life experience 
(Elliott, 2004).  Parens (2004) comments that those people who are able to help individuals 
struggling to achieve a ‗normal‘ life, disordered or not, should provide such relief when 
possible, even if medicalisation is a cultural problem, because ‗people who suffer want and 
deserve relief‘ (p. 26).  Prozac, and presumably other similar drugs, allow suffering 
individuals to regain a sense of autonomy and control over their life, who they are, and how 
they interact with the world, a transformation described by Peter Kramer in his book 
Listening to Prozac (cited in: Valenstein, 1998; Degrazia, 2000; Parens, 2004). 
Reflecting Kramer‘s anecdotal explanations of Prozac enhancement, Degrazia (2000) 
explores the ethical issues associated with using antidepressants for enhancement though the 
case of a woman who is requesting a prescription of Prozac in order to improve herself and 
overcome personal difficulties.  While there is no diagnosable disorder, the change is sought 
in hopes of increasing confidence and decisiveness and decreasing obsessions and the impact 
of perceived negative social interactions.  The discussion following the description of this 
case outlines similar issues to those raised above with neurostimulant enhancement in 
children: fairness, freedom, safety, that it is unnatural, that it changes who we are, and the 
implications of medicalisation.  In large part in this context, fairness refers to access to 
enhancement drugs; consequently, if enhancement became the norm, it would most likely be 
a luxury of wealth and act to further widen the socioeconomic gap.  Also, as enhancement 
normalises, the freedom to medicate would be controlled by the pressure to compete with the 
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rest of the population; in a society where everyone is medicated, medication would not 
promote advantage over others, but instead would level the competition, whereas the choice 
not to medicate would be a disadvantage.  While the safety of antidepressants is thoroughly 
tested in depressed adults, the risks of medication in otherwise normal adults are widely 
unknown, particularly with regard to appropriate dosages, the amount of physician 
monitoring required and long-term effects.  However, antidepressant enhancement would not 
be any more unnatural than other means of psychological and/or biological neural change, for 
instance psychotherapy, and merely reflects an individual‘s values with respect to the method 
opted to evoke such an adjustment.   
Therefore, the desired transformation itself should be the ethical concern, not the 
means of attaining it, which is the issue of changing oneself.  This idea of altering and 
manipulating personality raises questions of identity and authenticity mirroring the cognitive 
style argument by Farah et al. (2009).  While Elliott claims that such changes to a person 
would deem the result inauthentic, something other than who that person truly is, Degrazia 
says the opposite, calling the process ‗self-creation‘ (Degrazia, 2000, p. 35).  He suggests that 
the transformation accomplished through antidepressant use creates another version of 
oneself, not a different person, and as long as this ‗new‘ person fits one‘s conception of self, 
what is valued by the individual, and how the individual identifies him or herself, then it is 
authentic (the concept of identity will be discussed further in Chapter 4).  Furthermore, it is 
within human capacity to change, either by choice or inadvertently over time, but such 
capacity is also limited by genetic, developmental, and environmental factors, as well as 
uncontrollable consequences of human choice; so while individuals may choose to take 
antidepressants to manipulate their personality or identifying qualities, such control is not 
unbounded. 
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The remaining issue with regard to adult antidepressant enhancement is the rise of 
medicalisation.  As discussed above, medicalisation removes the emphasis on context and 
tends to diagnose, and often treat, any struggles within formerly ‗normal‘ life experience.  
Opponents to enhancement argue that medicalisation and treatment diminish the sense of 
autonomy in individuals.  This line of reasoning is countered by the assertion that the choice 
to pursue enhancement methods for self-improvement is an act of agency itself, as well as the 
original reasons for seeking treatment being perceived as controlling and hindering one‘s 
agency, hence the desire to change.  At the individual level, then, the increased use of 
diagnosis and treatment may show positive implications; however, at the societal level, this 
trend may be more troubling due to the cultural values it promotes (Degrazia, 2000) (the 
cultural implications of which will be discussed further in Chapter 6). 
 
3.9  Could antidepressant enhancement extend to the paediatric population? 
The ethical issues raised regarding the trend of cognitive enhancement in young 
people have generally referred to the use of neurostimulants, but antidepressants have also 
shown improvements in normal individuals, as indicated by the discussion of adult 
enhancement above.  However, at present, there are no published trials on antidepressant 
enhancement use in children or adolescents (Singh & Kelleher, 2010).  Although, given what 
is known about the enhancing qualities of antidepressants, could the future of paediatric 
antidepressant use include enhancement purposes as well?  What would the benefits be for 
normal people if not treating a disorder?  Typically, antidepressants do not make users happy, 
per se, but balance overwhelming negative mood, stabilizing the individuals‘ personality.  
Applying this to normal individuals, such treatment might be expected to stabilize anyone‘s 
personality and provide more clear thought processing, reducing anxiety and stress and 
increasing confidence.  Unlike neurostimulants, which help to focus thoughts, antidepressant 
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enhancement is used for performing in high-anxiety activities, such as ‗public speaking, 
sports performance, and musical performances‘ (Singh & Kelleher, 2010, p. 4).  This 
suggests that antidepressants would be used to dissipate restrictive thoughts and/or moods 
that could otherwise impede performance, allowing performers to achieve their full potential 
in more stressful conditions. 
Although, in view of the negative media attention given to antidepressant use in 
children after the updated black box labelling and suicide warnings, as discussed in Chapter 
2, using antidepressants in this population for enhancement may not occur in the immediate 
future.  However, considering that antidepressants are the second most common psychiatric 
prescription for children and adolescents, only after neurostimulants (Zito et al., 2000; 
Rushton & Whitmire, 2001), it is not unrealistic to consider the possibility of an emerging 
enhancement trend.  Once more safety and efficacy data is presented for antidepressant 
treatment in disordered paediatric patients, the next turn will go toward the same treatment in 
normal children and adolescents.  If these future studies on antidepressant enhancement in the 
young population see any possibility of positive results, particularly with the influence of 
pharmaceutical marketing, a trend mirroring that of neurostimulant enhancement could 
certainly be expected. 
With this possibility in mind, in addition to the ethical issues presented above 
concerning paediatric neuroenhancement, the shaping of personality by antidepressant 
enhancement raises further questions.  Similar to the ‗cognitive style‘ argument and its 
extension to adult antidepressant enhancement, this concept requires examination regarding 
whether it is acceptable to manipulate the way children and adolescents think, as the decision 
to medicate is not solely theirs to make.  Personality, like creativity, reflects who individuals 
are fundamentally, the authentic self and identity.  Medicalising normal personalities is 
diagnosing and treating what it is that makes people uniquely human; would this practice 
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discount human experience?  How people think and act is largely a result of experience in 
combination with biology.  Psychotropic medication alters biology, shifting this combination 
of influences towards biological causes.  By allowing the use of antidepressants in this way 
without full attention to the desires and needs valued by the paediatric patient, it would seem 
unethical to change how the patient will feel as a person.  However, is this giving too much 
credit to antidepressants‘ ability to alter the mind?  This presumption may in itself be 
discounting experience and psychology, which may not be lessened by manipulating biology, 
but rather altered itself.  These issues regarding the effects of medication on identity and 
experience will be addressed in Chapter 4. 
 
3.10  In summary, what are the ethical concerns involving antidepressant use with 
regard to medicalisation and enhancement of normal paediatric patients? 
 The subjective nature and arbitrary classification of diagnosis typically allow 
identification of those individuals who possess treatable symptoms of a disorder.  Level of 
impairment experienced by the individual, and thus the degree of need for treatment, is 
determined by his or her ability to function in his or her environment, which is generally 
limited to home and school during childhood and adolescence.  This implies a certain 
dependence on context in determining treatment; not only must the patients themselves be 
treated, but their environment must also be considered.  In the case of depression, a treatment 
plan involving psychotherapy and medication may address the patient‘s symptoms, but 
additional life stress in his or her environment should also be taken into account. 
 However, as medicalisation of normal sweeps through Western culture, less emphasis 
is placed on a child‘s context and more on the ability to clinically improve a struggling 
individual.  With the existence of medications that may benefit not only disordered patients 
but also normal individuals, providing such treatments even in the absence of clinical 
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impairments is becoming more common practice in order to allow individuals to succeed to 
their fullest potential.  Currently, the limited efficacy and safety data for psychotropic use in 
the paediatric population provide a very unclear balance between the benefits and risks of off-
label prescriptions for disordered, let alone normal, children and adolescents.  This challenges 
a physician‘s certainty that he or she is helping a patient who may arguably be unimpaired 
without treatment.  Hence, antidepressants are rarely used for enhancement purposes in the 
paediatric population.  Nonetheless, given that neurostimulant enhancement is common in 
children and adolescents, and SSRI enhancement has been practiced in adults for decades, it 
is not unreasonable to predict that this practice may extend to antidepressant enhancement in 
children in the future. 
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CHAPTER 4 
What does paediatric depression mean in terms of 
psychological development?: A psychological 
perspective 
 
 
4.1  To what extent can we apply adult diagnoses to the paediatric population? 
 Chapter 1 discusses how the adult diagnosis is adjusted to fit the child presentation of 
psychiatric disorders, but is this a frivolous attempt to apply an adult-centric concept of 
diagnosis?  Rather, would it be more effective to create entirely separate diagnoses to apply 
to children?  Considering the uniqueness of the paediatric presentation, classifying a distinct 
diagnosis may be more effective at identifying affected individuals as the symptoms will be 
more population-specific.  Often affected children and adolescents do develop adult 
disorders, but treatment of paediatric versus adult symptoms will be different, as additional 
consideration should be given to children as developing humans, both psychologically and 
biologically.  Biederman et al. (2003) calls attention to this issue of diagnosis in regard to 
paediatric bipolar disorder, noting factors which make diagnosing in this population 
particularly difficult.  By comparing the atypical features of the paediatric presentation to that 
of adults, the former seems to take its own form, which often develops into the more familiar 
presentation, that of adults, only later in life, with adolescents‘ symptoms most closely 
resembling the paediatric presentation.  In addition to atypical presentation, paediatric 
diagnosis is difficult due to high levels of comorbidity, overlap with other disorders; 
Biederman et al. (2003) call specific attention to the overlap of paediatric bipolar disorder 
with ADHD and conduct disorder (CD).  Another important factor identified is familial 
aggregation, the tendency for disorders such as paediatric bipolar disorder to have high 
prevalence within affected families.  While the familial aggregation of bipolar disorder is 
widely accepted, similar trends are not an uncommon feature of many other psychiatric 
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disorders, but often genetic and environmental influences cannot be disentangled.  The 
Beiderman et al. (2003) study goes on to evaluate common treatments.  Through studies such 
as this study of bipolar disorder, other paediatric disorders, such as depression, may be more 
easily identified and appropriately treated. 
 While no one individual study has gathered information about paediatric depression 
by aligning identifying features followed by an evaluation of available treatments in the way 
that Biederman et al. (2003) have done for bipolar disorder, Rao and Chen (2009) have 
elaborated on the identification and understanding of paediatric depression through a 
developmental psychopathology study of the epidemiology, clinical presentation, prognosis, 
and risk factors.  Developmental psychopathology is a new method of researching 
psychopathology that considers the influence of developmental processes as reflected in 
differences in a disorder over a lifetime.  By integrating studies of depression across different 
age groups, Rao and Chen (2009) highlight that depression appears to be increasingly 
common at younger ages, though such trends are difficult to interpret due to ‗increased 
clinical awareness of early-onset depression and changing diagnostic criteria‘ (p. 3).  
However, given that rates of depression have notably levelled out by early adulthood, it can 
be inferred that childhood depression may not just be a more recent problem, simply more 
recognised.  Further, it is noted that children who experience depression show psychosocial 
disturbances, not developing in the same way as their unaffected peers, but whether the 
depression causes this disturbance or vice versa is unknown, which is further complicated by 
the effects of comorbid psychiatric disorders, low socioeconomic status, and other life 
stressors (Rao & Chen, 2009; Ngui et al., 2011). 
Rao and Chen (2009) go on to describe the clinical presentation, noting the 
differences in children as compared to adults, specifically in regard to symptoms listed in the 
DSM IV-TR criteria (as outlined in Table 4.1 below).  Another developmental trend is the 
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observed gender difference in prevalence rates, depression becoming increasingly more 
common in girls than boys with increasing age.  Also associated with gender and age is the 
prevalence of comorbidity of depression with other psychiatric disorders.  While there is a 
shifting of symptoms from the paediatric presentation to that seen in adults, recurrence rates 
following a major depressive episode in childhood mirrors rates found in adults, and though 
not predictive of developing depression in adulthood, often leaves individuals at risk to adult 
depression.  Risk factors associated specifically with paediatric depression include the 
vulnerability imposed by the plasticity of development itself throughout childhood and 
adolescence (physical, cognitive, social, interpersonal), familial transmission (both genetic 
and environmental influences), neurobiological abnormalities (to be discussed in Chapter 5), 
difficult temperament, negative cognition, negative interpersonal relationships, stress and 
vulnerability to such stress (Rao & Chen, 2009). 
Table 4.1: Key symptoms of depression compared by age group.  Combining results by Rao 
and Chen (2009) and Ginicola (2007); it is important to note that while adolescents are shown 
here with adults, they present symptoms on a continuum between the two groups, but tend 
toward internalising their disorder. 
 
Child Adolescent/Adult 
Irritability Depressed mood 
Behaviour problems Melancholic symptoms 
Aggressive behaviour Feelings of guilt 
Changes in psychomotor patterns Worthlessness and hopelessness 
Somatic complaints Psychotic symptoms 
Auditory hallucinations Delusions 
Self-injuring behaviour Suicidal thoughts/attempts with high lethality 
Comorbid mixed disorder Comorbid internalising disorder 
 Hypersomnia 
 
 
Investigating the shift from child to adult psychiatric presentation through the 
developmental approach, research by Ginicola (2007) looks specifically at the shifting of 
depressive symptoms from early childhood through adolescence.  This study correlates 
symptoms to ‗mental age‘ (Ginicola, 2007, p. 2), a combination of chronological age and IQ 
to determine the developmental level of subjects in order to account for differences in the rate 
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of psychological development between individuals.  The correlation that was found reflected 
younger children demonstrating more external symptoms which gradually changed toward 
more internal symptoms later in development (as reflected by the symptoms outlined in Table 
4.1 above).  Ginicola (2007) concludes that these significant differences in presentation must 
be taken into account when diagnosing and treating paediatric depression. 
 
4.2  Are these children really experiencing a psychiatric disorder or are they just 
learning to cope with growing up?   
 Since affected children often show such inconsistencies with adult diagnoses, it may 
appear that these individuals are not disordered at all.  This is due in part to their stage of life.  
Children and adolescents have limited life experience, so how can they truly experience a 
psychiatric disorder if their mind is still in the process of developing?  It is possible that some 
children have not developed adequate or appropriate coping mechanisms to deal with stress, 
defined as ‗environmental conditions that threaten to harm the biological or psychological 
well-being‘ (Rao & Chen, 2009, p. 12).  For some children, this stress may be the common 
stressors, such as school transitions, conflict exposure or loss (friends moving away, pets 
dying); for others the stress may be more pathological, for instance trauma, abuse, or physical 
illness (experienced either by the individual or a family member) (Coghill et al., 2009; Rao & 
Chen, 2009).  Whatever the cause of psychological discomfort may be, young individuals 
have rarely had the opportunity to develop their own means of coping with life that is 
acquired through experience, and therefore, have not yet learned to deal with negative or 
stressful events appropriately.  This inability to cope leaves the child vulnerable either to the 
negative impact of stress and/or the development of maladaptive responses to stress, hence 
stress acting as a risk factor of depression, as mentioned by Rao and Chen (2009).  What 
level of psychological discomfort, as expressed through depressive symptoms for instance, is 
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necessary to warrant diagnosis and treatment, then?  Further, abnormal coping strategies may 
easily be identified as a psychiatric diagnosis and treated accordingly, but is that a fair 
assessment of the situation in context?  Treatment in this case could certainly be beneficial, at 
least in the short term, but it also provides the child with an alternate coping mechanism that 
may interfere with the ability for an individual to develop his or her own coping strategies.  
When faced with a problem, such an identified child will often be brought to a physician by a 
parent not knowing an alternative to alleviate the child‘s distress, and it may be suspected that 
over time the patient may independently turn to psychiatric treatment because he or she is 
unaware of any other effective strategy (Shearer & Bermingham, 2008).  Every child 
develops at a different rate, some children simply need more time to learn appropriate coping 
skills, which is why Ginicola (2007, p. 2) takes into account both chronological age and IQ to 
calculate a more applicable ‗mental age‘ when studying psychological development and 
symptoms in depressed children.  That being said, there is a difference between children and 
adolescents who will develop coping mechanisms naturally with time and those who are, in 
fact, disordered and require treatment.  Again, this addresses the difference between ‗normal‘ 
and disordered.  Similar to disordered adults, disordered children often lack appropriate 
coping mechanisms, which then tend to generate additional stress (Rudolph & Klein, 2010); 
thus, to counter their maladaptive coping skills, these children require treatment.  There is 
certainly validity to paediatric experience of psychiatric disorders; however, it must be 
acknowledged that such experiences are very unique to this population, i.e. not to be 
confused with the adult experience of a disorder.  Again, through studies such as that 
conducted by Biederman et al. (2003) and Rao and Chen (2009), identification of those 
individuals that need treatment will be clearer, and more accurate diagnoses may be applied. 
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4.3  What is identity and concept of self?  How do the diagnosis and/or disorder affect 
one’s development of identity and concept of self? 
 At a crucial age for identity development and self-understanding, deviations from 
‗normal‘ development, however subtle, have the potential to impact a child‘s concept of self 
substantially.  Identity, self-understanding, and concept of self will be used interchangeably 
here, as found in psychiatric literature, referring to an individuals‘ awareness of what they 
need and want, how they perceive the environment‘s impact on themselves, and how they 
perceive their impact on their environment.  Coghill et al. (2009) define self-concept as: 
An individual‘s awareness and the set of beliefs and attitudes  
that a person holds about themself [...] Many aspects of self- 
concept are unique to humans and higher-order primates as  
these are the only species that have the capacity to see  
themselves as both subject (e.g. ‗I‘, the person looking in the  
mirror) and object (e.g. ‗me‘, the person being looked at). (p. 22) 
The description goes on to divide self-concept into three major components: self-image 
(description of self, both objective and subjective), the ideal self (who an individual wishes to 
be), and self-esteem (perceived self-worth, often dependent on the comparison of the former 
two components).  Further, it is noted that the development of self-concept is a fluid process 
over a lifetime, beginning with an infant‘s recognition of his or her own physical self, 
followed by an older child/adolescent developing a psychological understanding of self 
(Coghill et al., 2009).   
As indicated by the risk factors of paediatric depression outlined above by Rao and 
Chen (2009), adolescence is a time of significant psychological vulnerability, and it may be 
inferred that this vulnerability refers in part to the plasticity of a developing identity.  
Through their research of depressive personality in children, Rudolph and Klein (2009, p. 6) 
note, ‗Because personality traits are still under construction during childhood, experiencing 
significant psychopathology may leave a developmental ―scar.‖‘  This concept implies that 
the experience of a psychiatric disorder during childhood is going to have a significant impact 
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on a child‘s developing understanding of self.  Rudolph and Klein (2009) believe this to be a 
negative ‗scarring‘ influence in regards to depressive symptoms, as they later state, 
‗Experiencing significant depressive symptoms and associated impairment early in life may 
undermine youths‘ sense of self and disrupt their emotional development, leaving youth 
feeling ineffective and pessimistic and creating lingering emotion dysregulation‘ (p. 21).  The 
implication is that negative self-concept developed early in life as a result of experiencing 
paediatric depression will persist into adulthood, whether in the form of adult depression or 
depressive personality; the disorder becomes incorporated into the individual‘s identity and to 
some degree leaves a lasting effect. 
Floersch et al. (2009) studied the integration of experiencing a disorder and treatment 
into adolescents‘ developing concept of self.  They conducted interviews with adolescent 
patients being treated with psychotropic medication, investigating how their experience of 
their illness and treatment shapes the subjects‘ view of themselves, identity, ability to cope, 
and relation to others, providing valuable qualitative information about psychological effects 
of psychiatric treatment in this population.  Adolescent subject responses in the interviews in 
this study were coded to link quotations to emerging themes, resulting in the following:   
(i) emotion—references to emotional problems; (ii) 
diagnosis/disorder/symptom—reference to psychiatric illness,  
disease, or diagnosis; (iii) self—reference to some aspect of the  
self as the problem; (iv) cognition/thought—reference to  
cognitive problems; (v) intersubjective—reference to  
relationship problems; (vi) body—reference to physical  
problems, and; (vii) behavior/action—reference to behavioral or  
school problems. (Floersch et al., 2009, p. 5) 
Often children, particularly adolescents who are beginning to gain self-awareness, can 
recognise their own disorder to some extent.  The work by Floersch et al. (2009) implies that 
sometimes an affected child may realize that, to varying degrees, he or she interprets the 
environment much differently than his or her peers, feels emotions or processes thought in 
unusual ways.  For example, a depressed child may notice that he or she does not enjoy 
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activities like other ‗normal‘ children appear to.  More often, however, teachers and peers 
may notice differences in the individual‘s behaviours and ways of interacting with others, 
resulting in that child experiencing a perceived rejection by others more than an awareness of 
psychiatric experience, as pointed out by Rao & Chen (2009).  Such factors may have greater 
influence on a very malleable developing identity, compared to a presumably more secure 
adult identity, perhaps causing a sense of self-identified isolation or eliciting negative 
interpersonal relationships, which then exacerbate the negative experience of a disorder. 
 As mentioned in the emerging themes listed above, many disordered adolescents 
make reference to their disorder and/or diagnosis.  Providing a label that indicates 
abnormality may have additional influence on identity development because it puts an 
identifiable name to the behavioural experience.  As demonstrated by the research of Floersch 
et al. (2009), this label can then be incorporated into children‘s developing concept of self as 
a significant part of who they are and how they view themselves. Some individuals 
externalize their diagnosis as an experience that they are treating; others recognize the 
disorder as a part of who they are internally.  Floersch et al. (2009, p. 5) point out the 
difference between the children believing that the diagnosis is who they are, ‗I am ADD,‘ 
compared to something that affects them: ‗I have depression.‘  Based on qualitative studies 
such as this, it may be suggested that the internalization of diagnosis into identity may be 
helpful for some individuals while detrimental for others.  By integrating a psychiatric 
diagnosis into who they are, certain children and adolescents may find such a facet of their 
identity better explains who they are, allowing both them and others to have a fuller 
understanding of themselves, a positive result of assigning a label to their atypical 
experiences.  Similarly, even for those patients who externalize the diagnosis, an available 
label can provide validation for their experiences as well as feelings of community; they are 
not alone and enough other people have similar feelings that their symptoms have been 
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grouped into an identifying label.  On the other hand, a negative effect of internalizing 
diagnosis may be development of helplessness and isolation produced by the stigma 
surrounding psychiatric illness.  With a label to identify them as abnormal, a diagnosis 
defines them as different from their peers, incorporating negative connotation and stigmatism 
into who they are, not simply possessing individuality but a noted deficit.  Further, if these 
diagnosed children view their disorder as a part of themselves, they may perceive attempts to 
improve their mental illness as futile or creating a self-conflict as they are encouraged to 
change who they are, not just how they act.  Thus, treatment will have additional impact on 
understanding of self, which will be addressed below.   
 Floersch et al. (2009) suggest another prevalent issue that follows identifying with a 
disorder and/or diagnosis: for a population so commonly diagnosed with comorbid disorders, 
the question becomes which diagnosis does an individual identify with?  Based on the 
understanding of incorporating diagnosis into identity, as described above, the diagnosis with 
which a patient identifies most strongly should be one that deserves the greatest attention in 
terms of treatment because presumably it is the most influential with regard to the patient‘s 
ability to interact and function within his or her environment.  However, with such strong 
association between the patient‘s concept of self and a particular diagnosis, such treatment 
should also be approached with additional consideration, as it is more personal to the patient 
than other disorders being experienced simultaneously.  That is to say, treatment of a 
diagnosis that is a greater part of a patient‘s identity will be expected to hold greater meaning 
to the patient and make a more significant impact on the patient‘s understanding of him or 
herself and interaction with the environment, whereas treatment of the less meaningful 
diagnosis will be expected to be less influential in affecting a patient‘s self-concept.  As 
mentioned above, Biederman et al. (2003) note the difficulty of making a diagnosis due to 
high comorbidity rates; would it be useful in paediatric psychiatry to create more specific 
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diagnoses that incorporate what currently exist as distinct but commonly comorbid disorders?  
For example, rather than diagnosing a child with depression and conduct disorder, the new 
diagnosis would be one diagnosis that would be a combination of the two, such as 
‗depression with conduct disorder‘.  Perhaps this would disentangle the complexity of 
incorporating multiple diagnostic labels into a child‘s developing identity, or would it 
complicate the already complex integration of diagnosis into identity formation? 
 
4.4  How does the experience of psychiatric treatment affect a young patient’s 
development of identity? 
Just as special attention is given to the child/adolescent experience with medical 
caregivers, such attention must also be applied to the patients‘ experience with the treatment 
itself and how it affects their understanding of themselves.  While in the process of 
developing their identity, children and adolescents integrate their personal experiences along 
with others‘ perceptions of themselves into their concept of self (Rao & Chen, 2009).  In 
other words, they form their identity by combining how they interact with the world and how 
the world seems to react to them.  In regard to adolescent psychiatry with relation to identity 
formation, in their investigation of effective psychopharmacology and motivational 
interviewing (described below) Dilallo and Weiss (2009, p. 110) comment, ‗Therefore, any 
information communicated to an adolescent about diagnosis or treatment options will be 
incorporated into his or her process of self-definition.‘  Psychiatric treatment at this age will 
take a greater effect in shaping the patient‘s identity than experiencing such treatment later in 
life when an identity has already had time to stabilize.  Therefore, it is important to 
understand how paediatric patients view their own treatment, how such treatment influences 
their view of themselves, and how much participation and responsibility they take in their 
treatment plan, for example incorporation in the consultation (as discussed in Chapter 2) and 
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willingness and motivation to follow prescriptions, both of which may be directly 
proportional to patient age. 
In the context of children taking neurostimulants for ADHD treatment, Singh (2008) 
and Singh and Kelleher (2010) discuss the impact on child identity.  Singh (2008) notes the 
limited empirical data available despite the amount of debate on the subject.  Many people 
call attention to the potential harms of medication to individual autonomy and identity, 
stigma associated with medication, and interference with the natural experiencing of 
childhood as a protected state of innocence; however what the evidence actually shows is 
children expressing positive effects of treatment on their sense of authenticity, at least prior to 
adolescence.  Singh and Kelleher (2010, p. 8) highlight this issue noting ‗strong concerns 
about potential threats to a young person‘s identity, agency, and responsibility because of the 
alterations in motivation, attention, interaction with others, and performance for those young 
people taking them‘.  This argument is referring to the child‘s development of ‗moral self-
understanding‘ (Singh & Kelleher, 2010, p. 8), which may be taken to mean one‘s feeling of 
control over who they are (authenticity) and their behaviour and interactions toward others 
(responsibility).  Again, these ethical arguments are countered by the evidence that younger 
children, at least, attribute more positive impact of medication treatments on their sense of 
control over their actions (agency), thus having greater ability to create a desirable outcome 
for themselves.  In terms of the negative attributes of labelling and stigma of psychiatric 
treatment, Singh and Kelleher (2010) note that bullying and negative interpersonal relations 
actually tend to improve for medicated individuals as compared to the negative interactions 
experienced as a result of ADHD-type behaviours prior to medication.  While these positive 
effects on personal identity should be considered, an observed complication in understanding 
a notion of responsibility arises, as well.  Some children express attribution of good 
behaviour to their medication and/or blame bad behaviour on a lack of medication; rather 
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than taking personal responsibility for their actions, children taking stimulants use their 
medication as the agent of their behaviour.  As suggested by Singh and Kelleher (2010), the 
extent to which children actually believe their medication explains their behaviour or if they 
are simply using medication as an excuse requires further study.  Additionally, both Singh 
(2008) and Singh and Kelleher (2010) omit any specific comment on medication impact on 
adolescent identity development, what does this older paediatric population experience, or is 
the evidence even more lacking than that for younger children on this subject? 
Relating the above discussion of neurostimulant treatment to the use of medication for 
treatment of paediatric depression, parallel arguments may be presented.  Those opposing 
medication may argue that medication will interfere with authentic childhood experience, 
which is the ‗nurture-neuroethics argument‘ (Singh, 2008, p. 962).  By giving children 
antidepressants, these children will experience an unnatural childhood; however, this outlook 
risks discounting the harm of a child experiencing a significantly depressive childhood, 
which also greatly impacts the ‗ideal state of innocence and freedom‘ (Singh, 2008, p. 962) 
that is the experience such proponents of this argument wish to protect.  Supporters of 
medicating children may counter this unnatural experience by pointing out the positive 
effects of medication.  As discussed above, children experiencing depression tend to have 
negative interpersonal experiences; thus, medication may improve relationships in a similar 
fashion to the way neurostimulants have (as described above).  Furthermore, medicated 
children may be able to take greater control of their actions and positively affect the outcome 
of their behaviours, where depressive behaviour may have seemed to control them prior to 
psychotropic treatment.  Then again, developing a sense of responsibility will likewise be 
complicated.  If the argument presented by Singh and Kelleher (2010) is applied to 
antidepressant treatment, children may use medication as an explanation of positive and 
negative behaviour and temperament rather than placing themselves as agents of control; any 
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good moods may be attributed to medication, while poor moods and disinterest may be 
excused by lack of medication.  Depressed children who are medicated, then, might not only 
discount personal agency, but also the impact of personal experience. 
 
4.5  How does expectation for their treatment relate to child and adolescent experience 
of and receptiveness to treatment? 
Receptiveness to treatment can be notably affected by patient expectations and 
influence by others.  The study by Floersch et al. (2009) explores the gap between 
expectation and experienced effects of treatment and medication in the paediatric population.  
As a qualitative study, the aims addressed the views held by adolescents treated with 
psychotropic medication in regard to their illness (as discussed above), their understanding of 
how their medication works, and their role in their own treatment.  Since expectations for 
psychiatric treatment are much less distinct, the difference between expected and experienced 
effects shows significant variability.  The authors discuss the expectation to experienced 
effects of psychotropic medication compared to that of medication for a more discrete 
condition such as a headache.  When a patient takes medicine to treat a headache, the 
expectation is that the headache symptoms will be alleviated, and generally the actual effect 
of treatment is an experience very similar to that expectation.  In contrast, the ambiguity of 
expectation for psychotropic treatment makes it difficult to pinpoint a reference to compare to 
the experienced effect.  As such, expectations are more skewed due to the limited knowledge 
of efficacy and long term effects. 
In terms of experienced effects, the data reported indicates ‗a belief that medication 
produced behavioral change‘ and ‗parents and others influenced their experience and 
understanding of illness and medication‘ (Floersch et al., 2009, p. 5).  Changes in behaviour 
led many adolescent subjects to note particular improvements in interpersonal relationships 
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and emotional stability.  As for expectations subjects had for their treatments, the following 
sentiments were communicated: ‗provide a cure; control their anger [...] not stop working [...] 
relieve family stress‘ (Floersch et al., 2009, p. 5).  Many expectations revolved around the 
influence of other people as well as the impact on others in their environment.  For example, 
the adolescents relied more on the knowledge of their medication imparted to them by their 
parents, doctors, and media to form their treatment expectations and even to understand their 
own experiences and feelings.  This weighted reliance on others in order to understand 
themselves suggests a level of plasticity in adolescent identity formation that will fade over 
time.  Presumably, by adulthood, while the influence of others on their self-understanding 
may not disappear entirely, it will diminish as they come to know themselves better.  
Additionally, adolescents noted an expected influence their treatment would have on others 
as a motivation for following prescribed treatment plans, taking into account how their 
treatment would affect their relationships with others, specifically pleasing family members.   
As indicated by the definition of identity described above, social relationships are a 
factor in identity formation, particularly in this age group, so prioritizing interpersonal 
relationships as such a strong motivation to change behaviour is not surprising.  Almost 
separate from the extent to which medication seems to make the patients themselves feel 
better, they note concern that at least others observing them notice an improvement (Floersch 
et al. 2009).  Based on this finding, this reliance on the opinions of others may be related 
back to the desire to be ‗normal,‘ which is relative to the sociocultural context within which 
an individual lives.  As discussed in Chapter 3, normality is the similarity to the average 
experience of others in the same population as determined, for example, by age, geography, 
socioeconomic status, and so on.  To be normal, then, is to be perceived, by oneself and 
others, to fall within the mainstream experience.  Hence, it may be suggested that the 
adolescents‘ expectation that their medication will enable them to approach normality is 
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actually more dependent on others‘ perception of the medication‘s effect than their own 
perception. 
Taking into account the effect of others‘ influence on paediatric psychiatric treatment, 
for more effective care, Dilallo and Weiss (2009, p. 108) suggest ‗motivational interviewing‘ 
to improve adolescents‘ receptiveness to treatment and help them develop stronger identities.  
The authors emphasize the relationship and rapport between the clinician and paediatric 
patient, and the importance of the clinician having a full understanding of the patient‘s 
context both prior to and following the prescription of medication.  ‗Motivational 
interviewing‘ is the term coined to describe this style of practice, and is defined as: 
An efficient and collaborative style of clinical interaction that  
can boost the effectiveness of the therapeutic alliance by  
enhancing three major elements: empathy that is accurate to the  
patient‘s experience, patient confidence in his or her ability to  
improve, and positive expectations regarding the recommended  
treatment.  (Dilallo & Weiss, 2009, p. 108) 
The therapeutic alliance is a reference to the interaction between patient, parent, and clinician 
in the context of paediatric care.  This approach incorporates both awareness of identity 
development and expectation for treatments.  Dilallo and Weiss (2009) note that originally, 
motivational interviewing was presented as a treatment strategy for substance abuse in adults 
and later adolescent adherence to type 1 diabetes treatment, but it has been modified for 
adolescent psychiatric treatment by addressing behavioural problems as ‗potential targets for 
change‘ (Dilallo & Weiss, 2009, p. 109), which are within the ability of the patient to develop 
control through improved self-awareness.  Responsibility for change is placed on the 
adolescent patient and away from the clinician and parents, recognizing the patient as the 
centre of control.  To effectively motivate change, then, the clinician must first evaluate the 
patient‘s initial understanding of his or her condition in order to determine the best way to 
communicate a treatment plan that the patient will best be able to adhere to based on such an 
understanding of his or her own needs.  It is a non-confrontational approach that provides 
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paediatric patients the necessary treatments while also providing opportunity for them to 
experience their own autonomy and develop a stronger sense of who they are (Dilallo & 
Weiss, 2009). 
 
4.6  In summary, what are the most prevalent ethical concerns in regard to the 
psychological implications of psychiatric diagnosis and treatment within the paediatric 
population, particularly in the case of paediatric depression? 
 As discussed in this chapter, the following ethical issues arise when treating children 
for psychiatric disorders.  Since children are not fully developed psychologically, their 
experience of their disorder is unique compared to that of adults; children are still integrating 
experience and their own reaction to experience into an understanding of themselves.  This 
difference from adult experience, as indicated by the difference in prevalent symptoms, needs 
to be considered in order to make an appropriate diagnosis because it affects children and 
adolescents‘ process of developing an identity and coping abilities.  Further, whether the 
existing diagnoses are suitable for the paediatric population or whether they require revision 
should be considered, particularly as psychiatric diagnoses have such a significant effect on 
the development of identity at this age.  The impact a diagnosis has on a child or adolescent 
patient who is only just developing a concept of self is noteworthy not simply as a means of 
determining the appropriate treatment plan, but also because it will leave a lasting effect on 
how the patient perceives him or herself in relation to the world in which he or she lives.  
What follows the effect of diagnosing, then, is the impact that the treatment will have on the 
paediatric patient‘s concept of self.  Taking medication or even cognitive and behavioural 
therapy will cause patients to alter their thinking, including thoughts about themselves, which 
will have a more significant consequence and meaning to those individuals (paediatric 
patients) who do not yet have a stable understanding of who they are, versus adult patients 
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who already have a more developed sense of themselves.  This influence may have both 
positive and negative effects on the development of self-understanding. 
 In the case of paediatric depression, for example, a number of questions concerning 
the psychological development of the young patient arise.  Prior to making a formal 
diagnosis, it must be determined if the individual‘s symptoms are truly outside normal child 
experience.  Once the diagnosis of depression has been given, how does the child or 
adolescent incorporate this label into his or her understanding of self?  Is the depression part 
of who he or she is internally?  Is it simply something that affects him or her but is separate 
from him or herself?  Is the child so young that he or she does not understand what 
‗depression‘ is and/or has not developed any meaningful concept of self yet?  Based on the 
information presented in this chapter, diagnosing children and adolescents with depression 
may have various levels of impact depending on each individual patient, how long he or she 
has been experiencing the disorder, how old he or she is when given the diagnosis, and where 
he or she is in terms of understanding his or her own identity.  In terms of treatment, then, 
how does a patient‘s understanding of him or herself change as compared to before beginning 
treatment?  Can he or she interact with peers and family members more effectively having 
received antidepressant treatment?  Has treatment made the individual feel more ‗normal‘ 
(either more emotionally stable and/or better aligned to the perceived mainstream 
experience)?  Does he or she feel more in control of his or her mood and behaviour?  How 
much of the individual‘s behaviour does he or she attribute to the medication?  Again, the 
effects of medication on the child‘s understanding of self and perceived autonomy varies by 
individual, and is dependent on the level of development the patient has reached at the time 
of treatment as well as his or her receptiveness and reaction to the medication.  This 
population is in the process of developing their individual identities, and by providing a 
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diagnosis and treatment, more complex factors are added to this process outside the ‗normal‘ 
experience. 
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CHAPTER 5 
What does paediatric depression mean in terms of 
neurodevelopment?: A biological perspective 
 
 
5.1  What is the expected brain development during childhood and adolescence? 
 Before addressing the differences in development of individuals with a disorder 
and/or undergoing treatment, it is important to identify normal brain development.  At an age 
when the brain is already subject to significant changes, which research is only just beginning 
to be able to describe and understand, it is difficult to predict the effects psychiatric 
experience has on the young brain and its development.  Following prenatal development of 
the neural tube into the brain, ventricles and spinal cord, and the migration and scaffolding of 
glial cells to form the cortex, rapid programmed cell death occurs over the last few months of 
gestation into the first month of postnatal life, resulting in the loss of approximately half of 
the individual‘s neurons.  Simultaneously, synapses are proliferating and organizing, a 
process known as synaptogenesis, which peaks around age two, when the brain has about one 
and a half as many synapses as an adult brain.  Elimination of certain synaptic connections 
follows synaptogenesis, a process that varies in rate across different brain regions and 
continues into early adulthood.  Further, myelination also begins prenatally and continues 
into early adulthood.  The myelination process follows an inverted U pattern, starting in the 
brain stem and progressing in the anterior direction toward the prefrontal cortex, and moving 
from inferior, proximal, sensory, and projection pathways toward superior, distal, motor, and 
association pathways (Coghill et al., 2009). 
 Investigating brain development in ages 5-22 years, the National Institute of Mental 
Health (NIMH), within the National Institute of Health of the U.S. Department of Health and 
Human Services, has undertaken a paediatric development mapping project.  Through a large 
sample of magnetic resonance imaging (MRI) scans taken every 2 years of both healthy and 
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disordered children, data are beginning to describe key brain changes over the course of 
development in the paediatric population.  The findings published thus far indicate: 
 Total cerebral volume peaks at 14.5 years in males and 11.5 
in females with the brain being 95% of this peak by 6 years 
 Male brains are approximately 9% larger than female 
brains 
 Lateral ventricular volume continues to increase across the 
age span 
 Cortical grey matter volume follows an inverted U 
developmental course.  The volume, however, peaks at 
different times in different regions [...] When mapped in 
more detail there are distinct patterns of development seen 
within these specific brain regions.  For example, the 
dorsolateral prefrontal cortex (important for impulse 
control and decision making) is particularly late to reach 
adult thickness 
 There are gender specific differences in the amygdala and 
hippocampus grey matter with amygdale volume only 
increasing with age in males and hippocampal volume only 
increasing in females 
 In contrast to the grey matter, white matter volume 
increases throughout childhood and adolescence  
(Coghill et al., 2009, p. 37) 
Given this research, it is no surprise that the overall plasticity of the child and adolescent 
brain leaves individuals at increased risk for psychiatric disorder.  It would also seem that 
more research in this area may help correlate the findings above with gender differences in 
prevalence of different disorders. 
 It may be possible to start tracing such developments by studying slow-wave activity 
(SWA) through sleep studies, as it has been found that changes in SWA patterns, indicating 
depth of sleep, appear to reflect trends in brain development (Kurth et al., 2010).  Kurth et al. 
(2010) present novel research correlating brain plasticity and remodeling with SWA during 
sleep through the developmental ages of 2.4 to 19.4 years of age.  In agreement with the 
developmental changes noted above, ‗the main finding shows that the location with maximal 
SWA undergoes a shift from posterior to anterior regions across childhood and adolescence‘ 
(Kurth et al., 2010, p. 13216).  Further, the resulting inverted U-shaped course of SWA over 
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time reflects the development of synapse density and pruning, as well as synaptic strength 
and regional maturation.  Generally, the study demonstrates patterns of SWA mirroring 
anatomical and behavioural development: 
  Our anatomical localization of maximal occurrence of SWA  
revealed that, first, the maxima occurs over occipital lobe in  
preschoolers, followed by parietal regions and posterior frontal  
lobe in school-age children (from 8 to 14 years) and, finally, the  
SWA maxima spreads to frontal lobes during adolescence.   
Young and older adolescents (after ~14 years of age) present a  
frontal predominance of SWA [...] not yet as pronounced as in  
adults. (Kurth et al., 2010, p. 13216-7) 
With these noted correlations between measurable sleep patterns and otherwise known brain 
development, this study seems to present a feasible method of observing brain plasticity, and 
Kurth et al. (2010) suggest using such sleep studies as a tool for detecting abnormalities that 
may lead to psychopathology in the paediatric population. 
 Another recently proposed method of brain development tracking is detailed by Shen 
et al. (2010), using MRI-reconstructed 3D neuroimaging as an efficient, cost-effective, and 
precise clinical tool to measure brain volume, and by extension, brain development.  This 
technique shows changes in grey, white, and total brain matter volume, and also allows 
visualization of ventricles, vessels, and pathological lesions.  Investigating the normal brain 
development of children ages 3 months to 12 years and 11 months old, the study suggests that 
grey matter grows primarily until age 4, and white matter increases from birth through 
adolescence.  The results found by this study parallel previously collected data showing 
myelination and synaptogenesis processes during early life, so this procedure may provide 
physicians a plausible method of observing and evaluating brain development and more 
easily detecting abnormalities in the clinical setting. 
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5.2  More specifically, are there neurosystems that are particularly plastic and/or 
vulnerable at this stage of development?   
As discussed in the previous chapters, emotional, social, and psychological 
development are very significant experiences during childhood and adolescence, but what are 
the underlying brain developments reflected by these experiences?  In terms of the influence 
of brain development on identity formation, findings outlined by Feinberg (2010) suggest key 
regions in the brain associated with self concept, specifically the frontal, medial frontal, 
medial and orbitomedial prefrontal cortices.  It is not surprising, then, that as children and 
adolescents develop their sense of identity, the prefrontal cortex is a region undergoing 
dramatic change through childhood into early adulthood.  In the study conducted by Feinberg 
(2010), results of different brain lesions were used to determine ‗neuropathologies of the self‘ 
(NPS), which ‗are a group of conditions in which a brain lesion causes a profound and 
specific alteration in the patient‘s personal identity or personal relationships between the self 
and the world‘ (p. 75).  Feinberg describes three categories of NPS identity disorders: those 
of the bodily self, the perceived constraints of one‘s physical body; those of the relational 
self, the interaction and perceived significance of oneself in the context of one‘s environment; 
and those of the narrative self, one‘s understanding of their past and present experiences.  
Feinberg (2010, p. 76) remarks,  
NPS differ from purely cognitive conditions [...] in that these  
[cognitive] conditions are neutral with reference to the  
individual‘s relatedness to the self and the world in contrast to  
NPS which are specifically related and in many cases restricted  
to something of personal significance to the individual.   
Based on this theory, if these regions of the prefrontal cortex are affected by abnormalities of 
a disorder and/or by treatment, then effects on identity should be expected.  Therefore, it is 
understandable that psychiatric conditions concerning identity are particularly meaningful to 
individuals, perhaps even more so in young individuals whose identities are still developing.  
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As such, experiences related to the disorder and treatment may be more likely to be a greater 
factor in a patient‘s developing concept of self than a language disorder, for instance. 
Further, the prefrontal cortex is also involved in emotional development, especially 
during adolescence, as is the amygdala and the connections between these two regions 
(Perlman & Pelphrey, 2011).  Problem-solving involving motivation and regulation of affect, 
which are those circumstances that elicit emotional responses, activate the ventral and medial 
prefrontal cortex (VMPFC) as well as the amygdala, and during childhood and adolescence 
individuals develop connections between, and regulation of, these brain regions.  The 
amygdala is believed to detect emotionally relevant stimuli, while the VMPFC appears to 
control emotional response; however, as discussed above, the prefrontal cortex (PFC) is one 
of the last brain regions to complete development into early adulthood.  Thus, as the VMPFC 
and its regulation of emotional response to stimuli activating the amygdala continue to 
change through childhood, temperament and emotion can be expected to be less controlled 
during adolescence.  In their study of PFC-amygdala connectivity during emotionally driven 
problem solving tasks, Perlman and Pelphrey (2011) demonstrated that in both children and 
adults during heightened negative mood amygdala activation increases, and over lasting 
periods of negative mood the connectivity between the PFC and amygdala also increases.  
The study also showed that effective connectivity from the PFC to the amygdala increased 
with increasing age through childhood, meaning the activity in the PFC has increasing impact 
over the activity in the amygdala as development progresses. 
 In addition to this emotional development, puberty and the changing of hormone 
balance greatly affects both brain structure and function, which allows affective and social 
brain systems to develop (Forbes & Dahl, 2010).  Puberty has a dramatic effect on what 
Forbes and Dahl (2010, p. 67) term the ‗social re-orientation of adolescence,‘ which includes 
organizational effects at the cellular level in the brain, such as testosterone‘s effect on the 
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growth of white matter, direct behavioural effects, and influence on experience.  The authors 
of this study call attention to the higher correlation of puberty rather than age to changing 
behaviour and motivation during adolescence, such as sensation-seeking tendencies, 
increased risk behaviours and increased social concerns, such as those pertaining to peer 
pressure, social rejection, popularity and status, developing friendships, romantic 
relationships, and sexual relationships.  A greater understanding of the connection between 
social and neural development is required, particularly as dysregulation of emotional and 
behavioural control has led to ‗the health paradox of adolescence‘ (Forbes & Dahl, 2010, p. 
66).  This is described as the notion that adolescence is a time of great physical health, but 
also has twice the morbidity and mortality rates than other periods in life.  This suggests that 
as adolescents begin to develop long-term behaviour patterns, puberty may be linked to an 
increased risk of emerging affective disorders and psychopathology. 
 
5.3  How does neurodevelopment affect psychopathology?  Why is the paediatric 
population at higher risk than adults for many psychiatric disorders?   
 As described above, the structure and activity of the brain are changing drastically 
during childhood and adolescence.  Paus, Keshavan, and Giedd (2008) review why mental 
health disorders appear to peak during adolescence (approximately 14 years of age).  Grey 
matter increases until puberty, and then begins to decline, as reflected in the inverted U-
shaped developmental pattern; whereas, white matter continually increases from childhood 
through early adulthood.  While less understood, functional changes through development are 
mostly noted in relation to executive functions, which include planning, decision-making, 
emotion and behaviour regulation, sensation-seeking and risk-taking.  The underlying 
mechanisms of these changes are proposed, such that ‗the apparent loss of grey matter 
reflects an increase in the degree of myelination of intra-cortical axons‘ and other changes in 
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axonal calibre to account for the increase in white matter (Paus, Keshavan & Giedd, 2008, p. 
949).  Furthermore, the development of neural connectivity between different regions of the 
brain appears to correlate to social development, measured by resistance to peer influences; 
stronger connections are associated with lower influence by peers.  This is indicated by three 
neural networks: the ‗action-observation network,‘ imitation processing by mirror neurons; 
the ‗biological-motion processing network‘ or ‗superior temporal sulcus (STS) network,‘ 
processing of social cues; and the ‗executive network,‘ cognitive processing, decision-making 
and memory (Paus, Keshavan & Giedd, 2008, p. 950). 
Using schizophrenia, substance abuse, and affective and anxiety disorders as 
examples, Paus, Keshavan and Giedd (2008) highlight that adolescent brain development 
puts individuals at risk for psychiatric disorders due to the vital changes the brain experiences 
as described, particularly when looking at how/when these changes occur.  Overall, the 
development of psychopathology appears as a result of interacting genetic and environmental 
factors.  Schizophrenia has been observed as exaggerated synaptic elimination, which may be 
influenced by both biological and external stress in early life.  It has been suggested that 
substance abuse may be the combination of over-sensitive reward circuitry, particularly in the 
nucleus accumbens, and less aversive activation of the developing GABAA receptor, and 
results in inhibition of NMDA receptors, particularly in the adolescent hippocampus.   
Lastly, and of particular relevance to this project, affective and anxiety disorders, 
including major depression, have been associated with abnormal brain activation in relation 
to social and emotion processing, which is also reflected by ‗reported structural anomalies in 
the superior temporal gyrus, the ventral prefrontal cortex and the amygdala‘ (Paus, Keshavan 
& Giedd, 2008, p. 953).  These affective disorders also show interesting gender differences, 
from nearly equal prevalence rates between genders in early life to approximately twice the 
prevalence in females to males after puberty.  Due to this trend, the prevalence difference 
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may be linked to changing hormones during and after puberty, particularly the stress-related 
steroid tetrahydroprogesterone (THP), which activates the hippocampal α4β2δ receptor 
located in the CA1 region and has been associated with increased anxiety (Paus, Keshavan & 
Giedd, 2008).   
However, this proposed mechanism associated with increased risk to affective 
disorder, along with other pathophysiology associated with paediatric development of 
psychiatric disorders require more investigation.  As Paus, Keshavan and Giedd (2008) 
indicate, any anomalous timing or magnitude of the changes experienced by the developing 
brain put individuals at risk of disorder, so it is important to gain a better understanding of not 
only what but also how these changes are occurring.  With that in mind, Ziermans et al. 
(2010) investigated potential markers in brain development that may indicate the 
development of psychosis.  Consistent with the information pertaining to schizophrenia 
development above, by following high risk individuals through development, Ziermans et al. 
(2010) found that adolescents at high risk for psychosis who eventually developed psychosis 
by the 2-year follow-up evaluation showed an exaggerated decline in total brain volume, 
reduced growth of white matter and significant cortical thinning.  Similar developmental 
research for other psychiatric disorders may allow for detection of specific brain changes and 
earlier intervention in psychopathology.  Though, with increasingly early intervention, more 
research also needs to investigate psychotropic treatment in the paediatric population. 
 
5.4  What are important factors to be considered when treating children with 
psychotropics that differ from treating adults in terms of neurobiological effects?  
 Based on the evidence presented here, the paediatric brain is particularly vulnerable to 
the risk of developing psychopathology, but this time of increased plasticity likewise presents 
unique responsiveness to psychotropic treatments.  While the evidence of long term effects 
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and safety of psychotropic drugs on the developing brain continue to build, the increase in 
diagnosis and prescription treatment for psychiatric disorders in children far overstretches the 
progress being made in the research data.  Further, an even greater disparity between the lag 
in research and actual prescription prevalence exists in combined pharmacology, as children 
are often diagnosed and treated for comorbid disorders (Wilens, 2009).  Carlezon and 
Konradi (2004) review what is understood of the link between behaviour and biological 
effects of psychotropic drug treatment.  The authors note the possibility of emerging public 
health issues with the increased consumption of psychotropic drugs, as well as caffeine, 
earlier in life, as the young developing brain experiences changes inflicted by treatment that 
result in long lasting adaptations that may or may not be beneficial to the individual.   
With repeated exposure to psychotropic drugs, levels of responsiveness change either 
by increasing tolerance or sensitization, that is reaction to drug effects show a progressive 
decrease or increase, respectively.  What Carlezon and Konradi (2004, p. 48) term ‗exposure-
dependent‘ adaptations are of concern due to their role as precursors to addictive behaviours.  
Furthermore, repeated exposure is associated with molecular alterations in the brain, causing 
changes in gene and protein expression.  More recently, research is beginning to describe 
how these molecular effects are connected to behavioural effects of drug treatment, for 
example linking CREB activity in the nucleus accumbens (NAc) shell to depressive 
behaviour as demonstrated by the work of Turgeon, Pollack and Finch (1997), Pliakas et al. 
(2001), Barrot et al. (2002), and Carlezon et al. (1998) (cited in: Carlezon & Konradi, 2004).   
Using methylphenidate exposure during early development as an example study, 
Carlezon and Konradi (2004) discuss how the exposure-dependent changes that are explained 
in adults with regard to behaviour-molecular models may be completely different in children, 
though paediatric results are also considerably inconsistent.  In terms of behaviour, it is 
undeniable that early exposure to neurostimulants alters responsiveness to stimulants later 
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and their rewarding effects later in life, though it is debated whether these alterations are an 
increase of tolerance or sensitivity to drug effects.  When investigating the molecular effects 
of early methylphenidate exposure, rat subjects showed increased CREB expression in the 
NAc shell later in life, which is associated with depressive behaviour; this contrasts the 
neuroadaptation associated with stimulant exposure in older subjects, which is linked to 
addiction risk.  This is suspected to only be one of many neuroadaptations of early stimulant 
exposure; other brain regions require closer investigation in this regard.  Similar studies of 
the molecular effects of other psychotropic drugs are also needed. 
There have been studies conducted to determine clinical effects of other psychotropic 
drugs for paediatric use.  Alacqua et al. (2008) interpret retrospective clinical charts 
reviewing the use and tolerability of antipsychotics and antidepressants to highlight 
prescribing trends and identify safety and reaction concerns in the paediatric population.  The 
study included the atypical antipsychotics risperidone, olanzapine, uetiapine, and clozapine, 
and SSRIs paroxetine, sertaline, citalopram, and fluoxetine, but this study only looked at the 
effects over the first three months of treatment.  Antipsychotics were found to be prescribed 
mainly to treat psychosis and autism, and conduct disorder and mental retardation to a lesser 
degree, with the highest number of prescriptions for risperidone and olanzapine.  However, 
nearly one third of subjects in the study discontinued treatment within three months due to 
adverse drug reactions, and only a minority of subjects reported major improvements during 
treatment.  The majority of SSRI prescriptions were indicated for OCD, anxiety disorder, and 
conversion disorder, with a few cases used for panic attack and conduct disorder.  While 
almost half of subjects saw no improvement or worsened condition with treatment and 
approximately 20% experienced adverse effects, none of the subjects discontinued treatment 
within the first three months that were studied.  Alacqua et al. (2008) carried out their 
research in southern Italy; however, their results were consistent with previous studies 
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conducted in the U.S.  It is interesting to note that SSRIs are not indicated to treat depression, 
but other disorders.  Further, at the time of this study both the FDA and EMEA were 
beginning to release warnings against the use of SSRIs in children with the exception of 
fluoxetine (in the US, this exception was extended to include sertraline and fluvoxamine 
indicated for OCD, as well; see Chapter 2), yet fluoxetine was the least prescribed SSRI in 
this study. 
  Looking specifically at antidepressant treatment in children and adolescents, Moreno 
et al. (2007) examined the literature through a systematic database search of both electronic 
and specialized collections, including published and unpublished information available to the 
public.  Their search determined that many drugs provide positive results, meaning treatment 
proved more effective than placebo, in the adult population, but that few studies have 
published positive results in children and adolescents; thus, antidepressants still lack efficacy 
for use in the paediatric population overall.  The study covered trials with TCAs, SSRIs, and 
other newer antidepressants, including venlafaxine, mirtazapine, and nefazodone.   
Moreno et al. (2007) propose a number of possible explanations for the efficacy 
differences between paediatric and adult populations.  TCAs may be less effective in children 
due to the noradrenergic neural system developing into early adulthood, and the neural 
changes related to puberty increase the risk of mania with the use of SSRIs nearing the age of 
14, after which mania is a more common risk with the use of TCAs.  In addition to these 
mechanistic findings, pharmacokinetics and pharmacodynamics, or the interactions between 
the drugs and youth physiology, are discussed.  Prior to puberty, young people have notably 
faster metabolisms, different water distribution in the body, as well as lower body fat 
concentration, and as a result, children may require higher, more frequent doses of 
medications metabolised in the liver, such as antidepressants and antipsychotics, to see 
effective results.  With regard to antidepressant metabolism, the authors note: 
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As antidepressants have two to three times shorter half-lives in  
youngsters, they need to be administered more often than to  
adults to avoid withdrawal symptoms between doses that can be  
wrongly interpreted as the absence of an adequate response with  
the exception of fluoxetine, which has a longer half-life.  Other  
factors, such as reduced drug protein binding and a more  
permeable blood-brain barrier in children, also play a role and  
increase drug availability. (Moreno et al., 2007, p. 189) 
Despite this knowledge, most clinical trials have only been carried out with adult subjects, 
hence the off-label prescribing practices.  Furthermore, it has been suggested that depression 
is heterogeneous, meaning the risk of developing depression increases in newer generations 
who have depressed parents.  Also, paediatric versus adult depression presents different 
biological signs and drug responses, including variation in placebo response, which may 
require a different approach to treatment.  With regard to placebo response, both Moreno et 
al. (2007) as well as Shearer and Bermingham (2008) note that research often shows that 
children respond comparably well to the placebo treatment as to SSRI treatment.  These data 
indicate the importance of further studies of child-specific efficacy.   
 
5.5  What are some necessary methodology considerations and directions for future 
research? 
 The combination of lacking clinical data and continuation of off-label treatment 
practices indicate an obligation for future research in order to find the safest and most 
appropriate treatment for children with psychiatric issues.  In terms of future directions, 
Carlezon and Konradi (2004) review what data exists already and suggest that the following 
should be addressed:   
One, to examine whether other classes of psychotropic drugs  
produce the same types of effects; two, to use more complex  
behavioral models to examine how these agents affect high level  
motivation and cognitive function; and three, to examine if there  
are periods of development in which it is particularly safe or risky  
to use psychotropic drugs. (p. 48) 
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Prior to clinical trials in humans, animal research models are discussed by Carlezon and 
Konradi (2004).  Especially in paediatric studies, it is difficult to find an appropriate model to 
represent human brain development.  Even in humans, the boundaries of childhood, 
adolescence and adulthood are variable, so applying parallel limits to animal models is even 
more challenging.  Moreover, animal models, typically rats, differ in the way they metabolise 
and react to drugs, particularly during development and with regard to psychiatric conditions.  
These factors make it difficult to measure appropriate dosages, as well as to uncover the 
differences of treating normal individuals, individuals with an underlying pathology and 
individuals with a known psychiatric disorder when trying to apply animal models to 
paediatric practice in humans. 
When designing clinical investigations with regard to antidepressant treatment in 
children, then, many variables need to be taken into account, as discussed by Moreno et al. 
(2007) as well as Vasa, Carlino and Pine (2006).  Firstly, diagnosis of child depression is 
subjective, as discussed in previous chapters, and there is no consistent tool of assessment for 
making the paediatric diagnosis.  Secondly, both comorbid disorders and polypharmacy 
practices make treatment results difficult to interpret; thus, the specific effects of 
antidepressants on paediatric depression will be unclear, but with the high rates of 
comorbidity and polypharmacy, an understanding of the resulting interactions also requires 
more research in itself.  Thirdly, different subtypes of depression may respond to 
psychotropic treatment differently, as indicated by different biological signs that have been 
studied previously; another important difference concerns distinguishing early onset of 
bipolar disorder (BPD) versus major depression because treatment, particularly with SSRIs, 
may aggravate manic symptoms in young undiagnosed BPD patients.  Lastly, inconsistencies 
in study design, as well as which studies are published, make it nearly impossible to compare 
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results between research projects, particularly when studies have limited sampling which may 
not be applicable to the entire population. 
 In Germany, Austria, and Switzerland, Mehler-Wex et al. (2009) suggest Therapeutic 
Drug Monitoring (TDM) as a method of more widespread data collection of psychotropic 
drug effects, including polypharmacy, as they appear in actual clinical practice in this 
population without carrying out unnecessary and excessive research.  TDM would closely 
monitor plasma/serum levels and side effects in treated patients at the time of treatment, and 
thus the dosages and treatment plan could be better tailored to the individual patient.  At the 
same time, this data would be entered into a network to build a database to support future 
treatment plans (Mehler-Wex et al., 2009).  Such a database would remove the challenges of 
variability in applying clinically controlled research to real clinical practice, and it would 
provide a much larger, fully representative sample of results. 
 
5.6  What legislation is in place to improve research and prescription safety for 
paediatric patients?  Why is paediatric protection vital? 
While doctors provide care in the best interests of their patients, it has already been 
highlighted above that holes of uncertainty remain in current medical treatment.  What 
legislation is in place to protect child/adolescent safety?  Since this population is especially 
vulnerable, what specific measures have been made to ensure their needs are met?  As 
outlined by Auby (2008), the following legislation has passed in the US with respect to 
paediatric medication: Pediatric Labeling Rule (1994); Modernization Act (1997); Pediatric 
Rule (1998); Best Pharmaceuticals for Children (2002); Pediatric Research Equity Act 
(2003); and amendments to the Pediatric Research Equity Act  (2007) and Best 
Pharmaceuticals for Children Act (2007).  Overall, these pieces of legislation encouraged 
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drug studies for the paediatric population by providing incentives for pharmaceutical 
companies.   
In the midst of the above legislation, the US Surgeon General, Dr. David Satcher, held 
a conference to highlight the growing mental health needs of children and adolescents and to 
present suggestions for future direction in the nation‘s attempt to address such needs (US 
Public Health Service, 2000).  There were eight major goals set for the conference: 
 1.  Promote public awareness of children‘s mental health issues  
and reduce stigma associated with mental illness. 
 2.  Continue to develop, disseminate, and implement  
scientifically-proven prevention and treatment services in the  
field of children‘s mental health. 
 3.  Improve the assessment and recognition of mental health  
needs in children. 
 4.  Eliminate racial/ethnic and socioeconomic disparities in  
access to mental healthcare. 
 5.  Improve the infrastructure for children‘s mental health  
services including support for scientifically-proven interventions  
across professions. 
 6.  Increase access to and coordination of quality mental  
healthcare services. 
 7.  Train frontline providers to recognize and manage mental  
health issues, and educate mental health providers in  
scientifically-proven prevention and treatment services. 
 8.  Monitor the access to and coordination of quality mental 
healthcare services. (US Public Health Service, 2000, p. 4) 
These goals were attended to by dividing the conference into three panel discussions: 
‗Identifying, Recognizing and Referring Children with Mental Health Needs‘; ‗Health 
Service Disparities: Access, Quality, and Diversity‘; and ‗State of the Evidence on 
Treatments, Services, Systems of Care and Financing‘ (US Public Health Service, 2000, pp. 
16, 27, 32).  While the goals outlined do adequately address the major difficulties present in 
current paediatric psychiatry, achieving them in the immediate future may be too idealistic; 
the aims focus on both system and social issues which are large enough problems that it will 
be years before any changes will impact care.  Following the press release of this conference, 
in 2001 the American Psychological Association put together a report in response, which 
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outlined strategies to achieve the goals set by the Surgeon General‘s conference.  The 
association then created a task force in order to carry out those strategies as addressed by five 
key points:  
1. Promoting public awareness of children‘s mental health  
issues;  
2. Improving the infrastructure to address funding and parity  
issues;  
3. Increasing access and coordination of quality mental  
health services;  
4. Training providers about child development and mental  
health; and  
5. Monitoring access and coordination of quality mental  
health care services.‘ (American Psychological Association,  
2001, p. 12). 
The task force serves to ensure the continuing advocacy of these strategies in mental health 
practice as well as policy creation and revision.  Though the task force has put forth realistic 
strategies, again, significant changes in care may be expected to progress slowly. 
Based on the previously instated US regulations, the EU passed Regulation (EC) No 
1901/2006 in 2006.  Prior to this legislation, Lehmann (2008, p. 1) notes, ‗The legal 
framework for conducting clinical trials, including children/minors, is set up in Directive 
2001/20/EC, the Clinical Trials Directive (CTD), for the European Union (EU).‘  Rocchi et 
al. (2010) discuss why there was a need for further regulation in the EU.  With the growing 
prevalence of off-label prescriptions for the paediatric population, the conflict intensifies 
between conducting paediatric research and the problem of medicating children without 
supporting experimental data.  On the one hand, it is costly and ethically problematic to carry 
out many paediatric studies; however, this is counterbalanced by the issue of prescribing 
untested dosages of drugs to children.  The new regulation specifically covered vulnerable 
populations, addressing research requirements, rewards, incentives and penalties, shared 
access to collected data, and providing appropriately tested medicines to be used in child 
populations (Auby, 2008; Lehmann, 2008; Rocchi et al., 2010).  Auby (2008) explains the 
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contrast to the US legislation, in that the new EU regulation encouraged more proactive 
development of paediatric medications, key points being increased quality research and 
information availability through the European Paediatric Committee (PDCO) and Paediatric 
Investigation Plan (PIP).  The PIP is a required development plan outlining paediatric 
application for all medicinal product research (unless the product is proven to treat adult-only 
conditions, as determined by the PDCO), and must be submitted to and approved by the 
PDCO, which includes members representing each EU state as well as three healthcare 
professionals and three patients‘ association representatives (Auby, 2008; Rocchi et al., 
2010).  While the influence of pharmaceuticals and its associated consumer market are not as 
notable as in the US, the industry does have considerable power in research across the world.  
Stoyanova-Beninska et al. (2010) propose that prior to the new EU regulation, paediatric 
research was lacking in part because there was little incentive for pharmaceutical companies 
to pursue such studies, and also due to the belief that paediatric psychopathology was mainly 
external and treatable through non-medicinal methods.  However, they further suggest 
triggers for regulation were the concern that adult data could not, in fact, be extrapolated to 
children, as found with SSRIs and increased suicide risk in adolescents, and that drug 
treatments in children needed more intense investigation (Stoyanova-Beninska et al., 2010). 
To support the collection of more experimental data within the new EU regulations, 
Manolis and Pons (2009) suggest model-based studies to minimize the number of necessary 
trials conducted in children in order to test safety and efficacy of drugs.  By definition: 
Modelling and simulation (M&S) is a methodology widely used  
to support drug development.  Modelling is the science of using  
mathematical language to describe and quantify a system.   
Simulation refers to the use of these models to make  
quantitative predictions. (Manolis & Pons, 2009, p. 494) 
If this method is employed correctly, it may be a way of increasing practical data without 
having to carry out many tests in children.  However, the authors make the important note 
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that it cannot replace human trials as it is only based on assumptions and parallel adult data, 
but it can provide supplemental data to support fewer paediatric trials. 
 
5.7  In summary, what are the most important ethical issues with regard to 
neurodevelopment and psychiatric treatment, particularly the use of antidepressants? 
 As discussed in this chapter, the human brain continues to develop through childhood 
into early adulthood.  While more research is required, emerging evidence suggests that the 
neurosystems underlying the development of identity, emotional control, and social 
integration are considerably plastic until the third decade of life, resulting in an increased risk 
of developing psychopathology during this time.  Any deviations from healthy 
neurodevelopment with regard to how or when neural changes occur have the potential to 
produce a substantial impact and disorder.  Depression, for example, may be linked to 
abnormalities in the superior temporal gyrus, ventral prefrontal cortex, and amygdala, which 
present as atypical development of social and emotional processing.  This is consistent with 
the neurodevelopment data described above.  Additionally, with the differences observed in 
depressed individuals‘ prefrontal cortex, it would not be surprising that this disorder may also 
affect identity formation. 
 In terms of introducing psychotropic drugs to the developing brain, then, the different 
physiology of children from that of adults in addition to neural plasticity must be considered.  
Firstly, children will metabolise drugs differently than adults, as described in the chapter 
above.  Secondly, heightened plasticity in the brain lends to more significant 
neuroadaptations with respect to drug responsiveness, i.e. tolerance and sensitization, which 
may leave extensive lasting effects.  Specifically in the case of antidepressant use in the 
paediatric population, overall the research lacks positive results, despite findings in the adult 
population.  There are numerous policies and legislation in place to protect children against 
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unsafe treatment and unnecessary research testing, but without clinical trials safety data will 
remain lacking.  Moreover, it is particularly challenging to find appropriately matched 
models that can reflect both human brain development and psychiatric conditions/treatment 
practices as they appear in the clinical setting prior to conducting clinical trials.  Through the 
combination of such methods suggested in this chapter, namely TDM and M&S, widespread 
and minimally invasive sample data reflective of actual clinical presentation and practice may 
be collected and analysed.  Future studies may then indicate the most appropriate prescription 
practices for psychotropics such as antidepressants in the paediatric population in hopes of 
diminishing off-label prescription prevalence. 
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CHAPTER 6 
What is the context of paediatric depression around the 
world?: A cultural perspective 
 
 
6.1  What do mental health services look like around the world? 
 
 Having focused on psychiatric practices in the US and UK up to this point, what is the 
global context for paediatric psychiatric care?  In 2005, the WHO published the Mental 
Health Atlas as part of the Atlas project, compiling data on available mental health resources 
across the 192 Member States.  Overall, despite finding a global awareness of a substantial 
mental health burden, there is a severe lack of available resources in the majority of countries 
across the world.  Looking at the child-specific data from 186 of the Member States, defining 
children as ages 0-14, 62.4% of the countries showed any child-specific mental health 
programmes.  When comparing the percentage of countries in a geographic region with the 
presence of child mental health programmes to the percentage of child population, Africa, the 
region with the highest proportion of children (42.6%), had the lowest percentage of 
countries with paediatric mental health programmes (37.0%); conversely, the Americas and 
Europe, the regions with the lowest proportion of children (30.4% and 19.1% respectively), 
had the highest proportion of countries containing mental health care facilities for children 
(81.3% and 77.6%, respectively; see Table 6.1). In terms of income stratification by country 
and the presence of paediatric mental health services, the percentage of countries with 
available services were proportionate to the income of the country, i.e. a higher percentage of 
wealthier countries have mental health care services for children than lower income countries 
(WHO, 2005a). 
 As another part of the Atlas project, the WHO provides a more extensive analysis of 
global paediatric mental health care in the Atlas: Child and Adolescent Mental Health 
Resources report (2005b).  However, this document contains information from only 66 of the 
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192 Member States based on data collected from questionnaires that were completed by key 
informants in each country, and excludes data from the US, Canada, France and Australia 
(see Appendix E).  While representing less than half of the Member States, the data present 
some critical information.  Globally, about 20% of children and adolescents are affected by 
mental disorders, 4-6% of whom are significantly distressed and require clinical intervention.  
With the exception of the Western Pacific region, regional presence of mental health 
programmes reflected the same trend as described above, but in this limited sample the 
percentage of countries found to have such programmes appeared much lower for some 
regions while higher for others.  This shift indicates that in Africa, the Americas, the Eastern 
Mediterranean, and Europe many countries that claimed to have mental health care 
programmes when surveyed for the original Mental Health Atlas chose not to participate in 
the survey for the specific Child Mental Health Atlas, while many countries in the Western 
Pacific and South-East Asia that did not report having special programmes in the original 
Atlas opted out of the Child Atlas.
3
  In the countries that did offer information for the Child 
Mental Health Atlas, the survey also investigated the proportion of countries in each region 
which have national policies regarding child and adolescent mental health care, and 
demonstrated that actual mental health care services lag behind the presence of relevant 
policy (see Table 6.1).  These trends are similarly observed when dividing countries based on 
income group.  The authors suggest that the gap between policy and services may be due in 
part to grouping mental health policies within national policies of ‗human rights, social 
welfare, child protection or education‘ (WHO, 2005b, p. 14).   
  
                                                 
3
 Unfortunately, since the Atlas was a voluntary survey, there was no follow up to determine 
why certain countries chose not to participate in the Child Mental Health Atlas. 
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Table 6.1:  Global child mental health care programme and policy distribution.  This table 
compares the proportion of the population under the age of 14, countries with paediatric 
mental health care services, and countries with national paediatric mental health care policy 
in the different WHO Regions, while also comparing data from the Mental Health Atlas 
surveying 186 countries and the Child Mental Health Atlas surveying 66 countries (WHO, 
2005a; WHO, 2005b). 
 Mental    Health Atlas Child     Mental Health   Atlas 
WHO Regions 0-14 years 
population (%) 
Countries with 
programme 
(%) 
Countries with 
programme 
(%) 
Countries with 
policy (%) 
Africa 42.6 37.0 6.3 33.3 
Americas 30.4 81.3 44.5 77.8 
Eastern 
Mediterranean 
34.6 72.7 33.3 100 
Europe 19.1 77.6 66.7 95.8 
South-East Asia 32.8 54.5 62.5 50 
Western Pacific 32.9 50.0 83.3 66.7 
World 31.3 62.4   
 
It is also noted that, ‗nowhere in the world is the documented need for child and 
adolescent mental health services fully met‘ (WHO, 2005b, p. 16).  The Child Mental Health 
Atlas (2005b) indicates the need for a continuum of care, which is a system that offers a 
variety of services from home-based to school-based to outpatient to hospital inpatient, 
among others, and states that at present, ‗in only 7 of 66 countries were the elements of 
essential services identified that could be considered to represent the presence of a continuum 
of care‘ (p. 18).  Barriers to care are listed and include lack of transportation, stigma, lack of 
resources, lack of communication due to language barriers, and lack of public knowledge.  
Particularly, the lack of resources is apparent when presented with the information that ‗a 
1999 survey in the European region showed the presence of a child psychiatrist in countries 
to range from one per 5,300 to one per 51,800‘, and more astonishingly ‗in most countries in 
the African, the Eastern Mediterranean, Southeast Asian, and Western Pacific regions the 
presence of a child psychiatrist is in the range of 1 to 4 per million with a few notable 
exceptions‘ (WHO, 2005b, p. 21).  Moreover, while more than half of the countries surveyed 
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indicated that paediatricians provide mental health care, only a small minority of 
paediatricians have any psychiatric training; on the other hand, most psychiatrists around the 
world are not trained to work with children and adolescents.  It is difficult both to improve 
the availability of trained professionals as well as increase accessibility to them as financial 
support for child and adolescent mental health care is mainly provided by temporary, 
unsustainable sources, such as international grants and patients‘ private funds, which lack the 
stability of government funds.  Further, there is a significant lack of accessibility to current 
medication and information regarding relevant psychotropic treatments.   
Prior to the Atlas project, the WHO published Caring for children and adolescents 
with mental disorders (2003), which also specifically addressed the mental health needs of 
children and adolescents, providing the perceived priority disorders, briefly addressing 
cultural context of diagnosis, barriers to care, interventions and policies, and emerging trends 
in paediatric mental health care.  Designated by typical age of onset, the following mental 
disorders are of particular concern in the paediatric population worldwide: learning disorders 
and hyperkinetic disorders (i.e. ADHD) in early childhood; tics (i.e. Tourette‘s syndrome) in 
middle childhood; and depression, associated suicide, and psychosis in adolescence.  
Pervasive Development Disorder, attachment disorders, anxiety disorders, conduct 
disorder/anti-social personality, substance abuse, and eating disorders are also of significant 
concern around the world, and require more intensive care than the disorders previously 
listed.  As discussed in previous chapters, it is further emphasised here that despite increasing 
knowledge of the biological factors involved in mental illness, social/environmental context 
remains an important component of the equation and should not be discounted.   
Extending the impact of environment to cultural context, then, the presentation and 
diagnosis of any one disorder may demonstrate considerable variability throughout the world.  
As diagnostic criteria are generally defined based on Western cultural context and may not 
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apply well to other cultures, the authors suggest that when diagnosing, ‗one should look at 
broader categories of disorder rather than narrower disease definitions‘ (WHO, 2003, p. 8).  
Particularly in developing countries, children are often subjected to ‗difficult circumstances‘ 
which may produce either reactive disorders or long term impairment, so it is vital to take 
context into account in order to determine the appropriate diagnosis/level of impairment so 
that the child receives the most effective care (WHO, 2003, p. 8).   
As expected, the barriers to care discussed above are especially significant in 
developing countries, but in fact, these barriers are also universal problems.  The Caring for 
children and adolescents with mental disorders report (2003) highlights the importance of 
family communication, awareness and training of adults in the community who work with 
young people, and developing national paediatric mental health policy as useful interventions 
to help overcome barriers to care.  As evidenced by statistics presented above, there is a 
universal lack of effective policies regarding child and adolescent mental health care.  Having 
published a report in 2001 with guidance for those countries designing their own policies, the 
WHO emphasises the necessity for policy, claiming: 
The development of child and adolescent health services in the  
absence of specific national policy leads to: (1) fragmentation  
of services, (2) inefficient utilization of scarce resources, (3)  
inability to provide effective advocacy for priority concerns,  
(4) lack of constituent participation in program development  
and (5) an inability to incorporate new knowledge in a  
systematic fashion. (WHO, 2003, p. 14) 
Regardless of the status of a national policy, mental health care is becoming a more 
privatized sector of medicine, which is then balancing more between insurance and managed 
care than relying on the state for funding and cost/quality control.  In theory, the shift toward 
privatization is to control and minimise costs of care, but without national policy to insure a 
certain quality of care, access to appropriate mental health care and treatment may easily 
decline.  There is particular concern with regard to medication treatment, as a trend of direct 
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marketing to patients has been emerging around the world, not just in the West.  While 
patients gather most of their information about medications from the pharmaceutical 
companies themselves, children and adolescents continue to receive off-label treatment, 
leading to the ethical dilemma discussed in earlier chapters. 
Psychiatric care should be a concern around the world, as Ngui et al. (2011, p. 2) 
state: 
The projected burden of mental health disorders is expected to  
reach 15% by the year 2020, where common mental disorders  
(depression, anxiety, and substance-related disorders including  
alchohol) will disable more people than complications arising  
from AIDS, heart disease, traffic accidents and wars combined.  
In their analysis of the global mental health burden, Ngui et al. (2011) note that less than 30% 
of the children who require mental health services receive the care that they need.  As such, 
the mental health burden becomes a public health issue sustained by social inequalities, 
unmet needs, stigma and discrimination, which in turn significantly affects economic 
development.  The correlation between socioeconomic status and mental health disorders 
becomes self-perpetuating as the lack of advocates and services for the poor continue to 
widen the gap between healthy and disordered as well as that between wealthy and poor.  In 
developing countries, where mental disorders tend to be much more prevalent, the lack of 
mental health care policy and access to services means that an estimated 75% to 85% of 
disordered individuals go untreated.  The overall shortage of mental health care workers is 
paralleled by the migration of these trained professionals away from the developing and rural 
areas in the most need because there are no structured jobs for them except in developed and 
urban societies.  This further reflects that stigma is not only affecting patients, but also 
healthcare professionals; medical professionals are often deterred from the mental health 
field, and in certain cultures more traditional beliefs, including the control of supernatural 
forces, evil spirits or curses, may leak into mental health practice.  Ngui et al. (2011) also 
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highlight the impact of a global mental health burden on economic development.  The cost of 
effective mental health care is exceeded by the economic loss as a result of mental disorders 
hindering success.  In addition to economic productivity, treating the mentally ill would be 
expected to result in lower crime rates and more political stability. 
 
6.2  What are some specific trends in services and treatment observed? 
 A number of reviews regarding regional-specific mental health services and 
treatment/prescription trends have been consulted from different countries and regions, 
including Pakistan, Eastern Europe, India, Australia, France, and Western Europe/US.  Some 
regions lag well behind the needs of the population, not just specifically children and 
adolescents, in terms of public awareness and availability of the most current prescriptions 
(Pakistan and Eastern Europe, respectively).  Other countries have relevant services available 
but are concerned with the increase in paediatric mental health treatment and prescription 
trends, and note the need for appropriate ethical guidelines and services (India and Australia, 
respectively).  On the other end of the spectrum, some regions, particularly in the West, are 
questionably over-treating the paediatric population for mental health disorders (France and 
Western Europe/US, respectively). However, with a recognised lack of services even in the 
West, over-treatment may actually reflect an inability of the available services to adequately 
monitor the treatment that is provided, which is notably not equally accessible by all within 
these developed countries. 
In Pakistan, Zafar et al. (2009) conducted a study to examine public perception of 
psychotherapy and pharmacotherapy as effective psychiatric treatment.  Most of those 
interviewed in this study supported pharmacotherapy, but it was also made clear that many do 
not understand the actual meaning of ‗psychotherapy‘.  In such a society, the general public 
simply requires more availability of treatment information.  It is also important to note, 
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however, that this survey indicated very little stigma associated with psychiatric care, and the 
overall results indicate that the ‗general public of the largest city of Pakistan perceive 
psychotherapy as a clinically effective, cost efficient and acceptable modality for 
management of mental ailments‘, with ‗a significantly greater preference for psychotherapy 
[...] among younger, females, more educated and financially independent participants‘ (Zafar 
et al., 2009, p. 3).  Based on this noted preference, it would be interesting to do future studies 
to determine a demographic survey of who is receiving psychiatric care in this region, 
particularly because, despite the positive perception of psychiatric care, the actual resources 
for mental health care are severely limited in Pakistan. 
Looking at an adult demographic, the study by Jordanova et al. (2010) in Eastern 
Europe presented psychotropic prescribing trends, which remained fairly similar across the 
five included countries (Albania, Croatia, Macedonia, Serbia, and Romania).  In terms of 
diagnosis, depression was the most frequent in Iasi, Targu Mures and Zagreb, and psychosis 
was the most frequent in Belgrade, Strumica, and Tirana.  Pharmacotherapy findings included 
polypharmacy as very common even when guidelines often suggested monotherapy, and 
typically older generation drugs are prescribed (independent of cost).  Due to these practices, 
it may be presumed that the patients in this region experience greater adverse effects; 
combining treatments may lead to negative drug interactions, and at least in the case of 
atypical antipsychotics, despite newer drugs being shown not to be significantly more 
effective, older drugs do have more negative side effects.  While antipsychotics and 
antidepressants are the most common prescriptions, the high prevalence benzodiazepine 
trends reflect those found in Western Europe.  Also, anticholinergics are commonly 
prescribed in order to offset extrapyramidal side effects caused by typical antipsychotics, 
which are frequently used in this region.  This study did not provide any paediatric data, but 
as paediatric psychopharmacology trends increase throughout the world it may be assumed 
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that children and adolescents in this area are receiving some form of psychotropic treatments 
likely paralleling those trends described for adults. 
With the increased prevalence of paediatric psychopharmacology, the need for 
research in this population is becoming vital, particularly as most children are receiving off-
label prescriptions.  As paediatric research expands in India, Malhotra and Subodh (2009) 
raise ethical issues that need to be addressed, particularly informed consent, balancing 
benefits and risks in research design, and population-specific concerns of conducting research 
in paediatrics.  When discussing informed consent, the authors note three key components.  
The first is competency, or cognitive capacity to make rational and informed decisions.  The 
second element is information, which should reasonably explain: ‗(i) the proposed course of 
treatment, (ii) alternative treatments available, (iii) existence of the potential 
benefits/potential risks of each treatment options, and (iv) no treatment at all‘ (Malhotra & 
Subodh, 2009, p. 22).  The third component is voluntarism, the patient‘s freedom of choice to 
do what is right for his or her circumstances based on his or her own understanding of the 
situation and options, values and history, without others‘ persuasion or coercion.  The 
elements of informed consent are complicated in the case of children and adolescents.  For 
instance, when is the child/adolescent considered competent enough to make their own 
decisions rather than rely on parent consent?  Research has found that from about age 7, 
children are cognitively competent enough to be involved in decision-making regarding their 
own care in the form of assent, and by age 12 may be competent enough to make their own 
decisions; though as implied by Chapter 4, cognitive competency is contingent on level of 
neurodevelopment, which is not precisely defined by age.  Based on fluctuations in decision-
making abilities in young people, generally independent consent is not granted to adolescents 
until ages 16-18 in the Western world, with few exceptions.  Special attention must also be 
given to particularly vulnerable populations, such as handicapped children, institutionalized 
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children, patients with chronically progressive and/or potentially fatal disease, and patients in 
emergency life saving care. 
In terms of research design, more scrutinising attention must be given to the predicted 
benefits outweighing the risks of the treatment in question.  Even with regard to placebo 
treatment, considerations should be made if withholding treatment would incur more 
potential risks than providing the active treatment.  Further risk assessment must be evaluated 
in paediatrics that may not be as of great importance in adult studies and treatment due to the 
intensified impact such factors may have on a young patient, including ‗discomfort, 
inconvenience, pain, fright and separation from parents or familiar surroundings, effects on 
growth or development of organs, and size or volume of biologic samples‘ (Malhotra & 
Subodh, 2009, p. 27).  Finding a balance between potential benefits and risks in paediatric 
research is further complicated by the ‗inherent paradox of clinical trials in psychiatry,‘ 
balancing the ethical dilemma of treating children and adolescents with untested treatment 
with the additional ethical challenges of conducting scientific research on treatment efficacy 
in the paediatric population (Malhotra & Subodh, 2009, p. 27).  This review of the issues in 
paediatric psychopharmacology implies that these are globally identified issues associated 
with treating children, not simply Western concerns. 
Furthermore, Malhotra and Subodh (2009) provide an overview of the clinical 
paediatric setting in India.  As a relatively young, heavily populated country, there is a large 
paediatric patient population.  Culturally, India‘s collectivist society typically encourages 
family participation in patient care, but authority remains largely with the physicians 
themselves, followed by parental authority, and children are given little to no inclusion in 
making decisions regarding their care.  While written consent by subjects/parents is required 
for participation in treatment and/or research, lack of education often leads to limited 
understanding of clinical implications being agreed to.  The authors make the following 
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suggestions for the future: developing a set of ethical guidelines and creating Ethical Review 
Boards (ERBs), allowing individuals over the age of 14 to grant consent as mature minors 
and including the community in determining the future of clinical research and practice.   
In Australia, McGorry (2007) investigates clinical practice of youth paediatric care 
and calls attention to the growing need to reform mental health facilities for the adolescents 
due to the high prevalence of mental health disorders in this population.  Including adolescent 
mental health care within the child sector of psychiatric care is a very recent development in 
Australia through Child and Adolescent Mental Health Services (CAMHS), and there is a 
noted misalignment of bridging CAMHS to Adult Mental Health Services (AMHS) for those 
patients approaching young adulthood.  At present, paediatric psychiatry is relatively under-
resourced and is addressed mainly through primary care physicians and paediatricians.  While 
CAMHS has made improvements in treating disorders prevalent at younger ages, such as 
ADHD and conduct disorders, the Australian medical system continues to struggle with the 
treatment of mental disorders prominent in adolescents and young adults, such as mood 
disorders, psychosis, and substance abuse. McGorry (2007) suggests reform in youth mental 
health services for those patients between 12 to 25 years old toward more age-specific 
services and overlapping care between child and adult services.  The author proposes two 
ways of developing such services:  
Firstly, the current system could be restructured and enhanced  
through a strengthening and extension of the adolescent  
component of the current CAMHS model. [...] Alternatively, a  
new stream of care originating at the lower age range of adult  
psychiatry could be created, as has been established with the  
early psychosis services developed all over the world in recent  
years. (McGorry, 2007, p. S55) 
Due to the structure of the current Australian system, such reforms are crucial in order to 
implement appropriate care for adolescents, but it is also an interesting notion that could be 
applied in other national health systems, as well. 
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 Turning now to countries that have a longer history of medication in the paediatric 
population, with France‘s historically high prescription rate, Acquaviva et al. (2009) sought 
to estimate national trends in psychotropic prescriptions among children and adolescents 
across the country by looking at specific regional data and comparing findings to other 
European trends.  While overall French psychotropic use is lower than the US, it is similar to 
that in the UK, Netherlands, and Germany, with a frequency of just over 2% across the 
paediatric population; however what is being treated and prescribed varies.  Methylphenidate 
is prescribed generally between ages 7 to 16, and has a higher prevalence in males versus 
females, with a peak in male prescriptions at age eight.  Benzodiazepines, SSRIs, and 
antipsychotics all show prevalence rates increasing with age. More males than females are 
prescribed benzodiazapines through age 13, and this ratio inverts after age 13.  The SSRI 
female to male ratio is relatively equal until age 13, after which females are prescribed SSRIs 
twice as much as males.  Antipsychotics are always prescribed more for males.  There is also 
a trend of self-medication that does not follow prescriptions, as ‗about half of the 
psychotropics used by young people at 17 years are taken without a decision by a doctor‘ 
after acquiring the prescription but not being monitored by a physician or following the 
indication (Acquaviva et al., 2009, p. 5).  This study also highlighted indications for 
psychotropic medication, noting gender differences as well as other non-psychiatric uses: 
  Girls use psychotropics to deal with anxiety whereas boys use  
psychotropics to treat sleep disorders.  The use of psychotropics  
for stimulation or for fun reaches 10% for girls and  
approximately 15% for boys. [...] It appears that tricyclic  
antidepressants are used to treat enuresis in children and could  
be marginally use to treat pain. [...] Methylphenidate has another  
official indication which is narcolepsy. [...] Haloperidol is used  
although infrequently as an antiemetic drug. (Acquaviva et al.,  
2009, p. 6) 
Due to the prevalence of self-medication and alternate indications, it is difficult to discern the 
definite prescribing practices for psychiatric use.  What can be determined, however, is that it 
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is more typical for ADHD to go underdiagnosed and for anxiety-related disorders to be 
overtreated in France as compared to other nations. 
 Making the comparison of paediatric psychotropic prescription practices between the 
Netherlands, Germany, and the US, Zito et al. (2008) found that while there were some small 
discrepancies among European countries, the most significant difference was between US 
and the generalised Western European practice.  This study investigated stimulant, 
antipsychotic , antidepressant, and overall psychotropic drug prevalence in patients ages 0-19 
for the year 2000, including analysis by age, gender, and concomitant drug use (simultaneous 
use of multiple psychotropics).  Overall, the US showed a much higher prevalence of 
psychotropic use than the European countries analysed (2.27 and 3.33 times more than the 
Netherlands and Germany, respectively), and the Netherlands showed significantly higher 
prevalence rates than Germany.  This trend is reflected in the individual prevalence of the 
antipsychotic, stimulant, and antidepressant drug classes, with fewer disparities among 
antipsychotic prevalence.  However, concomitant use was significantly more prevalent in 
Germany than in the Netherlands; though, since indication of prescription was not included, 
the higher trend of concomitant use in Germany may have been due to other factors.  Zito et 
al. (2008, p. 5), note, ‗Since the bulk (62%) of the German combinations involved 
anticonvulsant-mood stabilizer and an anxiolytic/hypnotic, it is not possible to determine the 
extent of seizure disorder treatment.‘  While the US did have a higher prevalence of this 
particular drug combination than Germany, the leading pair combination in the US was 
stimulants with antidepressants, whereas the leading Dutch pair was stimulants with 
antipsychotics.  The authors suggest that differences in prescribing trends may be influenced 
by a number of factors, including the use of different diagnostic systems (DSM versus ICD), 
drug regulations and policies, clinical setting (public versus private care; specialist versus 
general physician), financial/marketing sources and cultural values. 
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6.3  What are the global trends for antidepressant prescriptions in the paediatric 
population? 
 As mentioned above, paediatric depression is identified as a global issue, but as 
suggested by psychotropic treatment trends, receives various care reflecting an individual‘s 
cultural context.  In the WHO‘s publication Caring for children and adolescents with mental 
disorders (2003), the poor prognosis of major depressive disorder in young people is 
mentioned as a cross-cultural concern.  The development of paediatric depression has a high 
rate of continuing mental disorders into adulthood, including the continuation of major 
depression, bipolar disorder, substance abuse and suicidality, and shows significantly 
increased rates of hospitalisations and psychosocial impairments, along with lower academic 
success.  While paediatric data is not included, the Jordanova et al. (2010) study in Eastern 
Europe indicates depression as one of the most common psychiatric diagnoses in that region, 
and states that 83.4% of depression patients are prescribed antidepressants and 19% receive 
concomitant prescriptions for two antidepressants.  While overall psychotropic treatment in 
this study was suggested to be outdated and/or prescribed off-label, there is a higher 
prescription rate for newer antidepressants (46%), while SSRIs and older generations of 
antidepressants are prescribed at slightly lower rates (29.4% and 29.1% respectively).  As 
noted above, it would be interesting to see if and how these prescription practices are 
extended to the paediatric population in this region, whether it is common for children and 
adolescents to be diagnosed with depression and then receive similar antidepressant treatment 
to adults, as well. 
 While France is recognised as having one of the highest prescription rates in the 
world, the prevalence of SSRIs is not as high in the French paediatric population as the 
prevalence of some other psychotropics (i.e. antipsychotics and benzodiazepines).  As 
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asserted by Acquaviva et al. (2009), both boys and girls below the age of 13 had a 0.15% to 
0.25% frequency of SSRI prescriptions in 2004.  As mentioned above, this rate increases with 
age, rising from 0.4% to 1.4% in males aged 14 onwards and reaching 2.2% in females by 
age 18.  Similar age-specific trends are observed in other Western nations by Zito et al. 
(2008), though the rate in antidepressant prescription increase varied by region: ‗In Germany 
and the Netherlands, 15-19 year olds were over 3 times more likely to utilize antidepressants 
than 10-14 year olds, whereas in the US the 15-19 year old group use was only 28% higher 
than in the younger aged group‘ (p. 4).  The overall prevalence of antidepressant prescriptions 
also varied across the different regions, being more than five times more prevalent in the US 
than the Netherlands and Germany according to the data presented by Zito et al. (2008), and 
consistent with previous studies consulted asserting higher rates of US antidepressant use.  
The class of antidepressants prescribed also differed; TCAs represent the majority of 
antidepressant prescriptions in Germany, about half the prescriptions in the Netherlands, and 
only a minority of prescriptions in the US, and the inverse trend is observed for SSRI 
prevalence.  With the changes made to paediatric prescribing policy in the mid-2000s in both 
the US and EU since this data was collected, it would be interesting to see the effect on 
prevalence rates, particularly concerning the rates of SSRI prescriptions; however, it may be 
anticipated that the comparative trends between the different nations would remain consistent 
(i.e. the US showing the highest rate of antidepressant prescriptions, followed by the Dutch 
and then the Germans). 
 
6.4  What effect does culture appear to have on treatment?  Further, is medicalising 
normal a Western phenomenon? 
Noting that medical practice is considerably culture-dependent, especially in the field 
of psychiatry, exploring international trends puts western treatment in context.  The US in 
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particular has significantly higher rates of psychotropic use in the paediatric (and adult) 
population than the rest of the world.  While Western Europe has lower rates than the US, 
this region also has a fairly common practice of medicating children, and prescription rates 
both in Europe and in other parts of the world have been steadily increasing, as evidenced by 
the concern in developing policies.  From a survey taken from 2000 to 2002, the lowest 
increase in psychotropic prescription rate was 13% in Germany, while the highest increase 
was 68% in the UK over those three years (Timimi, 2008).  Despite this emerging trend, it 
may be expected that the US will remain in the forefront of prescription trends due to its 
‗individualist and activist therapeutic mentality‘ (Zito et al., 2008, p. 2), whereas other 
cultures have different values which are equally reflected by medical practice.  For example, 
the study of French paediatric prescription use by Acquaviva et al. (2009) described above 
notes the higher use of antianxiety medication and sleeping aids, versus the neurostimulant 
and antidepressant trends found in the US, and the associated diagnostic trends mentioned 
above.  These differences cannot be explained by accessibility to healthcare and medication, 
but are more likely due to culture beliefs.  Even in countries with less of a history of 
medicating in psychiatry, such as those investigated by Jordanova et al. (2010), common 
prescription trends differed from Western trends.  Eastern European practice tends to use 
older generation drugs; this was found to be in spite of cost efficiency, but may perhaps 
reflect the level of development of their mental health services in that region.  In what was 
formerly referred to as the ‗Second World‘4, as well as in other less developed regions, it is 
possible that the difference in treatment and/or lack of treatment is strongly influenced by 
limited availability of mental health services and access to those services, but it may also be 
influenced by different cultural beliefs and social attitudes toward mental health care.  
Moreover, just as prescribing trends differ due to culture, so too will diagnostic trends, in part 
                                                 
4
 The Second World refers to the former communist countries of the Soviet Union and Eastern Europe (Giddens, 
2006). 
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due to the use of different diagnostic systems, but also cultural views of particular disorders 
and the need to treat certain aspects of mental health.  This is evidenced, for instance, by the 
diagnostic tendencies in France noted above, as well as higher diagnosing of psychosis in 
Eastern Europe (Jordanova et al., 2010).  
A closer look at Western paediatric psychiatry by Timimi (2004; 2006; 2008) 
strengthens the notion that medicalisation is a phenomenon that is characteristic of Western 
culture.  In general, following World War II, the West has tended to promote permissiveness, 
individualism and the associated rights of children, which is suggested to be a consequence of 
the collapse of the stable family environment. This trend has resulted in evolving markets 
targeting the young population as consumers and blurring the distinction between childhood 
and adulthood.  Children develop a value system based the influence of their parents and 
especially their culture, and ‗in the West children are socialised into a system that embraces a 
particular idea of freedom through promoting individualism, competitiveness, inequality and 
the rejection of forms of authority‘ (Timimi, 2006, p. 36).  Consequently, the Western culture 
fosters an increase in self-examination and self-awareness, which then endorses 
medicalisation as individuals identify more of their own inadequacies.  Though 
medicalisation, then, is a product of cultural values, it inherently removes the examination of 
context, including the broader cultural context that advances it.  Further, this emphasis on 
competition and individualism causes parental and professional anxiety to increase in an 
effort to promote a child‘s achievement of his or her full potential, and such pressures also 
increase the child‘s anxiety and trigger psychopathology (Timimi, 2008).  In the case of 
paediatric depression, as identification of depressed children increases, whether this increase 
is due to the changing diagnostic criteria or the cultural context is unclear.  Timimi (2004) 
suggests that the greater influence on this increase is the sociocultural changes described 
above, which cause greater unhappiness during childhood. 
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Extending this analysis to other countries, Timimi (2006) discusses the imposition the 
West has made on other countries‘ cultural beliefs with regard to childrearing and paediatric 
mental health problems.  Many non-Western countries have a very different family-centred 
culture, where duty and responsibility to the extended family is the primary focus.  For 
instance, the Organization of African Unity has produced a child-protection policy that was 
structured around family responsibility, not child rights.  However, in Asia, Western theories 
are bleeding into childcare practices, as some Asian experts begin to argue that ‗many of the 
traditional beliefs and practices of Asians prevent them from seeking and using new scientific 
knowledge in childrearing‘ (Timimi, 2006, p. 37).  Although, why are Western scientific 
advances assumed to be better?  Normality and disorder are functions of culture, so if a 
culture does not view particular behaviours as problematic, imposing a medicalised view 
would seem unnecessary, and perhaps even counterproductive as context becomes 
increasingly discounted.  For example, Timimi (2006, 2008) describes a study carried out in 
2003 by Brewis and Schmidt in a Mexican school of 200 students, where only one child was 
diagnosed with ADHD despite 16 children fitting the diagnostic criteria.  When discussing 
the study with parents and teachers at this school, the finding was that ADHD-type 
behaviours were considered within the realm of normal, age-appropriate behaviours.  While 
Timimi (2006) notes the need to be conscious of context and culturally sensitive to child 
suffering rather than impressing Western medicalisation on the rest of the world, this view 
should not discount the attention required by those children who undeniably suffer from 
mental illness and could benefit from appropriate psychiatric care. 
By the evidence provided, it does seem that overall medicalisation is mainly a 
Western issue, not yet as common in other regions.  However, while the West arguably 
overtreats for mental disorders, countries with less developed mental health services have left 
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their populations at risk of undertreatment.  As Dr. Benedetto Saraceno writes in the 
Foreword of Caring for children and adolescents with mental disorders: 
We are well aware of the risks inherent of medicalization in any  
discussion of mental health problems of children and  
adolescents – or worse, it‘s ―psychiatrization‖ – of problems of  
normal living and normal psychosocial development.  We also  
aware of the many spurious interests endangering an unbiased,  
objective approach to normal developmental issues, that tend to  
unduly put many problems of normal living in the basket of  
―medical or mental disorders‖. 
 
However, this does not justify a responsible public health  
officer from shunning action that provides adequate and  
appropriate interventions for children and adolescents with  
unequivocal mental disorders. (WHO, 2003, p. 1) 
 
6.5  In summary, what are the ethical implications of treating paediatric depression 
around the world? 
 The incorporation of this global perspective infers that paediatric depression is a 
concern throughout the world.  As mentioned above, depression in children and adolescents 
is noted as a priority disorder by the WHO.  Depression in adults is certainly seen everywhere 
and treated where resources are available; likewise, it can be assumed that young people may 
have depression independent of where they are in the world, however treatment will be even 
more limited than that for adults due to minimal availability of appropriate resources (i.e. 
professionals trained in both mental health care and paediatrics).   
There is a spectrum of available mental health services throughout the world, as 
indicated by the discussion above, which in addition to access to material resources, is also a 
reflection of cultural values.  In the case of depression, consider the presentation of symptoms 
and criteria for diagnosis.  Chapter 1 explained that the DSM and ICD diagnostic systems are 
culturally sensitive; based on this assumption, does it make sense to fit these two diagnostic 
systems to various different cultures?  This practice would seem equivalent to the difficulty 
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of applying the adult diagnosis of depression to the atypical presentation found in children. 
The expression of psychiatric disorder signifies an individual‘s distress and inability to cope, 
and understanding of such behaviour is reliant on cultural context.  Rather than universally 
applying the adult diagnosis of depression set out by either the DSM or ICD, it would seem 
more appropriate to create cultural-specific systems across the world for both adults and 
children.  By sensitizing the diagnosis to the cultural context, global ‗depression‘ will not be 
addressing exactly the same psychiatric presentation, but it may be a means of identifying 
and providing appropriate treatment to affected individuals. 
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CHAPTER 7 
What does paediatric depression look like in the clinical 
setting?: A professional perspective 
 
 
7.1  Why should practicing clinicians be consulted for this thesis? 
 Up to this point in the thesis, a critical appraisal of peer-reviewed scientific and 
clinical literature as well as policy literature has provided a thorough review of relevant 
information published by researchers, physicians, and policymakers, produced an ethical 
analysis of this information, and drawn important conclusions concerning the diagnosis and 
treatment of children and adolescents with mental illness, namely that children are not little 
adults, diagnosis is subjective, both biology and context must be attended to, and treatment 
may have different psychological and biological effects in children than in adults.  While in 
published work researchers and clinicians alike may highlight general practice trends and 
raise specific points of concern or support with regard to the application of psychiatry to the 
paediatric population, a complete picture of how diagnosis, identity, and treatment fit 
together in reality is left unclear.  By speaking with clinicians directly, the interactive 
component gained from speaking about the specific issues addressed in this thesis allowed a 
more thorough analysis of a child‘s experience of psychiatric disorders, and more specifically 
depression.  Through a focus on depression as well as the use of other anecdotes and years of 
clinical experience, semi-structured interviews allowed paediatric mental health care 
specialists to speak directly to those three aspects as related to the care of children and 
adolescents. 
 Collecting information through semi-structured interviews is particularly 
advantageous in the context of this thesis; not only were relevant questions answered, but 
there was also a discussion element.  This method offered an opportunity to gather 
information and necessary clarification from experts in the field, while also providing these 
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experts with a fresh perspective on their work.  By calling attention to what they 
automatically do in practice, both the researcher and experts were able to draw novel 
connections through what has become an instinctive practice for the experts.  This new 
perspective does not evaluate the clinicians‘ work; rather it examines their work from a 
different viewpoint, focusing on why they make certain diagnosis and treatment decisions and 
how their thinking and practice is determined and reflected by the experiences of the 
paediatric patients.  Also, it is important to note that the practices described in the interviews 
should not be generalised to be typical national practice, but serve as examples of the way 
current medical knowledge and guidelines may be applied in a real clinical setting. 
  
7.2  How were the semi-structured interviews carried out? 
 There were five paediatric clinicians consulted for this thesis, two working for private 
practices in the US and three working for the NHS in Scotland.  The US participants were a 
doctorate-level general psychologist and a behaviour specialist consultant.  The UK 
participants were two consultant child and adolescent psychiatrists and a third year specialty 
registrar psychiatrist working with children and adolescents
5
.  Ethical approval for this 
research was granted on 11 March 2011 by the University Teaching and Research Ethics 
Committee (UTREC) and the Biology School Ethics Committee at the University of St 
Andrews.  The questions guiding the interview are included in Appendix F.  Each interview 
lasted for approximately 15 to 30 minutes, was recorded on a Sony ICD-PX820 Digital Voice 
Recorder, and deleted following transcription.  After the interviews were transcribed, a 
thematic analysis was carried out on these data to provide comparisons to the broader 
literature search conducted for this thesis with regard to the purpose of diagnosis, 
presentation of paediatric depression, common treatments in this population, impact of 
                                                 
5
 The third year of specialty training in psychiatry is abbreviated as ST3. 
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disorder, diagnosis and treatment on identity, and the possibility of future neuroenhancement 
practices in this population.  The following codes were applied for referencing purposes: the 
US psychologist=PC1; the behaviour specialist consultant=PC2; the first UK psychiatric 
consultant=PC3; the second UK psychiatric consultant=PC4; and the ST3 registrar=PC5.  
The results are discussed below. 
 
7.3  Based on the professional perspectives given, what is the purpose of diagnosis? 
 Put simply, diagnosis was described by those interviewed as an identifier.  It 
facilitates developing a treatment plan because it categorises a patient‘s symptoms and 
experiences.  One of the American clinicians described diagnosis as a means of providing a 
‗common language of the clinicians,‘ but also noted that one of the main reasons for 
providing a diagnosis is because the clinician is expected to do so, ‗that‘s the system‘ (PC1).  
As found in the literature search, the American clinicians who were interviewed highlighted 
the importance of diagnosis as a means of obtaining medical assistance and services, and 
diagnosis ‗starts this machine going‘ (PC2).  The clinical psychologist would determine a 
diagnosis through a minimum of two 2-hour assessment periods on separate days to take a 
history, conduct a clinical interview, and gather standardised behavioural reports from 
parents and teachers.  The behavioural specialist does not personally provide a diagnosis, but 
noted: 
Often children are brought in to see a psychiatrist sometimes  
for 20 minutes to a half hour, [who] listen to the parents‘ report  
and, without even having a conversation with the child,  
develop a diagnosis; they do not do any kind of sustained  
observation, they aren‘t getting information from other settings. 
(PC2) 
This tendency for misdiagnosis may be a result of too much haste to access services and/or 
medication treatment, as parents come in having read diagnostic criteria on the internet and 
relate those symptoms they know will grant a necessary, albeit inappropriate, diagnosis. 
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 Likewise, a British psychiatrist noted the inappropriate diagnosis and treatment for 
paediatric mental disorders as prescribed by general practitioners (GPs) in order to obtain 
treatment faster, without having to wait to see a specialist (PC3).  When patients come to the 
particular psychiatric clinic in Scotland visited for this thesis however, clinicians tend to 
avoid giving definitive diagnoses.  Except in more severe cases, particularly those with a very 
clear biological basis determined by a clinical assessment of the history and context of the 
psychiatric presentation, diagnosis would generally only be given if needed for GP records 
and is determined using such evaluations as the DSM-IV criteria and Kiddie-SADS semi-
structured interview
6
 (PC3) or an ICD checklist and biopsychsocial formulation (described 
below) (PC4; PC5).  For one clinician, the DSM-IV is used as part of the assessment of a 
patient‘s condition, but is only one part of a more holistic assessment process, which also 
integrates assessing the individual‘s family and school environments (PC3).  Based on this 
practice, a specific diagnosis fails to capture the whole picture. Further, if a diagnostic label is 
provided, it seems to imply that medication is the answer, and that is often not the case 
(PC3); and particularly for children, who ‗mostly are not as resourceful as adults‘, it is crucial 
to ensure a strong support system for the patient and address systemic issues in his or her 
environment, ‗e.g. family, school, friends‘, elements that fall outside a definitive diagnosis 
(PC4). 
 The specialty registrar agreed that relying too heavily on diagnosis can be detrimental 
to the process of receiving appropriate help.  While the diagnosis is formed based on a 
‗constellation of symptoms‘, the symptoms and the patient get lost behind the label, which 
medicalises and arguably dehumanises the patients feelings and experiences into a diagnostic 
code.  In this way, if the diagnosis is actually too condensed, then it may be misleading, and 
‗can result in people really being misunderstood [...] at best and inappropriately managed at 
                                                 
6
 The Schedule for Affective Disorders and Schizophrenia for School-Age Children (Kiddie-SADS) semi-
structured interview is a diagnostic tool used in the paediatric clinical setting to support DSM or ICD diagnosing 
practices (Lauth et al., 2008). 
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worst‘ (PC5).  However, the specialty registrar also acknowledged the benefits of giving a 
diagnosis, which yields to ‗guiding treatment, explaining feelings and behaviours, and also 
[...] accessing support‘ (PC5).  Leading up to whether a particular patient case warrants a 
diagnosis, the specialty registrar first takes a comprehensive clinical history from the child 
patient and family, has the patient and family complete a strengths and difficulties 
questionnaire to measure functioning, and tries to determine the context of the patient‘s 
problems in terms of biological, psychological and sociological aetiology (i.e. the 
biopsychsocial formulation mentioned above) .  After this analysis, if there is still a suspicion 
of a particular diagnosis, then typically a structured checklist or score chart is used to match 
the symptoms with an ICD-10 diagnosis.  Though, again, in an aim to treat symptoms, often 
patients will not necessarily meet strict diagnostic criteria. 
While ADHD and depression seem to be the most commonly seen disorders by the 
clinicians interviewed, there are a number of other patient issues that are typically seen, as 
well, such as autism, anxiety and anger problems.  Also, more recently bipolar disorder in 
children is becoming more recognised, but because it may present so similarly to other 
disorders in some cases within this age group, it is very difficult to diagnose in the paediatric 
population.  As one of the British psychiatrists explained, some bipolar patients experience 
very rapid cycles and are clear cases, but others may more easily get misdiagnosed with 
ADHD, misconduct, depression, and so on, when there is a more drawn out episodic mood 
disturbance.  Though the novelty of paediatric bipolar disorder sometimes raises concern of 
overdiagnosis, in actuality misdiagnosis and confusing bipolar with other issues appears to be 
more common (PC3). 
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7.4  How does paediatric depression typically present? 
 While the information gathered in the interviews may not be generalised to the entire 
population, it may provide an idea of the presentation expected to be seen, particularly in 
light of the consistency between the interviews, as well as compared to the literature 
referenced earlier in this thesis.  The American clinical psychologist has found that the 
general symptoms that depressed paediatric patients demonstrate include ‗cutting, lethargy, 
social withdrawal, really pervasively sad affect, and [...] a lot of anger,‘ as well as sleep 
disorders (PC1).  The psychologist also noted that adolescent depression will look different 
than child depression, and often significant anxiety in children is mistaken for depression and 
other disorders, including ADHD, misconduct, and even autism.  Similar findings were 
reported by the British clinicians, who listed common symptoms in the paediatric population 
to include irritability, anxiety, difficulty working, lack of concentration, lack of interest in 
hobbies, disengagement, social withdrawal (not going out seeing their friends, falling out 
with friends more, or just not being bothered with them), isolation, self-harm, suicidal 
thoughts, some sleep disturbance, worrying, very stressed, potential appetite changes, low 
energy, low mood and unhappiness, negative outlook with regard to oneself and the world, 
hopelessness and uselessness (PC3; PC4; PC5).  Further, a difference based on age was 
described by one of the British psychiatrists; younger patients will display more angry 
outbursts and perhaps uncharacteristic difficult behaviour at school, while adolescents show 
more internalised symptoms and tend to be much better able to explain their symptoms 
(PC3).  Another psychiatrist noted the tendency for girls to more often internalise symptoms 
than boys (PC4). 
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7.5  What are the common treatments prescribed for paediatric patients, particularly 
for depression?  And has this been impacted by the changing antidepressant warnings 
and guidelines over the past six years? 
While neither of the American clinicians interviewed can prescribe medications, both 
were able to comment on the medication use by their clients.  As mentioned by the 
behavioural specialist, children on the autism spectrum are much more commonly treated 
with psychotropic medication than children in the rest of the population; she estimated that 
more than 75% of her clients were on some form of psychotropic medication, and several of 
these children were on four different medications at the same time.  The most common 
medications used by patients coming to that clinic include Ritalin (methylphenidate), Abilify 
(aripiprazole), Tenex (guanfacine), Strattera (atomoxetine), Vyvance (lisdexamfetamine), and 
clonidine (PC2).  Autism spectrum disorders and associated treatments present a number of 
concerns, in addition to those discussed regarding child mental health, that will not be 
addressed in this thesis, but have been investigated elsewhere (e.g. Gerhardt et al., 1991; 
Elder, 1996; Fuentes & Martin-Arribas, 2007). 
The clinical psychologist estimated that about a third of his patients were prescribed 
psychotropic medication in conjunction with his psychotherapy services, and since he was 
consulted in order to provide the initial diagnosis, this number would go up to about half of 
his patients receiving medication at some point in their treatment, particularly for ADHD-
stimulant treatment.  While significantly less common than stimulants, antidepressants were 
noted as the second most prevalent drug treatment in the young population seen, and although 
rarely used in his clientele, the third most notable medication group was that of 
antipsychotics.  Specifically, the antidepressants most commonly prescribed were said to be 
Prozac (fluoxetine), Lexipro (escitalopram), and Zoloft (sertraline).  Often times the patients 
coming to see the clinical psychologist are medicated by their primary care physician, who 
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would ask the psychologist for treatment recommendations; the psychologist tends to 
recommend Prozac first, in part because it is reasonable and prudent to ‗hide a little bit 
behind what‘s approved at what age‘ but also because Prozac shows less withdrawal 
symptoms and lack of serotonin syndrome
7
 if children forget to take a dose of their 
medication (PC1).  After the FDA Black Box Warning was issued, which ‗started because of 
Paxil (paroxetine) with some children in Canada that weren‘t supervised‘, prescribing 
patterns have not seen noticeable changes in his experience; there is simply more concern 
regarding the monitoring and supervision of children taking antidepressants (PC1).  Despite 
the observation that many parents do not want to bother with the behavioural work and 
assume the medication will ‗take care of it‘, it is very rare that a child on antidepressants will 
not also be in therapy. 
The interviews with British psychiatrists suggested that treatment practices in the UK 
are comparable to those found in the US.  One psychiatrist estimated that up to a third of her 
patients were taking psychotropic medication (PC3), while the specialty registrar noted that 
less than 10% of the patients on his caseload were on medication (PC5).  Mainly stimulants 
and antidepressants are the most prevalent in this population, with the rare prescription for 
antipsychotics.  When treating ADHD, the prescriptions are typically for stimulants (e.g. 
methylphenidate) or atomoxetine, which is a selective norepinephrine reuptake inhibitor 
(NRI) (PC3; PC4); generally, though, it is more common for GPs to manage ADHD (PC5).  
In addition to psychotherapy, treatment of severe OCD might call for an SSRI, such as 
fluoxetine or sertraline.  For psychotic illness or more aggressive behaviours accompanying 
autism, antipsychotics would be prescribed, such as the atypical antipsychotic risperidone or 
quetiapine.  For the treatment of depression in children, following first-line CBT and other 
psychotherapy, fluoxetine tends to be the first antidepressant prescribed.  If fluoextine 
                                                 
7
 Serotonin syndrome is an adverse effect to drugs which increase the level of serotonin in the brain, and may be 
a life threatening reaction (NCBI, 2010). 
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appeared ineffective, a reassessment of the patient and further family therapy or CBT might 
be employed, or the prescription of sertraline as a second-line alternative antidepressant if 
side effects had been an issue with fluoxetine.  Both psychiatrists PC3 and PC4 commented 
on the huge impact the changing guidelines have had on prescription practices, putting 
fluoxetine at the forefront if medication is the necessary treatment, yet also noted concern 
with the tendency of GPs to prescribe other treatments despite the guidelines.  For instance, 
one psychiatrist mentioned a specific case of a patient with clear depressive symptoms who 
was coming in to the psychiatric clinic for an urgent referral due to mismanagement of a 
citalopram prescription by the GP (PC3). 
Also as a result of the changing guidelines and black box warning, the specialty 
registrar pointed out the benefits of this publicity.  The attention given to SSRI use in 
children and adolescents and the associated increased suicidality has helped raise awareness 
of antidepressant drug effects in the young population.  It has also stimulated finding 
alternative treatments for paediatric depression other than medication.  Alternatives include 
psychological treatments, such as CBT, interpersonal therapy or psychodynamic-focused 
therapy exploring past experiences and trauma, and social treatments, such as raising 
awareness in other people, education, encouraging patients to go out more, helping to plan 
their day or seeking support from someone willing to go out for lunch or other activities once 
or twice a week with the patient.  If these alternative treatments, particularly talking therapy, 
are able to help increase motivation, then often the need for (potentially harmful) medication 
may be negated (PC5). 
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7.6  What impact does the experience of a mental disorder, diagnosis, and treatment 
appear to have on identity development? 
 Before discussing identity explicitly, apparent self-awareness in paediatric patients 
was addressed in the interviews.  Generalised from all the interviews, while perhaps a 
function of the patient‘s age or severity of disorder, often patients are aware that there is a 
problem, and thus, are aware of why they are seeing a mental health specialist.  Many 
paediatric patients, particularly those in adolescence, can recognise their own distress.  That 
being said, despite this awareness, children and adolescents are not the ones who decide 
whether or not they should see a specialist, rather it is decided by their parents.  As the 
American psychologist stated, ‗We don‘t see kids because they want to be seen, we see them 
because the adults want them to be seen.  That‘s an essential difference between working 
with children and working with adults‘ (PC1). 
 Whether paediatric patients are aware of their disorder or not, their experiences 
resulting from the disorder, diagnosis, and/or treatment may certainly affect their sense of 
who they are and how they view themselves as they continue to develop an identity as 
individuals.  Though medicalising experience by providing a diagnostic label is arguably 
forcing an internalization of the disorder, it may also remove a sense of self-blame and yield 
relief for some.  The American psychologist suggested that children may be more upset by a 
lack of diagnosis due to the ‗impact that they‘re less capable and the negative judgemental 
quality of the interactions‘ experienced by disordered individuals; therefore, a diagnosis in 
such cases would mean that the individual may not feel at fault for these negative 
experiences, and in fact, there may be hope for improvement through treatment (PC1). 
 On the other hand, use of the diagnostic label may be considered less helpful for some 
patients.  As described above, the British clinicians interviewed suggested avoiding definitive 
diagnostic labels in order to take the focus away from solely biological causes and/or 
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medication treatments.  There are some patients who may clearly show a more isolated 
biological (versus psychological) illness, which appears to interrupt normal premorbid 
functioning and identity development; for example, if a previously normally developing child 
becomes depressed, that child may experience a disturbance in his or her sense of identity 
and/or daily functioning due to the depressive process.  In such a case, diagnosing, explaining 
and treating the disorder effectively makes the child better and is the straightforward path 
toward the child ‗getting back on track‘ (PC3).   
Though, getting better in chronic cases may not be as simple; in addition to 
experiencing the disorder itself, these patients may have been subject to bullying at school or 
family difficulties, issues which definitely affect the child‘s development of identity and 
should be dealt with through CBT and family therapy sessions.  The specialty registrar gave 
an example of a 14 year old girl with ADHD whom he had on his caseload, who despite the 
usefulness of stimulant medication to resolve some issues, the disorder itself included 
relationship problems between the patient and her mother and teachers, for example, which 
could not simply be taken care of by medication.  The patient required more extensive 
psychotherapy and support because the ADHD impacted her identity in more ways than a 
tablet could resolve by only addressing biology (PC5).  For young patients who are already 
struggling with their identity, giving such a specific diagnostic label only addresses part of 
the problem.  Thus, it is even more important that paediatric patients receive CBT as part of 
their treatment, which would address self-esteem and the way the patient views the world, 
giving the disorder personal context.  Particularly for younger patients, they may feel very 
little sense of autonomy, whereas older adolescent patients may feel more in control of 
themselves, but in either case psychotherapy could speak to this issue.  Through family 
sessions, pathology and normal adolescent behaviour can become more distinguishable, 
which may lead to a greater ability to trust the young patient and help him or her develop a 
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stronger sense of autonomy and responsibility for their actions (PC3). However, in some 
cases, as discussed by the specialty registrar, the stigma associated with treatment regardless 
of the form, may negatively impact identity development as well.  Having to explain that he 
or she needs to see a psychiatrist or take medication can cause so much additional stress that 
psychiatric treatment is stopped, even if the patient was initially open to CBT, medication, 
and/or other psychiatric treatment (PC5). 
 
7.7  Is there a future for neuroenhancement in the paediatric population? 
 The practice of paediatric neuroenhancement continues to be considerably 
controversial.  In light of the antidepressant enhancement trend in adults (e.g. as discussed by 
Degrazia, 2000; Elliott, 2004; Parens, 2004) and the increasing neurostimulant enhancement 
trend in children (e.g. as discussed by Singh, 2008; Singh & Kelleher, 2010; Parens & 
Johnston, 2011), this topic was discussed briefly during the interviews with clinicians.  All 
five clinicians interviewed voiced opposition to the use of medication for enhancement 
purposes.  The American psychologist would discourage neurostimulant use unless 
absolutely necessary for treatment of a disorder ‗because it‘s not a cure and we‘re also 
looking at duration‘.  In this context, duration is referring to the length of time one dose 
remains effective; the example given was Strattera, which lasts for 24 hours, making it less 
prone to the misuse and abuse by university students, for instance.  He also noted, however, 
the importance of psychotropic drugs as a valuable and effective tool if used selectively and 
properly for those requiring treatment of a disorder. 
Due to the effectiveness of newer psychotropic drugs in general, not only 
neurostimulants, the grey area between treatment and enhancement in paediatric psychiatry 
increases, in terms of depression as well as other disorders; if not treating a distinct disorder 
or dysfunction, then ‗treatment‘ may edge toward ‗enhancement‘, as discussed earlier in this 
119 
 
thesis.  One of the British psychiatrists commented on the difficulty of making the decision to 
medicate in such borderline cases.  The thought process in such cases might be, ‗Well, they 
don‘t quite fit the criteria, but they really want [medication].  Maybe that‘s the way to get 
them engaged, and they are going to come and talk to me, as well; ok, we‘ll go for it, [...] in 
general, it‘s not particularly harmful as long as you follow them up. [...] We‘re very clear 
about what we‘re expecting to see from this and what you can‘t expect to see‘ (PC3).  Some 
patients show improvements and others do not; and whether improvements might just be 
placebo effects is also unclear.  However, in terms of a patient desiring medication 
specifically for the purpose of enhancement, one of the psychiatrists stated, ‗I can see why 
people might want to do that and maybe perform better in exam situations but think it gives a 
person a better sense of self worth and achievement if they feel they did it themselves‘ (PC4). 
On the other hand, as the specialty registrar pointed out, it is very common to take 
stimulants, such as coffee or Red Bull, or other enhancers, such as omega-3 fish oils, so 
enhancement itself is already being practised.  Although, when introducing prescription drugs 
into the enhancement context, the debate over who gets treatment and who does not becomes 
an issue, and may presumably be even more problematic for the NHS if it supports non-
essential medicine.  Further, the risks of taking drugs such as SSRIs for enhancement 
purposes may be fairly dangerous as the drugs are not without side effects, including ‗GI 
disturbances, [...] increased agitation, [...] increased suicidality, [...] precipitating hypomania 
or mania‘, and certainly might not outweigh the benefits of enhancement; whereas, the 
benefit of relieving impairment could more realistically outweigh those same risks (PC5).  
The specialty registrar went on to say that many people have maladaptive personality traits 
and stress may cause some level dysfunction (e.g. getting angry when hungry), and giving 
someone Prozac, for instance, might help manage these traits; however, as mentioned by the 
clinical psychologist, this is not curing the cause of the problem, which may be better 
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addressed by psychotherapy instead.  The difficulty with counselling as an alternative 
enhancement is partially access, public acceptance, and the inconvenience as compared to 
just taking a tablet.  Then the issue of medicalisation arises; giving a diagnosis and focusing 
on the biological treatment through medication can help some people, but should this be the 
practice for treating and essentially enhancing ‗normal‘ people who are more likely 
experiencing psychological problems?  According to the clinicians interviewed for this thesis, 
the latter psychological issues faced by normal people may be better treated through CBT and 
other methods addressing contextual problems faced by the individual, rather than medicating 
non-disordered children and adolescents. 
 
7.8  In summary, did the information conveyed by practicing clinicians reflect what was 
found in the literature? 
 Overall, the interviews with clinicians were consistent with information found in the 
literature.  Furthermore, the various clinicians often reflected similar information pertaining 
to the use of diagnosis, presentation of paediatric depression, psychiatric treatment in the 
paediatric population, the effect of psychiatric experience on identity development, and 
paediatric neuroenhancement, regardless of specific profession or location of practice.  In 
certain cases, a diagnosis was found to be very helpful in order to best explain a patient‘s 
experiences and feelings as well as direct treatment, but the clinicians also specified that it 
should be applied with careful consideration due to the tendency to discount a patient‘s 
context when there is a specific diagnosis given.  Though every case of depression has a 
unique presentation, there are a number of very common symptoms listed by the different 
clinicians, generally shifting from externalising behaviours towards internalising symptoms 
as a function of age.  Both in the US and UK, prescribing practices outlined by the literature 
and interviews tend to concern mainly stimulants and antidepressants, and SSRI prescriptions 
121 
 
are most often for fluoxetine, as suggested by UK guidance and the FDA black box warning.  
Further, the clinicians interviewed commented that there is typically a noticeable negative 
effect on identity development caused by experiencing a psychiatric disorder during 
childhood and adolescence, which is often, but not always, improved through appropriate 
treatment.  While all the clinicians initially rejected the practice of neuroenhancement, 
particularly in children, they also acknowledged the possibility of an increasing trend in 
enhancement.  Although psychotropic medications have become a very valuable clinical tool, 
serious risks remain associated with use in the paediatric population, whether for treatment or 
enhancement purposes, and thus, should be used with caution. 
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Chapter 8 
Conclusion 
 
This thesis has investigated the key ethical concerns involved in the diagnosis and 
treatment of paediatric mental health disorders, and specifically examined these concerns 
within the context of paediatric depression.  By addressing these issues through the lens of 
depression, the experience of disordered children and adolescents highlights the relevant 
ethical considerations, and may serve as ethical guidance in the treatment of paediatric mental 
health care.  Specifically, ethical guidance refers to the standard points involving moral 
judgements that must be taken into account by both the clinician and patient (including 
parents) in order to most benefit child and adolescent psychiatric patients.  While this thesis 
explores the ethical issues from the historical, philosophical, psychological, biological, 
cultural, and professional perspectives individually, many of the points raised are not 
confined to one perspective, nor are they entirely independent from one another.  There are 
thirteen major ethical concerns to be considered when diagnosing and treating children for 
mental health disorders, which may be grouped into three parts: identity development and 
paediatric physiology within developmental issues; subjectivity of diagnosis, accuracy and 
appropriateness of diagnosis, medicalisation and prevalence of disorder within diagnostic 
issues; and consent and confidentiality, access to services, paradox of psychotropic use in 
paediatrics, lack of treatment data, inability to directly apply adult data to paediatrics,  
treatment paradox with normal individuals and linking neurobiology to psychology within 
treatment issues. 
 Due to their stage of development, children and adolescents cannot be considered as 
simply little adults.  Firstly, in terms of psychology, paediatric patients are in the process of 
developing their identity.  Based on the findings in this thesis, by giving a diagnosis and/or 
providing treatment, these labels and experiences often appear to be integrated into the young 
123 
 
patients‘ understanding of themselves, leaving a lasting imprint on their concept of self more 
so than if they had already held a matured understanding of self.  This psychological 
sensitivity relates to the issues of diagnosis discussed below.  Secondly, children and 
adolescents are physiologically different than adults, and within the context of psychiatry, the 
plasticity of the immature brain leaves young patients particularly vulnerable to the 
development of psychopathology as well as to the effects of psychotropic treatment.  
Physiological immaturity relates to the treatment issues discussed below. 
 Within the area of diagnosis itself, there are four elements.  Firstly, the subjectivity of 
a diagnosis requires consideration, particularly in borderline cases.  While diagnosis is based 
on an arbitrary distinction, as determined by a discrete number of symptoms and/or a 
clinician‘s professional judgment, it is associated with both benefits and detriments; 
therefore, the lack of an absolute definition brings up the second diagnostic issue, that of 
accuracy and appropriateness.  A diagnosis rarely provides a perfect definition of a patient‘s 
problems, and though the diagnosis typically directs an appropriate treatment plan, if the 
diagnosis is not accurate, the treatment associated with the given diagnosis can have negative 
effects, such as unnecessary and inappropriate prescriptions, added stress or inadequate 
support services.  Thirdly, the issue of medicalisation when treating the paediatric population 
requires additional attention for two reasons: its tendency to discount context and its 
implications for the future of both the patients themselves as well as society as a whole.  With 
respect to context, this is a crucial factor of any psychiatric disorder, for which diagnoses are 
made based on impaired functioning within an individual‘s environment.  Thus, removing 
context from the equation that formulates a treatment plan seems contradictory; although 
medicalising problems may improve a patient‘s condition to some extent, it has the tendency 
to yield a biological and medication-orientated focus which cannot fully dissolve psychiatric 
problems.  In terms of the future implications of medicalisation practices, this runs the risk of 
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subjecting young patients to treatments that will affect both their psychological and 
physiological development, as discussed above, and ultimately questions our society‘s 
definition of normal and what is expected behaviour and functioning.  This relates to the 
fourth and final diagnostic issue, which is the true prevalence of psychiatric disorders in 
children across the world.  While psychiatric disorders have been found to exist worldwide, 
the definition of ‗normal‘ behaviour versus diagnosable pathology is subjective by nature, as 
mentioned above.  Medicalisation is considered a Western issue, but is bleeding into 
psychiatric practices everywhere, again narrowing focus farther away from a patient‘s 
context, which is in fact a crucial element of psychiatric problems and treatments. 
 As stated above, paediatric patients are not little adult patients, and cannot be treated 
as such.  Treatment issues may be described in seven parts, which are all intertwined.  Firstly, 
the process of treating paediatric patients is complicated by different consent and 
confidentiality practices than those for adults.  While children may provide assent for 
treatment, consent is granted by adults; therefore, treatment will always be out of the child‘s 
control to some degree and requires adults in order to access care.  Further, confidentiality 
between the clinician and child patient is muddied by the inclusion of parents or other adults 
required for treatment consent.  The second issue in paediatric treatment is physical access to 
services.  Appropriate treatments are made available by adults, whether it be the 
parent/guardian decision to seek services or the presence of resources in the region, both of 
which are guided by environmental context.  The third treatment issue is the paradox of 
psychotropic use in the paediatric population; the paradox is a result of the risk of treating 
children with drugs lacking appropriate data countered by the difficulty of conducting 
research in paediatrics, a vulnerable population.  Fourthly, the lack of treatment data in the 
paediatric population is an issue in itself.  The practice of treating adults off-label is generally 
avoided and potentially dangerous; this should also be the case for treating children, and the 
125 
 
only way to remedy the issue is to conduct the required research of treatment effects.  This 
feeds into the issue of extending adult data to paediatric practice; due to physiological 
differences both the short and long term effects of drugs are different in children than adults, 
so adult data cannot simply replace paediatric-specific studies.  The sixth issue concerns a 
further complication of the paediatric treatment paradox when prescribing medications for 
arguably ‗normal‘ individuals, because not only do psychotropic effects differ between adults 
and children, but also between pathological and normal individuals.  Again, it is even more 
ethically challenging to conduct research on treatment effects in ‗normal‘ children than in 
disordered children due to the lack of dysfunction and impairment.  Lastly, particularly when 
providing treatment for enhancement purposes, the effects that biological changes will have 
on psychology must be considered.  Neurophysiology and cognition should both be included 
in clinical assessments, both through the treatment of psychotherapy and medication, because 
they are so closely linked, as suggested for instance by the effect psychological stress has on 
neurochemical levels and the effect of psychotropic medications on cognitive style. 
 While all of these issues have been identified in the available literature, they have 
previously been presented with regard to a specific perspective, i.e. biology, psychology, 
culture, etc.  However, as the ethical issues are drawn together in this thesis, it becomes clear 
that the different disciplines are actually raising many similar and/or related concerns, which 
cannot be isolated from one another.  The shared interface between the different perspectives 
should not be overlooked, as the various angles share the same objective of raising awareness 
and improving treatment of paediatric mental health care.  With the added perspective 
provided by professional interviews focused to the context of this thesis, the interdisciplinary 
application within the clinical setting of the various ethical concerns highlights the 
importance of recognising the overlap of disciplines as it appears in actual care practices, 
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particularly considering the consistency of results across the different professions within 
paediatric mental health care, a comparison not found in the literature. 
 The strengths of this thesis include its scope of the various disciplines, interplay 
between generalised and disorder-specific application of the ethical concerns and inclusion of 
both literature and interpersonal data.  Exploring the ethical arguments presented by different 
disciplines regarding the same topic, paediatric mental health care, allows a unique 
interdisciplinary perspective to develop.  Further, by incorporating both general paediatric 
mental health care as well as information specific to depression, the thirteen points outlined 
above provide ethical guidance applicable to the entire field of paediatric psychiatry through 
the example of paediatric depression; it demonstrates how general issues may apply to a 
particular diagnosis as well as how concerns raised in the treatment of depression may be 
extended to a broader context.  Additionally, the interviews followed the literature-based 
section, in order to tie together the wide scope of disciplines in the way that appears in real 
practice, an element that becomes lost in literature focused on specific aspects of care. 
 Weaknesses of this thesis include the limited sample size of clinicians interviewed 
and the inability to include data collected directly from paediatric patients.  Due to the small 
number of clinicians included in the data set, results are very specific, both in terms of 
profession of individuals interviewed and the location of their clinical practices, and thus, 
may not be extended to typical national practice trends.  Not including primary data from 
children and adolescents requires that paediatric experiences are based only on the relaying of 
information from the literature and clinicians, which risks the accuracy of portraying a child 
or adolescent‘s true experience.  While the constraints of this thesis did not allow for the 
collection of such data, other similar studies which do include a more extensive data set are in 
progress.  Currently, the Voices On Identity, Childhood, Ethics and Stimulants (VOICES) 
project by Dr. Ilina Singh and colleagues addresses many of the issues noted in this thesis 
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within the context of ADHD through a collection of interviews conducted between 2008 to 
2010 with children ages 9-14 in the US and UK, investigating the impact of disorder, 
diagnosis and treatment on paediatric patients from the children‘s perspective (VOICES, 
2008); the results of this study are still in the process of being analysed, but once completed 
will provide a very interesting parallel to the conclusions drawn in this thesis.   
 Overall, this thesis provides a framework for future investigation of the ethics of 
diagnosing and treating paediatric mental health disorders by drawing together an 
interdisciplinary overview of the ethical concerns and how those concerns ought to be 
considered and applied relative to a specific disorder.  Despite the limited data available at 
present, an ever-increasing number of children are being treated.  As these trends continue, 
research should address the longitudinal impact increased paediatric treatment will have on 
the future of these individuals—what is the prognosis for today‘s young patients?  Also, how 
will medicalisation shape the future of society?  Since medicalisation, diagnosis and 
treatment decisions are subjective, further studies regarding the factors determining these 
judgments may look into the interplay of clinician opinion, media influence, and individual 
patients‘ access to information.  With the first generation of more medicalised and heavily 
treated children entering adulthood, the implications of earlier treatment trends are beginning 
to surface on a broader cultural scale that cannot be overlooked. 
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Appendix A 
ICD 10 Diagnosis of Depression 
(Sections F33 and F32) 
 
As found in: 
Internet Mental Health, 2009. Major Depressive Disorder. [online] Available at:  
<http://www.mentalhealth.com/icd/p22-md01.html> [Accessed: 3 June 2011]. 
 
 
 
F33 Recurrent Depressive Disorder 
The disorder is characterized by repeated episodes of depression as specified in depressive 
episode (mild, moderate, or severe), without any history of independent episodes of mood 
elevation and overactivity that fulfill the criteria of mania. However, the category should still 
be used if there is evidence of brief episodes of mild mood elevation and overactivity which 
fulfill the criteria of hypomania immediately after a depressive episode (sometimes 
apparently precipitated by treatment of a depression). The age of onset and the severity, 
duration, and frequency of the episodes of depression are all highly variable. In general, the 
first episode occurs later than in bipolar disorder, with a mean age of onset in the fifth 
decade. Individual episodes also last between 3 and 12 months (median duration about 6 
months) but recur less frequently. Recovery is usually complete between episodes, but a 
minority of patients may develop a persistent depression, mainly in old age (for which this 
category should still be used). Individual episodes of any severity are often precipitated by 
stressful life events; in many cultures, both individual episodes and persistent depression are 
twice as common in women as in men. 
 
The risk that a patient with recurrent depressive disorder will have an episode of mania never 
disappears completely, however many depressive episodes he or she has experienced. If a 
manic episode does occur, the diagnosis should change to bipolar affective disorder. 
 
Recurrent depressive episode may be subdivided, as below, by specifying first the type of the 
current episode and then (if sufficient information is available) the type that predominates in 
all the episodes. 
 
Includes:  
* recurrent episodes of depressive reaction, psychogenic depression, reactive depression, 
seasonal affective disorder  
* recurrent episodes of endogenous depression, major depression, manic depressive psychosis 
(depressed type), psychogenic or reactive depressive psychosis, psychotic depression, vital 
depression 
Excludes:  
* recurrent brief depressive episodes 
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F32 Depressive Episode 
In typical depressive episodes of all three varieties described below (mild, moderate, and 
severe), the individual usually suffers from depressed mood, loss of interest and enjoyment, 
and reduced energy leading to increased fatiguability and diminished activity. Marked 
tiredness after only slight effort is common. Other common symptoms are: 
 
(a) reduced concentration and attention;  
(b) reduced self-esteem and self-confidence;  
(c) ideas of guilt and unworthiness (even in a mild type of episode);  
(d) bleak and pessimistic views of the future;  
(e) ideas or acts of self-harm or suicide;  
(f) disturbed sleep;  
(g) diminished appetite. 
 
The lowered mood varies little from day to day, and is often unresponsive to circumstances, 
yet may show a characteristic diurnal variation as the day goes on. As with manic episodes, 
the clinical presentation shows marked individual variations, and atypical presentations are 
particularly common in adolescence. In some cases, anxiety, distress, and motor agitation 
may be more prominent at times than the depression, and the mood change may also be 
masked by added features such as irritability, excessive consumption of alcohol, histrionic 
behaviour, and exacerbation of pre-existing phobic or obsessional symptoms, or by 
hypochondriacal preoccupations. For depressive episodes of all three grades of severity, a 
duration of at least 2 weeks is usually required for diagnosis, but shorter periods may be 
reasonable if symptoms are unusually severe and of rapid onset. 
 
Some of the above symptoms may be marked and develop characteristic features that are 
widely regarded as having special clinical significance. The most typical examples of these 
"somatic" symptoms are: loss of interest or pleasure in activities that are normally enjoyable; 
lack of emotional reactivity to normally pleasurable surroundings and events; waking in the 
morning 2 hours or more before the usual time; depression worse in the morning; objective 
evidence of definite psychomotor retardation or agitation (remarked on or reported by other 
people); marked loss of appetite; weight loss (often defined as 5% or more of body weight in 
the past month); marked loss of libido. Usually, this somatic syndrome is not regarded as 
present unless about four of these symptoms are definitely present. 
 
The categories of mild, moderate and severe depressive episodes described in more detail 
below should be used only for a single (first) depressive episode. Further depressive episodes 
should be classified under one of the subdivisions of recurrent depressive disorder. 
 
These grades of severity are specified to cover a wide range of clinical states that are 
encountered in different types of psychiatric practice. Individuals with mild depressive 
episodes are common in primary care and general medical settings, whereas psychiatric 
inpatient units deal largely with patients suffering from the severe grades. 
 
Acts of self-harm associated with mood (affective) disorders, most commonly self-poisoning 
by prescribed medication, should be recorded by means of an additional code from Chapter 
XX of ICD-10 (X60-X84). These codes do not involve differentiation between attempted 
suicide and "parasuicide", since both are included in the general category of self-harm. 
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Differentiation between mild, moderate, and severe depressive episodes rests upon a 
complicated clinical judgement that involves the number, type, and severity of symptoms 
present. The extent of ordinary social and work activities is often a useful general guide to the 
likely degree of severity of the episode, but individual, social, and cultural influences that 
disrupt a smooth relationship between severity of symptoms and social performance are 
sufficiently common and powerful to make it unwise to include social performance amongst 
the essential criteria of severity. 
 
The presence of dementia or mental retardation does not rule out the diagnosis of a treatable 
depressive episode, but communication difficulties are likely to make it necessary to rely 
more than usual for the diagnosis upon objectively observed somatic symptoms, such as 
psychomotor retardation, loss of appetite and weight, and sleep disturbance. 
 
Includes:  
* single episodes of depression (without psychotic symptoms), psychogenic depression or 
reactive depression) 
 
 
F32.0 Mild Depressive Episode 
Diagnostic Guidelines: 
Depressed mood, loss of interest and enjoyment, and increased fatiguability are usually 
regarded as the most typical symptoms of depression, and at least two of these, plus at least 
two of the other symptoms described above should usually be present for a definite diagnosis. 
None of the symptoms should be present to an intense degree. Minimum duration of the 
whole episode is about 2 weeks. 
 
An individual with a mild depressive episode is usually distressed by the symptoms and has 
some difficulty in continuing with ordinary work and social activities, but will probably not 
cease to function completely. 
 
A fifth character may be used to specify the presence of the somatic syndrome: 
 
F32.00 Without somatic symptoms 
The criteria for mild depressive episode are fulfilled, and there are few or none of the somatic 
symptoms present. 
 
F32.01 With somatic symptoms 
The criteria for mild depressive episode are fulfilled, and four or more of the somatic 
symptoms are also present. (If only two or three somatic symptoms are present but they are 
unusually severe, use of this category may be justified.) 
 
 
F32.1 Moderate Depressive Episode 
Diagnostic Guidelines: 
At least two of the three most typical symptoms noted for mild depressive episode should be 
present, plus at least three (and preferably four) of the other symptoms. Several symptoms are 
likely to be present to a marked degree, but this is not essential if a particularly wide variety 
of symptoms is present overall. Minimum duration of the whole episode is about 2 weeks. 
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An individual with a moderately severe depressive episode will usually have considerable 
difficulty in continuing with social, work or domestic activities. 
 
A fifth character may be used to specify the occurrence of somatic symptoms: 
 
F32.10 Without somatic symptoms 
The criteria for moderate depressive episode are fulfilled, and few if any of the somatic 
symptoms are present. 
 
F32.11 With somatic symptoms 
The criteria for moderate depressive episode are fulfilled, and four or more or the somatic 
symptoms are present. (If only two or three somatic symptoms are present but they are 
unusually severe, use of this category may be justified.) 
 
 
F32.2 Severe Depressive Episode Without Psychotic Symptoms 
In a severe depressive episode, the sufferer usually shows considerable distress or agitation, 
unless retardation is a marked feature. Loss of self-esteem or feelings of uselessness or guilt 
are likely to be prominent, and suicide is a distinct danger in particularly severe cases. It is 
presumed here that the somatic syndrome will almost always be present in a severe 
depressive episode. 
 
Diagnostic Guidelines: 
All three of the typical symptoms noted for mild and moderate depressive episodes should be 
present, plus at least four other symptoms, some of which should be of severe intensity. 
However, if important symptoms such as agitation or retardation are marked, the patient may 
be unwilling or unable to describe many symptoms in detail. An overall grading of severe 
episode may still be justified in such instances. The depressive episode should usually last at 
least 2 weeks, but if the symptoms are particularly severe and of very rapid onset, it may be 
justified to make this diagnosis after less than 2 weeks. 
 
During a severe depressive episode it is very unlikely that the sufferer will be able to continue 
with social, work, or domestic activities, except to a very limited extent. 
 
This category should be used only for single episodes of severe depression without psychotic 
symptoms; for further episodes, a subcategory of recurrent depressive disorder should be 
used. 
 
Includes:  
* single episodes of agitated depression  
* melancholia or vital depression without psychotic symptoms 
 
 
F32.3 Severe Depressive Episode With Psychotic Symptoms 
Diagnostic Guidelines: 
A severe depressive episode which meets the criteria given for severe depressive episode 
without psychotic symptoms and in which delusions, hallucinations, or depressive stupor are 
present. The delusions usually involve ideas of sin, poverty, or imminent disasters, 
responsibility for which may be assumed by the patient. Auditory or olfactory hallucinations 
are usually of defamatory or accusatory voices or of rotting filth or decomposing flesh. 
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Severe psychomotor retardation may progress to stupor. If required, delusions or 
hallucinations may be specified as mood-congruent or mood-incongruent. 
 
Differential Diagnosis: 
Depressive stupor must be differentiated from catatonic schizophrenia, from dissociative 
stupor, and from organic forms of stupor. This category should be used only for single 
episodes of severe depression with psychotic symptoms; for further episodes a subcategory of 
recurrent depressive disorder should be used. 
 
Includes:  
* single episodes of major depression with psychotic symptoms, psychotic depression, 
psychogenic depressive psychosis, reactive depressive psychosis 
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Appendix B 
DSM IV Diagnosis of Depression 
 
As found in: 
Depression Today, 2010.  DSM IV Criteria. [online] Available at: < http://www.mental- 
health-today.com/dep/dsm.htm> [Accessed: 3 June 2011]. 
 
 
Major Depressive Episode 
 
A.  Five (or more) of the following symptoms have been present during the same 2-week 
period and represent a change from previous functioning; at least one of the symptoms is 
either (1) depressed mood or (2) loss of interest or pleasure. 
 
Note: Do not include symptoms that are clearly due to a general medical condition, or mood-
incongruent delusions or hallucinations. 
 
(1)  Depressed mood most of the day, nearly every day, as indicated by either subjective 
report (e.g., feels sad or empty) or observation made by others (e.g., appears tearful).  Note: 
In children and adolescents, can be irritable mood. 
(2)  Markedly diminished interest or pleasure in all, or almost all, activities most of the day, 
nearly every day (as indicated by either subjective account or observation made by others). 
(3)  Significant weight loss when not dieting or weight gain (e.g., a change of more than 5% 
of body weight in a month), or decrease or increase in appetite nearly every day.  Note: In 
children, consider failure to make expected weight gains. 
(4)  Insomnia or hypersomnia nearly every day. 
(5)  Psychomotor agitation or retardation nearly every day (observable by others, not merely 
subjective feelings of restlessness or being slowed down). 
(6)  Fatigue or loss of energy nearly every day. 
(7)  Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) 
nearly every day (not merely self-reproach or guilt about being sick). 
(8)  Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by 
subjective account or as observed by others). 
(9)  Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a 
specific plan, or a suicide attempt or a specific plan for committing suicide. 
 
B.  The symptoms do not meet criteria for a Mixed Episode. 
 
C.  The symptoms cause clinically significant distress or impairment in social, occupational, 
or other important areas of functioning. 
 
D.  The symptoms are not due to the direct physiological effects of a substance (e.g., a drug 
of abuse, a medication) or a general medical condition (e.g., hypothyroidism). 
 
E.  The symptoms are not better accounted for by Bereavement, i.e., after the loss of a loved 
one, the symptoms persist for longer than 2 months or are characterized by marked functional 
impairment, morbid preoccupation with worthlessness, suicidal ideation, psychotic symptoms 
or psychomotor retardation. 
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Major Depressive Disorder 
 
Single Episode: 
 
A.  Presence of a single Major Depressive Episode. 
 
B.  The Major Depressive Episode is not better accounted for by Schizoaffective Disorder 
and is not superimposed on Schizophrenia, Schizopheniform Disorder, Delusional Disorder, 
or Psychotic Disorder Not Otherwise Specified. 
 
C.  There has never been a Manic Episode, a Mixed Episode, or a Hypomanic Episode.  
Note: This exclusion does not apply if all the manic-like, mixed-like, or hypomanic-like 
episodes are substance or treatment induced or are due to the direct physiological effects of a 
general medical condition. 
 
 
Recurrent: 
 
A.  Presence of two or more Major Depressive Episodes. 
 
Note: To be considered separate episodes, there must be an interval of at least 2 consecutive 
months in which criteria are not met for a Major Depressive Episode. 
 
B.  The Major Depressive Episodes are not better accounted for by Schizoaffective Disorder 
and are not superimposed on Schizophrenia, Schizophreniform Disorder, Delusional 
Disorder, or Psychotic Disorder Not Otherwise Specified. 
 
C.  There has never been a Manic Episode, a Mixed Episode, or a Hypomanic Episode.  
Note: This exclusion does not apply if all the manic-like, mixed-like, or hypomanic-like 
episodes are substance or treatment induced or are due to the direct physiological effects of a 
general medical condition. 
 
 
 
Specify (for current or most recent episode): 
Severity/Psychotic/Remission Specifiers 
Chronic 
With Catatonic Features 
With Atypical Features 
With Postpartum Onset 
 
Specify 
Longitudinal Course Specifiers (With and Without Interepisode Recovery) 
With Seasonal pattern 
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Appendix C 
List of Antidepressant Drugs Requiring FDA 
Medication Guides 
 
As found in: 
FDA, 2010b. Antidepressant Use in Children, Adolescents, and Adults. [online] (Updated: 12 
August 2010) Available at: <http://www.fda.gov/Drugs/DrugSafety/Informationby 
DrugClass/ucm096273.htm> [Accessed: 11 June 2011]. 
 
 
•  Anafranil (clomipramine)  
•  Asendin (amoxapine)  
•  Aventyl (nortriptyline)  
•  Celexa (citalopram hydrobromide)  
•  Cymbalta (duloxetine)  
•  Desyrel (trazodone HCl)  
•  Elavil (amitriptyline)  
•  Effexor (venlafaxine HCl)  
•  Emsam (selegiline)  
•  Etrafon (perphenazine/amitriptyline)  
•  fluvoxamine maleate  
•  Lexapro (escitalopram oxalate)  
•  Limbitrol 
(chlordiazepoxide/amitriptyline)  
•  Ludiomil (maprotiline)  
•  Marplan (isocarboxazid)  
•  Nardil (phenelzine sulfate)   
•  nefazodone HCl  
•  Norpramin (desipramine HCl)  
•  Pamelor (nortriptyline)  
•  Parnate (tranylcypromine sulfate)  
•  Paxil (paroxetine HCl)  
•  Pexeva (paroxetine mesylate)  
•  Prozac (fluoxetine HCl)  
•  Remeron (mirtazapine)  
•  Sarafem (fluoxetine HCl)  
•  Seroquel (quetiapine)  
•  Sinequan (doxepin)  
•  Surmontil (trimipramine)  
•  Symbyax (olanzapine/fluoxetine)  
•  Tofranil (imipramine)  
•  Tofranil-PM (imipramine pamoate)  
•  Triavil (perphenazine/amitriptyline)  
•  Vivactil (protriptyline)  
•  Wellbutrin (bupropion HCl)  
•  Zoloft (sertraline HCl)  
•  Zyban (bupropion HCl) 
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Appendix D 
Revisions to FDA Black Box Product Labeling 
 
As found in: 
FDA, 2010c. Revisions to Product Labeling. [online] Available at: <http://www.fda.gov/ 
downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM173233.pdf> [Accessed: 
11 June 2011]. 
 
 
[These changes should be made to the box warning at the beginning of the 
package insert.] 
 
DRUG NAME  
 
Suicidality and Antidepressant Drugs   
  
Antidepressants increased the risk compared to placebo of suicidal thinking and 
behavior (suicidality) in children, adolescents, and young adults in short-term studies of 
major depressive disorder (MDD) and other psychiatric disorders.  Anyone considering 
the use of [Insert established name] or any other antidepressant in a child, adolescent, 
or young adult must balance this risk with the clinical need.   Short-term studies did not 
show an increase in the risk of suicidality with antidepressants compared to placebo in 
adults beyond age 24; there was a reduction in risk with antidepressants compared to 
placebo in adults aged 65 and older.  Depression and certain other psychiatric disorders 
are themselves associated with increases in the risk of suicide.  Patients of all ages who 
are started on antidepressant therapy should be monitored appropriately and observed 
closely for clinical worsening, suicidality, or unusual changes in behavior.  Families and 
caregivers should be advised of the need for close observation and communication with 
the prescriber.  [Insert Drug Name] is not approved for use in pediatric patients.  [The 
previous sentence would be replaced with the sentence, below, for the following drugs: 
Prozac: Prozac is approved for use in pediatric patients with MDD and obsessive 
compulsive disorder (OCD).   Zoloft: Zoloft is not approved for use in pediatric patients 
except for patients with obsessive compulsive disorder (OCD).  Fluvoxamine: 
Fluvoxamine is not approved for use in pediatric patients except for patients with 
obsessive compulsive disorder (OCD).]  (See Warnings: Clinical Worsening and Suicide 
Risk, Precautions: Information for Patients, and Precautions: Pediatric Use)   
 
[The following changes should be made to the current language under the  
WARNINGS-Clinical Worsening and Suicide Risk section.]  
 
WARNINGS-Clinical Worsening and Suicide Risk 
 
Patients with major depressive disorder (MDD), both adult and pediatric, may experience 
worsening of their depression and/or the emergence of suicidal ideation and behavior 
(suicidality) or unusual changes in behavior, whether or not they are taking antidepressant 
medications, and this risk may persist until significant remission occurs. Suicide is a known 
risk of depression and certain other psychiatric disorders, and these disorders themselves are 
the strongest predictors of suicide.  There has been a longstanding concern, however, that 
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antidepressants may have a role in inducing worsening of depression and the emergence of 
suicidality in certain patients during the early phases of treatment.  Pooled analyses of short-
term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these 
drugs increase the risk of suicidal thinking and behavior (suicidality) in children,adolescents, 
and young adults (ages 18-24) with major depressive disorder (MDD) and  other psychiatric 
disorders.  Short-term studies did not show an increase in the risk of suicidality with 
antidepressants compared to placebo in adults beyond age 24; there was a reduction with 
antidepressants compared to placebo in adults aged 65 and older.   
 
The pooled analyses of placebo-controlled trials in children and adolescents with MDD, 
obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 
short-term trials of 9 antidepressant drugs in over 4400 patients.  The pooled analyses of 
placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 
295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 
patients.  There was considerable variation in risk of suicidality among drugs, but a tendency 
toward an increase in the younger patients for almost all drugs studied. There were 
differences in absolute risk of suicidality across the different indications, with the highest 
incidence in MDD.  The risk differences (drug vs placebo), however, were relatively stable 
within age strata and across indications.  These risk differences (drug-placebo difference in 
the number of cases of suicidality per 1000 patients treated) are provided in Table [add table 
number].     
    
Table [add table number] 
Age Range Drug-Placebo Difference in  
Number of Cases of Suicidality  
per 1000 patients Treated 
 Drug-Related Increases 
<18 14 additional cases 
18-24 5 additional cases 
 Drug-Related Decreases 
25-64 1 fewer case 
>65 6 fewer cases 
 
No suicides occurred in any of the pediatric trials.  There were suicides in the adult trials, but 
the number was not sufficient to reach any conclusion about drug effect on suicide.  
 
It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several 
months.  However, there is substantial evidence from placebo-controlled maintenance trials 
in adults with depression that the use of antidepressants can delay the recurrence of 
depression.         
 
All patients being treated with antidepressants for any indication should be monitored 
appropriately and observed closely for clinical worsening, suicidality, and unusual 
changes in behavior, especially during the initial few months of a course of drug 
therapy, or at times of dose changes, either increases or decreases.       
 
The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, 
aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, 
have been reported in adult and pediatric patients being treated with antidepressants for major 
depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. 
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Although a causal link between the emergence of such symptoms and either the worsening of 
depression and/or the emergence of suicidal impulses has not been established, there is 
concern that such symptoms may represent precursors to emerging suicidality.    
 
Consideration should be given to changing the therapeutic regimen, including possibly 
discontinuing the medication, in patients whose depression is persistently worse, or who are 
experiencing emergent suicidality or symptoms that might be precursors to worsening 
depression or suicidality, especially if these symptoms are severe,  abrupt in onset, or were 
not part of the patient's presenting symptoms.    
 
[The labeling for the following drugs with discontinuation language would include the 
next paragraph: Celexa, Cymbalta, Effexor, Fluvoxamine, Lexapro, Paxil, Pexeva, 
Prozac, Sarafem, Symbyax, and Zoloft.]  
 
If the decision has been made to discontinue treatment, medication should be tapered, as 
rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with 
certain symptoms (see PRECAUTIONS and DOSAGE AND ADMINISTRATION—
Discontinuation of Treatment with [Insert established name], for a description of the risks of 
discontinuation of [Insert established name]).    
 
Families and caregivers of patients being treated with antidepressants for major 
depressive disorder or other indications, both psychiatric  and nonpsychiatric, should 
be alerted about the need to monitor patients for the emergence of agitation, irritability, 
unusual changes in behavior, and the other symptoms described above, as well as the 
emergence of suicidality, and to report such symptoms immediately to health care 
providers.  Such monitoring should include daily observation by families and 
caregivers. Prescriptions for [Insert Drug Name] should be written for the smallest quantity 
of tablets consistent with good patient management, in order to reduce the risk of overdose.   
 
Screening Patients for Bipolar Disorder:  A major depressive episode may be the initial 
presentation of bipolar disorder. It is generally believed (though not established in controlled 
trials) that treating such an episode with an antidepressant alone may increase the likelihood 
of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any 
of the symptoms described above represent such a conversion is unknown. However, prior to 
initiating treatment with an antidepressant, patients with depressive symptoms should be 
adequately screened to determine if they are at risk for bipolar disorder; such screening 
should include a detailed psychiatric history, including a family history of suicide, bipolar 
disorder, and depression.  It should be noted that [Insert Drug Name] is not approved for use 
in treating bipolar depression.  [The previous sentence would be replaced for the following 
drugs: Seroquel: It  should be noted that Seroquel is approved for use in treating adult bipolar 
depression.   Symbyax: It should be noted that Symbyax is approved for use in treating adult 
bipolar depression.   
 
[The following changes should be made in current language under the 
PRECAUTIONS-Information for Patients section.]  
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PRECAUTIONS-Information for Patients  
 
Prescribers or other health professionals should inform patients, their families, and their 
caregivers about the benefits and risks associated with treatment with [Insert Drug Name] and 
should counsel them in its appropriate use.  A patient Medication Guide about 
―Antidepressant Medicines, Depression and other Serious Mental Illness, and Suicidal 
Thoughts or Actions‖ is available for [Insert Drug Name].  The prescriber or health 
professional should instruct patients, their families, and their caregivers to read the 
Medication Guide and should assist them in understanding its contents.  Patients should be 
given the opportunity to discuss the contents of the Medication Guide and to obtain answers 
to any questions they may have.  The complete text of the Medication Guide is reprinted at 
the end of this document.    
 
Patients should be advised of the following issues and asked to alert their prescriber if these 
occur while taking [Insert Drug Name].     
 
Clinical Worsening and Suicide Risk:    Patients, their families, and their caregivers should 
be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, 
irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), 
hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal 
ideation, especially early during antidepressant treatment and when the dose is adjusted up or 
down. Families and caregivers of patients should be advised to look for the emergence of 
such symptoms on a day-to-day basis, since changes may be abrupt.  Such symptoms should 
be reported to the patient's prescriber or health professional, especially if they are severe, 
abrupt in onset, or were not part of the patient's presenting symptoms.  Symptoms such as 
these may be associated with an increased risk for suicidal thinking and behavior and indicate 
a need for very close monitoring and possibly changes in the medication.    
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Appendix E 
WHO Atlas Project Participants 
 
Information collated from: 
WHO, 2005b. Atlas: child and adolescent mental health resources: global concerns,  
implications for the future. Geneva: World Health Organization. 
 
 
Member States of the WHO by Region
8
: 
 
WHO region Participating countries 
Africa Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, 
Cameroon, Cape Verde, Central African Republic, Chad, Comoros, 
Congo, Côte d‘Ivoire, Democratic Republic of the Congo, Equatorial 
Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, 
Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, 
Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, 
Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, 
South Africa, Swaziland, Togo, Uganda, United Republic of 
Tanzania, Zambia, Zimbabwe 
Americas Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, 
Bolivia, Brazil, Canada, Chile, Colombia, Costa Rica, Cuba, 
Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, 
Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, 
Panama, Paraguay, Peru, Saint Kitts and Nevis, Saint Lucia, Saint 
Vincent and the Grenadines, Suriname, Trinidad and Tobago, United 
States of America, Uruguay, Venezuela 
South-East Asia Bangladesh, Bhutan, Democratic People‘s Republic of Korea, India, 
Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand, Timor-
Leste 
Europe Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, 
Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Georgia, Germany, 
Greece, Hungary, Iceland, Ireland, Israel, Italy, Kazakhstan, 
Kyrgyzstan, Latvia, Lithuania, Luxembourg, Malta, Monaco, 
Netherlands, Norway, Poland, Portugal, Republic of Moldova, 
Romania, Russian Federation, San Marino, Serbia and Montenegro, 
Slovakia, Slovenia, Spain, Sweden, Switzerland, Tajikistan, The 
former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, 
Ukraine, United Kingdom, Uzbekistan 
                                                 
8
 Countries in bold participated in the Child Mental Health Atlas. 
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Eastern 
Mediterranean 
Afghanistan, Bahrain, Djibouti, Egypt, Iran (Islamic Republic of), 
Iraq, Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya, Morocco, 
Oman, Pakistan, Qatar, Saudi Arabia, Somalia, Sudan, Syrian Arab 
Republic, Tunisia, United Arab Emirates, Yemen 
Western Pacific Australia, Brunei Darussalam, Cambodia, China (and Hong Kong 
SAR), Cook Islands, Fiji, Japan, Kiribati, Lao People’s Democratic 
Republic, Malaysia, Marshall Islands, Micronesia (Federated States 
of), Mongolia, Nauru, New Zealand, Niue, Palau, Papua New Guinea, 
Philippines, Republic of Korea, Samoa, Singapore, Solomon Islands, 
Tonga, Tuvalu, Vanuatu, Viet Nam 
 
 
 
 
 
 
 
 
Countries included in the Child Mental Health Atlas: 
 
WHO region Total number of 
countries 
Atlas questionnaire 
received from 
countries 
Population of 
responding countries 
(percent) 
Africa 46 15 (32.7%) 34.4% 
Americas 35 9 (25.7) 46.9% 
South-East Asia 11 3 (27.3%) 71.1% 
Europe 52 25 (48.1%) 64.7% 
Eastern 
Mediterranean 
21 8 (38.1%) 38.5% 
Western Pacific 27 6 (22.2%) 87.7% 
World
9
 192 66 (34.4%)  
 
 
 
                                                 
9
 World statistics based on information found in Child Atlas. 
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Appendix F 
Interview Outline 
 
Hello, as previously stated, my name is Molly Deacutis, and I am working on my Master of 
Philosophy degree in Neuroscience at the University of St Andrews.  I am here in (state 
location) to speak with you today, (state date), in order to gather a professional perspective 
concerning the diagnosis and treatment of children and adolescents with mental health 
disorders, particularly depression.  The information we will discuss may be included in my 
thesis to support the literature research I have collected, as well as provide data for the 
possibility of related publications.  All this information is included for you on the information 
sheet and debriefing form, as well.  I would like to thank you again for taking the time to talk 
to me today. 
 
 
Before we get started, can you please state your clinical position? 
 
 
Now, the first major topic of my research concerns the process of diagnosing children; that is, 
classifying or labelling patients with a specific disorder or disorders.  As mentioned before, 
diagnosis is not commonly used at this clinic; why is this the practice?  Why is diagnosis 
used in certain cases and not others?  What is the purpose of diagnosing? 
 
 
When diagnosis is used, what method is used to determine a patient‘s diagnosis?  A checklist 
based on the diagnostic criteria set out by the ICD (or other diagnostic system)?  A written 
evaluation?  Etc? 
 
 
I‘m also interested in why children are being brought in for treatment.  How self aware of 
their disorder do your patients seem?  How much is treatment sought more based on the 
observation of parents, teachers, or others? 
 
 
My research also looks at the impact of mental health disorders and treatment on children‘s 
development of identity, how children view themselves in the context of their world, as well 
as a development of autonomy, an understanding of self-control.  How much of an impact on 
a patient‘s identity do you notice following a diagnosis/treatment or by the disorder itself?  
And how much of an impact do you notice on their sense of autonomy? 
 
 
What is the most common disorder(s) that comes into your clinic?  And what is the most 
common disorder that you see?  (Do you have a specialization?) 
 
 
The other major topic in my research is paediatric treatment.  Of the patients that you see, 
approximately what percentage is medicated for a mental health disorder?  And 
approximately what percentage of your patients do you prescribe medication for? 
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Which drugs are most commonly prescribed at this clinic?  Which drugs do you most 
commonly prescribe? 
 
 
And as my thesis focuses on depression as a case study, which antidepressants are most 
commonly prescribed here?  And which antidepressants do you most commonly prescribe? 
 
 
Over the past six years, there has been a change in antidepressant guidelines recommending 
only the prescription of fluoxetine to young people between the ages of 8-25 due to increased 
risk of suicidality related to SSRI use.  How has this change impacted medication practices in 
your clinic and/or by you, if at all? 
 
 
Also suggested by these guidelines has been using psychotherapy (CBT) as the frontline 
treatment, followed by fluoxetine as a first-line medication treatment, and only then to use 
other antidepressants as second-line treatment.  In reality, what is the treatment plan used in 
this clinical practice?  If real practices differ from the guidelines, what are the pressures 
causing those discrepancies? 
 
 
In general, what are the common symptoms that you see in depressed patients?  Do you see 
variation based on age/gender? 
 
 
Lastly, while the NHS focuses only on treating impairment, do you think it is plausible that 
neuroenhancement may become widespread practice in coming years? 
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